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Ovine herpesvirus 2 (OvHV-2) is the causative agent of sheep-associated malignant 
catarrhal fever (MCF) in susceptible ruminants.  Through an unknown mechanism, 
presence of the virus leads to proliferation of NK-like T cells that are not target-
restricted by the MHC class molecules.  These host cells cause the symptoms found in 
MCF; fever, swollen lymph nodes, and necrotic lesions of the nasal, conjunctival, and 
oral mucosa, which usually leads to death of the host.   
  
MicroRNAs (miRNAs) are ~22 nt RNA molecules expressed by eukaryotes and viruses 
that regulate genes post-transcriptionally.  Viral miRNAs have been found to regulate 
cellular genes to control the cell cycle and have a role in pathogenesis.  It was 
hypothesised that OvHV-2 expresses miRNAs and these play a role in MCF 
pathogenesis.  The aim of this project was to determine if OvHV-2 encodes miRNAs. 
  
Bioinformatic analysis was conducted on deep sequencing data from RNA of OvHV-2-
immortalised T cells.  Candidate miRNAs were selected if they adhered to miRNA 
secondary structure.  46 candidate miRNAs were found, with three clusters on the minus 
strand; one at the 5’ end and the other two in a 9.3 kb region that contains no predicted 
open reading frames.  The 8 most abundant candidates were successfully validated by 
northern hybridisation for small RNAs.  The majority of the predicted targets for the 8 
validated OvHV-2 miRNAs were from the OvHV-2 genome.   
  
This study adds OvHV-2 to the list of herpesviruses that encode miRNAs and provides 
another tool for studying the pathogenesis of MCF. 
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1.1 MALIGNANT CATARRHAL FEVER 
Malignant catarrhal fever (MCF) was first described in Africa in the early 1920s and in 
Europe in 1930 as a mostly fatal condition affecting cattle that had associated with 
apparently healthy wildebeest or sheep (Løken, et al., 1998 referring to Mettam, 1923 
and Götze et al., 1930).  Since then, this disease has been found throughout the order 
Artiodactyla (cloven-hoofed mammals) (Ackermann, 2006).  Wildebeest-associated 
MCF (WA-MCF) was found in 1960 to be caused by a virus that was later classified as a 
gammaherpesvirus in the Macavirus genus; alcelaphine herpesvirus 1 (AlHV-1) 
(Plowright et al., 1960).  Sheep-associated MCF (SA-MCF) was found to be caused by 
the antigenically related ovine herpesvirus 2 (OvHV-2) in 1993 (Rossiter, 1983, 1981).  
These viruses are members of a family that maintain life-long, persistent infections and 
this is what is observed in their natural hosts (wildebeest and sheep).  So why is it that 
other related species develop disease?  Persistence in a host requires herpesviruses to 
maintain a latent life stage which balances viral genome replication with immune 
evasion.  At times of stress and suppression of the immune system, these viruses can 
reactivate, produce new virions and cause clinical symptoms.  In the situation of sheep 
and cows in a pasture, stress and immunosuppression as a trigger for reactivation and the 
development of disease do not seem to fit.  I hypothesize that the pathology of these 
viruses is due to an imbalance of regulatory factors that effect the expression of both 
viral and cellular transcripts.     
1.1.1 Clinical Forms of MCF 
Clinical symptoms of MCF in susceptible species appear 2-12 weeks after initial 
infection and can present as five overlapping syndromes; head and eye (most common) 
peracute, alimentary, neurological, and cutaneous (Russell et al., 2009).  The head and 
eye form presents as fever, lack of appetite, diarrhoea, depression, and discharge from 
the nose and eyes (Figure 1.1).  Additional presentations include weight loss, 
shivering/trembling, red urine, lethargy, loss of balance, ocular swelling, drooling,  
 















Figure 1.1: A cow exhibiting clinical signs of MCF.   
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clouding of the cornea, bloodshot eyes, sensitivity to light, hyperventilation, increased 
heart rate, and/or death (Costa et al., 2009, Sanford et al., 1977).  Mortality and severity 
of morbidity are species-dependent; deer and bison have a high mortality rate (death can 
occur within a few days of the appearance of clinical symptoms) while up to 50% of 
cattle can recover and maintain a persistent infection (Coulter et al., 2001, O’Toole et 
al., 1997, Powers et al., 2005, Russell et al., 2009). 
1.1.2 Gross Pathology 
Post-mortems of MCF fatalities show swollen lymph nodes, inflammation, ulcers and 
necrotic lesions of mucosal membranes, and petechial haemorrhages of the systemic 
mucosal epithelium (Metzler, 1991, Russell et al., 2009).  Mucosa of the respiratory 
tract can be covered by a mucopurulent exudate and the digestive tract shows 
inflammation and gas retention (Costa et al., 2009).  The surface of the liver, spleen and 
kidneys can be covered with white foci and the epi- and myocardium of the heart can be 
infiltrated by macrophages and lymphocytes.   
1.1.3 Microscopic Pathology 
Microscopic investigation shows a decrease in the number of white blood cells found in 
the blood due to accumulation in necrotic tissue, systemic vasculitis (due to 
lymphocytes) and fibrinoid degeneration of the small and medium blood vessels, and 
necrotic germinal centres of lymph nodes and the adrenal cortex (Costa et al., 2009, 
Metzler, 1991, Russell et al., 2009, Sanford et al., 1977).  Necrotic epithelium overlies 
the inflamed vessels (Sanford et al., 1977).  The most affected organs include the 
kidneys, heart, liver, spleen, lungs, lymph nodes, and brain (Costa et al., 2009).  The 
spleen is depleted of lymphocytes and engorged with erythrocytes.  The cerebrum and 
cerebellum of the brain show lymphocyte perivascular cuffing and there is an increase in 
protein deposited in the liver.  
Chapter One                                                                                                      Introduction 
 5 
1.1.4 Proposed Model for MCF Pathogenesis 
MCF is characterized by depleted levels of IL-2 in host lymphnodes and the 
proliferation of immortalized large granular lymphocytes (LGLs) with a lymphokine-
activated killer cell phenotype, i.e. cytokines released from other lymphocytes activate 
these cells to begin killing other cells.  These cells have the ability to infiltrate various 
tissues and target cells without the restriction of the major histocompatibility complex 
class II (MHC) (Cook et al., 1988, Meier-Trummer et al., 2009).  Different alleles of 
MHC II have been found to be associated with susceptibility and resistance to MCF in 
American bison (Traul et al., 2007).  MHC II presents antibodies from outside the cell to 
CD4+ T cells which is unexpected in relation to the pathogenic mechanism of OvHV-2 
given that MHC II is not associated with viral-induced cytotoxicity (viral-induced 
cytotoxicity is catalyzed by MHC I presentation of antibodies from inside the infected 
cell to CD8+ T cells).  There has not been a study on the various alleles of MHC I at 
present, but it appears that some effect of OvHV-2 infection can lead to an immune 
response against non-OvHV-2-related antigens.   
 
The cause of the necrotic lesions in the vasculature has been hypothesized to be the 
OvHV-2 latently-infected γ/δ T lymphocyte subpopulation (Liggitt et al., 1980, Nelson 
et al., 2010, Simon et al., 2003).  It is hypothesized that the cells may autostimulate each 
other via an interaction between CD2 and CD58 (Schock et al., 1998).  The OvHV-2 
transcriptome in cells of susceptible species lies somewhere between the normal gene 
expression patterns expected of lytic and latent virus.  MCF may be a result of a lack of 
control over OvHV-2 gene expression in these animals (Russell et al., 2009); for 
example, OvHV-2 replication in lambs is restricted to the respiratory tract (mostly in the 
turbinates) whereas in cattle, OvHV-2 replication has been found in the brain, kidney, 
intestine, and bladder (Cunha et al., 2008).   
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1.2 HERPESVIRUSES 
Herpesviruses are widespread throughout the animal kingdom and are able to control 
their own genome replication and virion production by encoding and expressing a large 
number of protein coding open reading frames (ORFs) (Roizmann et al., 1992).     
1.2.1 Herpesvirus Structure 
Herpesviruses are enveloped with a linear double-stranded DNA (dsDNA) genome 
contained within an icosahedral capsid (nucleocapsid) (Figure 1.2) (Roizmann et al., 
1992).  Between the envelope and nucleocapsid is a protein-filled space called the 
tegument.  The capsids range from 100-110 nm in diameter but the size of the virions 
increase to 120-300 nm once the tegument and envelope are included.   
 
The tegument of herpesviruses has yet to be clearly defined but recently there has been 
evidence that suggests the tegument is more structured than previously thought; the 
tegument consists of a densely packed inner protein layer associated with the 
nucleocapsid and a loosely-packed outer protein layer between the inner tegument and 
the envelope (Yu et al., 2011).   
 
The envelope of herpesviruses is made up of a lipid biolayer (originating from the host 
cell it was released from) incorporated with a number of glycoproteins (g/gp) that are 
associated with the outer tegument to relay stimuli from the outside environment to the 
nucleocapsid (Roizmann et al., 1992).     
1.2.2 Herpesvirus Genomes 
As of March 2011, 45 species of herpesvirus have had their genome completely 
sequenced and published online (http://www.ncbi.nlm.nih.gov/); they range in size from 
108,409 base-pairs (bp) (gammaherpesvirus ateline herpesvirus 3 in new world 
monkeys) to 295,146 bp (alloherpesvirus cyprinid herpesvirus 3 in sturgeon) and express 
from 69 ORFs (alphaherpesvirus suid herpesvirus 1 in pigs) to 223 ORFs 
(betaherpesvirus macacine herpesvirus 3 in macaques).  Through the rest of this thesis, 
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“ORF50” (as an example) will designate open reading frame 50 or the RNA transcript 
transcribed from open reading frame 50 and “orf50” will designate the protein product 
of “ORF50”.  Of the ORFs encoded by herpesviruses, 43 are conserved by all members 
and the remainder range in specificity between sub-family (alpha, beta, and gamma) 
genus and species levels (McGeoch and Davison, 1999).  The roles of the conserved 
ORFs are related to viral replication, structure, egress, and the tegument whereas the 
unique ORFs are related to infectivity, immune evasion and pathogenesis (McGeoch et 
al., 2006). 
 
Herpesvirus genomes are organized in six different ways; consisting of a long unique 
sequence flanked or separated by sequence repeats of varying length (Roizmann et al., 
1992).  These six organizations are described with the letters A-F.  A genomes have a 
single long unique sequence with a shorter sequence repeated exactly at both termini; B 
genomes have a long unique sequence with shorter sequences repeated many times at 
both termini; C genomes have short sequences that are repeated at both termini, but are 
repeated less than in B genomes and may also contain additional unrelated repeat 
regions that divide the long unique sequence; D genomes have a long unique sequence 
with two sequence repeats; one at a terminus and one within the unique sequence in an 
inverted orientation to that of the terminal repeat; the E genome unique sequence is 
flanked by two shorter sequences that are both repeated internally and inverted; F 
genomes do not contain repeated regions (Figure 1.3). 
 
Upon entry of the viral genome into the host cell’s nucleus, the genome becomes 
associated with cellular histones (forming nucleosomes) which alter the structure, and 
therefore the availability of ORFs to be expressed, based on the stage of the viral life 
cycle (Nevels et al., 2011).   
 
“Plus” and “minus” can be used to describe each of the DNA strands in the herpesvirus 
genome.  ORFs are numbered left to right based on homology within the taxonomic  
 








Figure 1.2: The structure of a typical herpesvirus virion; herpes simplex virus is 
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Figure 1.3: Schematic of the six different organizations (A-F) of the herpesvirus 
genome (adapted from Roizmann et al., 1992).  The black line represents the unique 
sequence, and each box represents a repeat region; colour fade shows the direction of the 
repeated region. 
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groups.  In this orientation, those that are transcribed left to right are on the plus strand 
and those that are transcribed right to left are on the minus strand. 
1.3 HERPESVIRUS CLASSIFICATION 
The herpesvirus family (Herpesviridae) is divided into three subfamilies 
(Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae) based on genome 
content and biological properties; range of host species and cell type, replication 
efficiency, and clinical symptoms where they occur.        
1.3.1 Alphaherpesviruses 
Alphaherpesviruses have a variable host range, they reproduce quickly, are efficient at 
destroying their host cells, and maintain latency in sensory ganglia (Roizmann et al., 
1992).  There are 4 genera in this sub-family comprised of 36 species; Simplexvirus, 
Varicellovirus, Mardivirus, and Iltovirus (Davison et al., 2009). 
 
The best studied of the alphaherpesviruses are the Simplexvirus.  Descriptions of the oral 
blisters (cold sores) caused by the Simplexvirus member herpes simplex virus 1 (human 
herpesvirus 1, HSV-1) have been documented since ancient Greece (Hunt, 2011).  The 
virus is transmitted through the epithelial mucosa of the mouth or genitals and replicates 
in the reciprocal cells of the new host while latency is established in the sensory neurons 
that innervate these tissues; the trigeminal ganglia or the sacral ganglia, respectively.  
Reactivation of the virus is generally stress-related and results in migration of HSV-1 
back down the neuron and causes a blister to form on the epithelial surface which will 
fill with newly replicated virions to be passed to a new host.  HSV-1 can also cause 
more severe clinical symptoms such as eczema, ulcers, blindness (if the eye is infected), 
and seizures. 
 
The Varicellovirus member varicella-zoster virus (human herpesvirus 3, VZV) infects 
most people worldwide during childhood causing varicella lesions across large areas of 
skin (chicken pox) (Arvin, 1996).  Latency is established in the dorsal root ganglia and 
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reactivation in adults leads to localized lesions (herpes zoster).  The chance of VZV 
reactivating (to cause shingles) becomes more likely as people age, if the immune 
system is suppressed e.g. with use of steroids.  VZV is transmissible through skin-skin 
contact as well as through the respiratory tract and is most easily passed in temperate 
climates.  Primary infection occurs in mucosal membranes and then migrates to lymph 
nodes during incubation where virions spread to CD4+ and CD8+ T cells.  These cells 
enable access to the epidermis where virion replication leads to the varicella rash.  In 
immunosuppressed individuals, VZV can infect most organs leading to varicella 
pneumonia, liver failure, varicella encephalitis, cerebellar ataxia, thrombocytopenia, 
necrotic adrenal glands, and congenital varicella syndrome when a mother is infected 
with VZV in early pregnancy.    
 
The Mardivirus member Marek’s Disease Virus 1 (gallid herpesvirus 2, MDV-1) 
initially infects and replicates in B lymphocytes of poultry (Mwangi et al., 2011).  
Within a week of infection, MDV establishes latency in CD4+ T cells with a 
subpopulation infecting feather follicle epithelial cells.  The epithelial cells are shed into 
the environment and transmit the virus through the respiratory route.  Within a month of 
infection, CD4+ T cell lymphomas can be produced throughout the entire body of the 
host.  Vaccines have been developed that prevent tumour formation but they do not 
prevent infection or transmission.  
 
The Iltovirus member infectious laryngotracheitis virus (gallid herpesvirus 1, ILTV) 
establishes latency in the central nervous system of chickens (Lee et al., 2010).  
Reactivation of the virus results in a largely fatal upper respiratory disease of the trachea 
involving increased mucus production and haemorrhaging.      
1.3.2 Betaherpesviruses 
Betaherpesviruses have a narrow host range, they reproduce slowly, infected cells 
become enlarged rather than lyse, and they maintain latency in lymphoreticular cells 
(Roizmann et al., 1992).  Beta- and alphaherpesviruses maintain a latent infection in a 
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small range of cell types whereas the lytic stage of their life cycle is able to engage in 
the larger range of cells that they are able to infect (Ackermann, 2006).  There are 4 
genera in this sub-family comprised of 14 species; Cytomegalovirus, Muromegalovirus, 
Roseolovirus, and Proboscivirus (Davison et al., 2009). 
 
The Cytomegalovirus member human cytomegalovirus (human herpesvirus 5, HCMV) 
is transmitted through body fluids and is highly seroprevalent, usually resulting in an 
asymptomatic infection in immunocompetent individuals (Crough et al., 2009).  
Occasionally, primary HCMV infection can lead to the presentation of a syndrome 
similar to that caused by primary infection of the gammaherpesvirus Epstein Barr virus 
(human herpesvirus 4, EBV) infectious mononucleosis.  HCMV biology is still poorly 
understood, but latency is thought to be maintained in cells derived from bone marrow.  
Reactivation of HCMV occurs when these cells differentiate.  The majority of 
pathogenic affects of HCMV are observed in children and the immunocompromised.  
Congenital infection can lead to sickness and death in newborns and neurological 
abnormalities and deafness in children.  In immunocompromised individuals, HCMV 
disease presents as systemic inflammation.      
 
The Muromegalovirus member murine cytomegalovirus (murid herpesvirus 1, MCMV) 
is closely related to and used as an animal model to study HCMV (Wiebusch et al., 
2008).    
 
The Roseolovirus members human herpesvirus 6A and human herpesvirus 6B (HHV-6A 
and HHV-6B) infect the majority of people within the first two years of life (Braun et 
al., 1997).  Replication takes place in CD4+ T cells and latency is established in 
macrophages.  HHV-6A has yet to be associated with any disease but primary infection 
with HHV-6B causes roseola infantum in children.   
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The Proboscivirus member elephant endotheliotropic herpesvirus 1 (EEHV-1) mostly 
infects juvenile Asian elephants in zoos, circuses, or sanctuaries and causes systemic 
haemorrhaging which is usually fatal (Latimer et al., 2011).    
1.3.3 Gammaherpesviruses 
Gammaherpesviruses are limited to the family or order of their natural host and they 
tend to be specific for either B or T lymphocytes (Roizmann et al., 1992).  Replication 
can take place in lymphoblastoid, epithelioid and fibroblastic cell lines and latency in 
lymphoid tissue.  Differing from the other two sub-families, gammaherpesviruses 
preferentially maintain a latent infection once cells have been infected (Ackermann, 
2006).  There are 4 genera in this sub-family comprised of 34 species; 
Lymphocryptovirus, Rhadinovirus, Macavirus, and Percavirus (Davison et al., 2009). 
 
The Lymphocryptovirus member EBV was first discovered in 1964 in a lymphoblastoid 
cell line derived from a Burkitt’s lymphoma (B cell lymphoma) (Epstein et al., 1964).  
The virus is shed from epithelial cells of the tonsils and transmitted through saliva and 
found in the majority of people worldwide (Ascherio et al., 2010).  Transmission during 
childhood does not result in the development of any clinical symptoms, whereas 
infection in adolescence and adulthood usually results in the development of infectious 
mononucleosis, a lymphoproliferative disease lasting a few weeks.  The virus initially 
infects epithelial cells of the oropharynx for replication and then targets naïve B cells to 
establish latency.  EBV expresses a number of viral genes that initiate the maturation of 
the cells to memory B cells in which EBV establishes latency without the risk of 
activating the host’s immune response.  Occasionally, infection by EBV can lead to the 
development of various malignancies; immunocompromised individuals can develop 
post-transplantation lymphoproliferative disorder, lymphomas, oral hairy leukoplakia, 
leiomyosarcomas, and X-linked lymphoproliferative disorder.  Immunocompetent 
individuals can develop Burkitt’s lymphoma in sub-Saharan Africa, nasopharyngeal 
carcinoma in northern Africa, southeast Asia, and among Inuits, and Hodgkin lymphoma 
in western countries. 
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The Rhadinovirus member human herpesvirus 8 (HHV-8, Kaposi’s sarcoma-associated 
herpesvirus [KSHV]) was identified in 1994 in AIDS patients who had developed 
Kaposi’s sarcoma (Chang et al., 1994); although the standard name for this virus is 
HHV-8, for the remainder of this thesis it will be referred to as KSHV so as to 
complement the microRNA nomenclature.  Kaposi’s sarcoma is caused by latent KSHV-
infected endothelial spindle cells (Ganem, 1997).  KSHV is primarily found in sub-
Saharan Africa and the Mediterranean (Uldrick et al., 2011).  KSHV virions may be 
produced by pharyngeal lymphoid or epithelial tissue or salivary glands and is 
transmitted by saliva; latency is established in B cells.  Additional malignancies caused 
by KSHV include B cell lymphomas (such as primary effusion lymphoma), multiple 
myeloma and multicentric Castleman’s disease. 
 
The Macavirus members AlHV-1 and OvHV-2 cause the disease MCF in cloven-hoofed 
animals (described in section 1.1) and will be discussed in further detail below (Russell 
et al., 2009).  
 
The Percavirus member equid herpesvirus 2 (EHV-2) is transmitted through the 
respiratory tract of horses and establishes latency in B cells (Brault et al., 2011).  EHV-2 
is thought to be the cause of respiratory disease, pharyngeal lymphoid hyperplasia, 
enlarged lymph nodes, inflammation of the eyes and skin, and abortion. 
1.3.4 MCF Viruses 
MCF can be caused by a number of gammaherpesviruses including hippotragine 
herpesvirus 1 (naturally infects roan antelopes) caprine herpesvirus 2 (naturally infects 
goats) an unidentified herpesvirus found to cause disease in white-tailed deer, and the 
most well known; AlHV-1 and OvHV-2 (Russell et al., 2009).  Alcelaphids (wildebeest, 
hartebeest, and bonteboks) are the natural host of AlHV-1 and act as a reservoir for the 
virus.  Genome analysis of AlHV-1 and OvHV-2 show a high degree of sequence 
identity (62%) extending even to the majority of unique ORFs.      
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Caprids (sheep and goats) are the natural host of OvHV-2 (C genome, 135135 bp).  
Bovids (cattle, bison, and water buffalo) cervids (deer and moose) and suids (pigs) are 
prone to the lymphoproliferative disease MCF.  OvHV-2 DNA was first detected in 
susceptible host species in 1991 and in sheep in 1993 (Baxter et al., 1993, Bridgen et al., 
1991).  The virus initially infects and replicates in type II alveolar epithelial cells before 
targeting lymphocytes for latency (Baxter et al., 1997, Taus et al., 2010).  Though the 
details of cell entry have yet to be ascertained for OvHV-2, homologues in other 
herpesviruses have been characterized (will be discussed in section 1.4) so it is assumed 
that a similar mechanism is used (Table 1.2).  Latency in susceptible species is 
established in a subset of T cells, while in sheep B cells are also latently infected (Baxter 
et al., 1997, Taus et al., 2010).  The T cells infected are CD2+ peripheral blood 
mononuclear cells that are cytotoxic, with long-term latency in the CD8+ subpopulation 
(Table 1.1) (Burrells et al., 1991, Kaufmann, 1996, Meier-Trummer et al., 2010, Thonur 
et al., 2006).  It is these long-term latently-infected cells that have been hypothesized to 
cause MCF (Ellis et al., 1992, Meier-Trummer et al., 2009, Simon et al., 2003).  Lytic 
replication from reactivated virus is initiated by orf50, orf57 and (putatively) ov6 and 
takes place in epithelial turbinate cells for shedding into the environment (Ackermann, 
2006, Cunha et al., 2008).  These cells undergo a single cycle of viral replication and 
released virions are unable to infect neighbouring epithelial cells (Li et al., 2004). 
 
Table 1.1: T cell populations targeted by OvHV-2 in susceptible species. 
 
T cell Receptor T cell Subset Role Infectious 
α/β CD4-/CD8+/CD2+/T19- Cytotoxic/ Suppressor No 
α/β CD4+/CD8-/CD2+/T19- Helper/Inducer No 
γ/δ CD4-/CD8+/CD2+/T19+ Cytotoxic/Inducer Yes 
 
1.3.5 Transmission of AlHV-1 and OvHV-2 Infection 
Though episodes of MCF have been observed to coincide with lambing (Collery et al., 
1996) no evidence for an increase in viral shedding from dams has been found (Li et al., 
Chapter One                                                                                                      Introduction 
 16 
2004).  Even so, it is thought that the stress of parturition in wildebeest cows and dams 
reactivates AlHV-1 and OvHV-2, respectively, and allows spread to the new generation.  
During primary infection of wildebeest calves and lambs, the viruses replicate in the 
respiratory tract (to a much higher degree than in adult animals) and are spread 
horizontally through tears and nasal secretions (Hüssy et al., 2002, Li et al., 2008, 2004, 
Russell et al., 2009).  In wild pigs, incidents of venereal transmission have also been 
observed; boars have been found to be asymptomatic carriers that can transmit OvHV-2 
to sows via virus-containing semen - the sows then go on to develop MCF (Costa et al., 
2010).               
 
Lambs seroconvert to OvHV-2-positive around 3 months of age and produce a peak of 
cell-free virus in nasal secretions around 8 months to maintain the viral reservoir (Li et 
al., 2004, 1999, 1998).  Direct nose-nose contact is not necessary for transmission as 
outbreaks of MCF have been observed in susceptible species that have had varying 
contact with sheep (Moore et al., 2010).  Transmission of OvHV-2 has been observed 
over a distance of at least 5 km between lambs and bison without having workers in 
common between the feedlots and the lambs being downwind of the bison (Li et al., 
2008).  It may be that birds act as a vector by landing in the feed of both lots and pick up 
and transfer virus-containing secretions with their feet.  Susceptible species are dead-end 
hosts and cannot transmit OvHV-2 to other animals (Muller-Doblies et al., 2001); this is 
due to the cell-association of the virus they shed in comparison to the cell-free virus shed 
by sheep (Kim et al., 2003, Metzler, 1991). 
1.3.6 Immunization 
Treatment is difficult as death can occur within a couple days of the appearance of 
clinical symptoms.  AlHV-1 (unlike OvHV-2 due to a lack of a permissive cell culture 
system) can be produced in a cell-free virulent and cell-free attenuated form; which is 
currently being exploited in hopes of finding a vaccine (Russell et al., 2009).  Thus far 
however, exposure to attenuated AlHV-1 does not provide any protection against natural 
or experimental challenges.  Any immunity observed in cattle has been short-lived and is 
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not associated with serum neutralizing antibody.  Antibodies that recognize AlHV-1 
antigens have been found to cross-react with those produced by OvHV-2, so 
theoretically a vaccine found for AlHV-1 could be effective for OvHV-2.  Though 
sporadic, MCF is an economical issue for purveyors of American bison and Indonesian 
Bali cattle as they are extremely susceptible.  For those locals that cannot keep sheep 
and susceptible species separate, OvHV-2-free sheep can be raised by separating 2 
month old lambs from the OvHV-2-hosting herd (Hüssy et al., 2001, Li et al., 1999, 
1998). 
1.3.7 Large Granular Lymphocyte Cell Lines 
Immortalized single-cell, LGL cell lines containing OvHV-2 DNA can be established 
from the lymph nodes of OvHV-2-infected cattle; e.g. BJ971, BJ1004, BJ1035, BJ1044, 
and BJ1104 (Russell et al., 2009, Schock et al., 1998).  These cell lines are unresponsive 
to concanavalin A (ConA) stimulation unlike uninfected T cells, and contain a mixed 
population of latent and lytic virus.  BJ1004, BJ1035, and BJ1104 are made up of 
CD4+/CD8- T cells, BJ971 cells are CD4-/CD8+ T cells, and BJ1044 is a mixed 
population of CD4+/CD8+ cells.  All five cell lines are CD2+/CD5+ and produce IFNγ, 
TNFα, and IL-10, and all but BJ1044 express IL-4.    
1.4 HERPESVIRUS LIFE CYCLE 
Given the conservation of the proteins involved in cell entry, replication, and egress 
between herpesviruses, research on one can suggest similar mechanisms in others.  
Therefore, the life cycle of herpesviruses will be described based on research on a 
number of viruses; where possible, proteins will be gammaherpesvirus specific because 
the mechanism is likely to be more accurate in regards to OvHV-2.       
 
During initial infection, herpesviruses make cell contact using a glycoprotein to bind to a 
cell receptor.  EBV uses gp350/220 to bind to CD21/CR2 (Carel et al., 1990).  Once this 
contact is made, a complex made up of three other glycoproteins interacts with another 
specific receptor based on cell type; EBV gp25 (gL) gp42 and gp85 (gH) interact with 
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cellular human leukocyte antigen class II (HLA II) on B lymphocytes and a glycoprotein 
complex without gp42 is used when initiating entry into epithelial cells (epithelial cells 
lack HLA II) (Borza et al., 2002, Li et al., 1997, 1995, Molesworth et al., 2000, Wang et 
al., 1998, 1998).  To initiate membrane fusion, a glycoprotein complex containing gB, 
gL and gH is necessary (Haddad et al., 1989, Miller et al., 1988).  gB is a class III fusion 
protein which plays a role in attachment to target cells, fusion of the envelope with the 
cell membrane and viral maturation (Backovic et al., 2011).  When endocytosed, a 
lysosome-independent decrease of pH within the formed vacuole causes a modest 
conformational change in gB that leads to the fusion of the two membranes and 
deenvelopment of the virion, releasing the nucleocapsid and tegument into the 
cytoplasm (Stampher et al., 2010). 
 
For HSV-1, upon entry into the cytoplasm, phosphorylation by a tegument protein 
(uL13) disassociates the outer tegument from the inner tegument and nucleocapsid 
(Kelly et al., 2009).  Tegument proteins uL36 and uL37 remain associated with the capsid 
for transport to the nucleus while uL11 and uL14 remain in the cytoplasm.  Although no 
interaction has yet been found, it is thought likely that transport along microtubules to 
the nucleus is mediated by the interaction of uL36 and uL37 with cellular dynein.  uL36 
directs the capsid to the nucleus and interacts with the nuclear pore to aid the insertion of 
the viral genome into the nucleus.  In HSV-1, uL14 directs an alphaherpesvirus-specific 
tegument protein to the nucleus which initiates transcription of the viral genome.  It is 
reasonable to assume that the conserved uL14 has a similar role with a 
gammaherpesvirus-specific tegument protein that has yet to be characterized.  Once in 
the nucleus, the genome circularizes and the virus initiates lytic replication and virion 
production or establishes latency whereby the viral episome becomes associated with 
cellular histones.   
1.4.1 Lytic Replication 
Hepesviruses can replicate upon infection of a host cell or reactivate from latency and 
undergo replication during times of stress, immunosuppression, and inflammation 
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(Crough et al., 2009).  During reactivation the viral nucleosomes (1.1.2) become 
unstable and less dense, allowing access to previously blocked ORFs for transcription 
(Nevels et al., 2011).  Herpesvirus replication is achieved through three waves of viral 
ORF expression; immediate-early (peak 2-4 hrs post-infection) early (peak 5-7 hrs post-
infection) and late (peak 7-15 hrs post-infection) (Alwine et al., 1974, Boehmer et al., 
1997).  EBV BGLF3.5 (functional homologue to HSV-1 uL14) catalyzes the 
transcription of the immediate-early ORFs (BRLF1, BSLF2/BMLF1, and a species 
specific gene) which once translated, initiate the transcription of the early ORFs that 
replicate the viral episome (Ackermann, 2006).  The immediate-early ORFs initiate the 
transcription of early genes including the virally encoded DNA polymerase (OvHV-2 
ORF9) ssDNA-binding protein (OvHV-2 Ov4.5) DNA helicase-primase (made up of 
OvHV-2 ORF40, ORF44 and ORF56) an origin-binding protein (as yet undefined in 
OvHV-2) and enzymes associated with nucleotide metabolism (Boehmer et al., 1997).   
 
Initially, the episome undergoes origin-dependent theta replication, but then switches 
(by an as yet unknown mechanism) to sigma/rolling-circle replication (RC) (Boehmer et 
al., 1997).  Theta replication describes the denaturing of the dsDNA of the episome at 
the origin of replication allowing binding of an RNA primer which facilitates coupled-
DNA synthesis of the leading and lagging strands (del Solar et al., 1998).  RC 
replication involves uncoupled-DNA synthesis whereby the leading strand is replicated 
before the lagging strand resulting in an intermediate state where the parental plus strand 
is single-stranded and the parental minus strand is double-stranded with the newly 
synthesized plus strand.  The whole mechanism results in concatamers of the genome 
which are fed into the capsid and cleaved at the terminus of one unit length.            
 
Genome replication initiates transcription of the late ORFs which encode for the 
structural proteins that make up the capsid in which the newly produced genome will be 
packaged.  Once translated in response to viral DNA replication, the late structural 
capsid proteins (EBV BdRF1 complexed with BcLF1, BFRF3 (HSV-1 uL35) and 
BVRF2 and BORF1 complexed with BDLF1,) are shuttled to the nucleus (Henson et al., 
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2009).  BdRF1 acts as a scaffold on which BcLF1, BFRF3, BORF1 and BDLF1 form a 
spherical procapsid.  This structure interacts with the DNA packaging complex and 
BVRF2 cleaves the BdRF1 scaffolding as the newly replicated viral DNA is packed 
inside, resulting in the formation of a mature icosahedral nucleocapsid.  DNA packaging 
and capsid maturation are ATP-dependent, in part to disassociate the viral DNA from 
the cellular histones (Dasgupta et al., 1999, Paulus et al., 2010). 
 
Once the nucleocapsid is formed, it exits the nucleus by budding through the nuclear 
membrane (becoming enveloped at the inner nuclear membrane and deenveloped at the 
outer nuclear membrane) and enters the cytoplasm for association with tegument 
proteins, reenvelopment by the Golgi, and release into the extracellular space by 
exocytosis (Kelly et al., 2009).  For HSV-1, the nucleocapsid is docked to the inner 
nuclear surface by uL31 and uL34 and enters the perinuclear space upon destabilization 
of the nuclear surface by uL13.  Once in the cytoplasm, the nucleocapsid is transported 
to the Golgi where it becomes associated with uL36 and uL37 which form the first layer 
of the tegument.  The outer tegument layer, made up of uL11, uL16, and uL21, is 
necessary for reenvelopment (Johnson et al., 2011).   
 
EBV gB and gH facilitate deenvelopment of the nucleocapsid at the outer nuclear 
membrane and release into the cytoplasm and BcLF1 facilitates the association of the 
nucleocapsid with the inner tegument proteins (Kelly et al., 2009).  Reenvelopment of 
the nucleocapsid and tegument at the Golgi is facilitated by gB (Johnson et al., 2011).  
The glycoprotein BKRF4 interacts with cellular kenesin-2 to transport the completed 
virion to the cell surface for exocytosis (Kelly et al., 2009). 
1.4.2 Herpesvirus Latency 
During latency, the viral nucleosomes increase in density and stability (similar to the 
host cell’s chromatin) allowing transcription of only a minority of ORFs (Nevels et al., 
2011, Paulus et al., 2010).  ORF expression during latency is not conserved among 
herpesviruses; some express numerous ORFs whereas others may not express any 
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(Ackermann, 2006).  Latency in gammaherpesviruses is maintained in part by 
homologues of EBV EBNA-1/KSHV LANA.  This protein interacts with both viral and 
cellular proteins to achieve viral quiescence; it shuts down viral ORF expression by 
blocking expression of BRLF1/orf50 (1.3.1) aids in the replication and successful 
migration of the viral episome during cell mitosis by tethering the copies to the host’s 
chromosomes, as well as blocking ubiquitin-dependent degradation to avoid immune 
detection (Cotter et al., 1999, Garber et al., 2002, Hu et al., 2002, Leight et al., 2000).  
To achieve this, LANA disrupts a number of cellular pathways including those that 
suppress tumour formation and transformation (Dittmer et al., 1998, Field et al., 2003, 
McCormick et al., 2005, Rosbottom, et al., 2002, Szekely et al., 1998, Verma et al., 
2007, Zhong et al., 1996). 
 
For EBV, latency is initially established in primary B cells where numerous latency-
associated genes (EBNAs, LMPs, EBERs, and BARTs) are expressed from the Cp and 
Wp promoters (Ackermann, 2006, Babcock et al., 2000).  These viral genes transform 
the B cells causing proliferation and protection from apoptosis (Ackermann, 2006).  
Long-term latency (expressed from the Qp promoter) is established in resting memory B 
cells in the blood where only viral LMP2A is expressed (Babcock et al., 1999) or the 
same B cell subset in lymph nodes where EBNA-1, LMP1, LMP2A, and LMP2B are 
expressed (Babcock et al., 2000).  These more restricted latency states are the ones 
found in EBV-associated tumours (1.2.3). 
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Table 1.2: Described herpesvirus ORFs and their OvHV-2 homologs. 
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1.5 MICRORNAS 
MicroRNAs (miRNAs) are a class of small (18-30 nt) RNA molecules that regulate gene 
expression post-transcriptionally (Olsen et al., 1999).  The first miRNA was discovered 
in Caenorhabditis elegans in 1993 (Lee et al., 1993).  It was 22 nt long, expressed by the 
lin-4 gene, and was found to downregulate the expression of the protein product of lin-
14 by targeting seven complementary sites in the 3’UTR of the lin-14 mRNA 
(Wightman et al., 1993, 1991).  In 2000, orthologs of a second miRNA found in C. 
elegans (expressed by the let-7 gene) were found in other species, which began an 
explosion of miRNA discovery in different organisms (Lagos-Quintana et al., 2001, Lau 
et al., 2001, Lee et al., 2001, Pasquinelli et al., 2000).  As of April 2011, miRNAs have 
been found in water/slime moulds, animals, green plants, and viruses (miRBase, Release 
16; http://www.mirbase.org/index.shtml).  miRNAs can be highly conserved among the 
various groups with the exception of viruses possibly due to their accelerated response to 
natural selection. 
1.5.1 miRNA Biogenesis 
miRNAs are derived from longer RNA polymerase II and III primary transcripts (pri-
miRNA) which range in size from hundreds to thousands of nt in length (Aparicio et al., 
2006, Lagos-Quintana et al., 2001, Pfeffer et al, 2005).  A distinguishing secondary 
structure of a pri-miRNA is an imperfectly duplexed, stem-loop (which includes the 
mature miRNA in one arm of the stem) flanked by single-stranded, unstructured RNA 
(Meister et al., 2004, Zeng et al., 2005).  A pri-miRNA may contain a single miRNA or 
a cluster of distinct miRNAs within the arms of multiple stem-loops (Cai et al., 2004,  
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Figure 1.4: Schematic of miRNA biogenesis. 
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Lagos-Quintana et al., 2001).  The unstructured flanking regions and stem-loop structure 
are recognized by a heterodimer made up of an RNase III enzyme (Drosha) and its 
cofactor (DGCR8).  DGCR8 binds to the flanking regions which allows Drosha to 
cleave the pri-miRNA, leaving a 60-110 nt hairpin with a characteristic 5’ phosphate and 
a 3’ 2 nt overhang that defines one edge of the mature miRNA (Figure 1.4) (Basyuk et 
al., 2003, Han, et al., 2006, Hutvágner et al., 2001, Lee et al., 2003).  Once released 
from Drosha, this pre-miRNA is taken up by another heterodimer made up of Exportin 5 
(Exp-5) and a GTP-bound form of its cofactor (Ran) which recognizes the pre-miRNA 
based on the 3’ 2 nt overhang and adjacent stem (Lund et al., 2004, Yi et al., 2003).  
Once bound, the pre-miRNA is transported from the nucleus and into the cytoplasm. 
 
Hydrolysis of the GTP-bound Ran releases the pre-miRNA into the cytoplasm where it 
is bound by a heterodimer of another RNase III enzyme (Dicer) and its cofactor (TRBP) 
(Grishok et al., 2001, Hutvágner et al., 2001, Ketting et al., 2001) which also recognizes 
the 3’ 2 nt overhang through the RNA binding domain, PAZ (piwi-argonaute-zwille) 
(Cerutti et al., 2000).  Once bound, Dicer cleaves the terminal loop from the hairpin 
structure, leaving another 5’ phosphate and a 3’ 2 nt overhang.  What is left is an 18-30 
nt duplex that makes up the second intermediary structure.  
 
The duplex is quite short-lived as Dicer passes it directly to a protein complex which 
will use the miRNA as a guide to target mRNA transcripts; RISC (RNA-induced 
silencing complex)/miRNP (miRNA ribonucleoprotein) (Hammond et al., 2000, 
Hutvágner et al., 2002, Mourelatos et al., 2002).  The components that make up RISC 
have yet to be completely defined but it is known to include an Argonaute (Ago, 
eIF2C2) protein which interacts directly with the miRNA duplex (Liu et al., 2004, 
Maniataki et al., 2005).  Different organisms have different numbers of Ago proteins but 
all Ago proteins contain two distinct domains; PAZ and PIWI (Cerutti et al., 2000, 
Meister et al., 2004).  The specific recognition of PAZ for the unique 2 nt terminal 
overhangs of miRNAs reduces the chance of incorporating a non-miRNA into RISC and 
PIWI closely resembles members of the RNase H family and is thought to interact with 
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Dicer and cleave the target RNAs (Lingel et al., 2003, Song et al., 2004, 2003, Yan et 
al., 2003, Tahbaz et al., 2004).  It is unknown how the incorporation of different Ago 
proteins into RISC is regulated but it is known that Ago-1-4 all associate with miRNAs 
(Liu et al., 2004).     
 
RISC is only functional when it contains a single strand of RNA so the final step in 
miRNA processing, is to unwind the two RNA strands that make up the miRNA duplex, 
keeping one as the mature miRNA, and releasing the other strand (miRNA*) for 
degradation or to act as another miRNA incorporated in another RISC (Hutvágner et al., 
2002, Okamura et al., 2008).  The nucleotide sequence of the RNA strands that make up 
the miRNA duplex contribute to the bias of one strand remaining with RISC over the 
other; the strand whose 5’ end is less tightly based paired is more energetically favoured 
to unwind and become incorporated into the multi-protein complex by Ago (Khvorova 
et al., 2003, Schwarz et al., 2003).  ATP is required to initiate the unwinding of the 
miRNA duplex and it is thought that this may be accomplished by DEAD-box RNA 
helicases (Meister, 2004).  Once integrated into RISC, the miRNA is used to guide the 
complex to target RNAs that contain sites of complementarity to the miRNA. 
1.5.2 miRNA Functions 
miRNA target sites can be found throughout mRNA transcripts (5’UTR, coding region 
and 3’UTR) and binding of RISC leads to translation inhibition (spatial interference of 
the translation machinery) or mRNA cleavage and degradation (Grey et al., 2010, Lin et 
al., 2011, Muylkens et al., 2010, Tang et al., 2009, Tay et al., 2008, Yekta et al., 2004).  
It may be that the expression patterns of the Ago proteins affect the degree to which the 
RNA silencing processes work; Ago-1 is associated with translational inhibition and 
Ago-2 is associated with transcript cleavage (Rossi, 2005).  The mechanism of inhibition 
is thought to be linked to the degree of complementarity of the miRNA to the target site; 
in general, perfect complementarity results in cleavage whereas imperfect 
complementarity results in impaired translation (Zeng et al., 2003).  Though cleavage 
appears to require only one RISC complex, translational inhibition appears to require the 
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targeting of multiple sites (Doench et al, 2003).  Out of the ~22 nt that make up a 
miRNA, nucleotides 2-8 from the 5’ end make up the  “seed region” which is 
particularly important for target recognition (Doench et al., 2004, Gottwein et al., 2007, 
Jackson et al., 2003, Lai, 2002, Lewis et al., 2003).  More than a complementary seed 
region is required for target recognition, but those mechanisms are presently still 
unknown; length variation at the 3’ end of a miRNA does not appear to affect mRNA 
targeting.  Once a target transcript is bound by RISC, the complex localizes to the 
cytoplasmic P-bodies for inhibition or degradation (Liu et al., 2005).  The cleavage site 
of the target RNA is in the middle of the complementarity region (10 nt upstream of the 
nucleotide paired up with the 5’ end of the miRNA) by hydrolysis of the target RNAs 
phosphodiester linkage, which yields a 5’ phosphate and a 3’ hydroxyl termini (Elbashir 
et al., 2001).  This reaction requires magnesium ions but does not require ATP, though 
the presence of the energy-storing nucleotide causes the reaction to be more efficient 
(Hutvágner et al., 2002, Nykanen et al., 2001).  This change in efficiency may be due to 
the presence of an RNA helicase, which might aid in the removal of target RNA 
products from RISC or reorganize the multi-protein complex so that it may bind to 
another target (Meister et al., 2004). 
 
miRNAs regulate a large number of cellular processes by targeting mRNA transcripts of 
proteins with roles involved in transcription activation, embryonic development, tissue 
morphogenesis and differentiation, cell migration, angiogenesis, the cell-cycle, 
metabolism, apoptosis, tumour suppressors/oncogenes and host-virus interactions (Chen 
et al., 2004, Chen et al., 2011, Fish et al., 2008, Johnston et al., 2003, Otsubo et al., 
2011, Petrocca et al., 2008, Reinhart et al., 2000, Tay et al., 2008, Wang et al., 2008, 
Xu, et al., 2009, Xu et al., 2003, Zheng et al., 2011).   
 
A detailed discussion of the functions of all miRNAs is outside the scope of this thesis.  
I will however describe a few examples to illustrate the range of processes regulated by 
miRNAs.  The presence of the C. elegans miRNA lsy-6 on the left side of the body 
during embryonic development leads to the right/left asymmetry observed in the 
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bilateral taste receptor neurons (Johnston et al., 2003).  C. elegans let-7 is a temporal-
regulating miRNA that controls the expression of a number of genes (lin-14, lin-28, lin-
41, lin-42, and daf-12) so that each is present at the correct level for the given stage of 
development (Reinhart et al., 2000).  Under- or overexpression of let-7 leads to a repeat 
of larval cell fates in the adult stage or adult cell fates in the larval stage, respectively.  
Drosophila miR-14 suppresses Reaper-dependent cell death and is necessary for fat 
metabolism (triacylglycerol and diacylgylcerol) (Xu et al., 2003). 
 
The vertebrate miR-181 is necessary for the B cell lineage of cells to differentiate from 
hematopoietic cells in the bone marrow (Chen et al., 2004).  miR-134, miR-145, miR-
296 and miR-470 target transcription factors (Nanog, Oct4, KLF4 and SOX2) to push 
cellular differentiation and morphological changes in embryonic stem cells (Tay et al., 
2008, Xu, et al., 2009).  miR-92a targets CDH1 and leads to metastasis of cancerous 
oesophageal squamous cells (Chen et al., 2011).  miR-126 targets negative regulators of 
the VEGF pathway throughout an organisms life which supports vascular expansion and 
integrity of the vessels (Fish et al., 2008, Wang et al., 2008).  Additionally, miR-126 
also targets SOX2 which leads to an increase in PLAC1 - this can lead to the 
development of gastric carcinoma (Otsubo et al., 2011).  Other miRNAs have been 
found to be associated with gastric cancer; in a negative feedback-loop, E2F1 activates 
the expression of the miR-106b-25 cluster which then downregulates E2F1 (a 
transcription factor that controls the cell cycle and tumour suppressor proteins) and 
suppresses the TGFβ tumour suppressor pathway (GeneCards®, Petrocca et al., 2008).  
Human miR-101 targets cellular ATP5B resulting in the inhibition of HSV-1 replication 
(Zheng et al., 2011).  A single miRNA species could target hundreds of different 
proteins and in combination with others could target thousands (Bartel et al., 2004, 
Doench et al., 2004) - miRNA clusters tend to be functionally associated (Kim et al., 
2009).   
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1.5.3 Viruses and miRNAs 
The first virus-encoded miRNAs were from EBV (Pfeffer et al., 2004).  Given that pri-
miRNA processing occurs in the cell nucleus, only those viruses that replicate and 
express their genomes in the nucleus can express miRNAs without running the risk of 
having their genomes destroyed by Drosha processing (Grundhoff et al., 2011, Cullen, 
2006).  This excludes most RNA viruses and the DNA virus group, poxviruses, as they 
replicate in the cytoplasm.  It is also less likely that a virus would express miRNAs if it 
undergoes rapid replication cycles as miRNAs are only able to regulate those genes that 
are expressed post-infection.  As has been observed, the most likely viruses to express 
miRNAs are nuclear DNA viruses that set up persistent latent infections; as such viral 
miRNAs have been discovered in polyomaviruses (BK, JC, merkel cell and simian virus 
40) viruses similar to polyomaviruses and papillomaviruses (bandicoot papillomatosis 
carcinomatosis virus type 1 and 2) and the majority in herpesviruses (Cai et al., 2006, 
Cui et al., 2006, Jurak et al., 2010, Pfeffer et al, 2005, 2004, Samols et al., 2007). 
 
Though the functions of the majority of herpesvirus-encoded miRNAs remain unknown, 
those that have been described follow the prediction that they would regulate viral and 
host gene expression to maintain persistent infection, support immune evasion and have 
a role in viral pathogenesis (Table 1.3-4).  Viral targets of alpha- and betaherpesvirus 
miRNAs include the transcripts of immediate-early genes to support latency by 
suppressing those factors that would initiate gene expression, DNA replication, and 
virion production as well as those genes that would activate the host’s immune response 
(Grey et al., 2007, Murphy et al., 2008, Muylkens et al., 2010, Stern-Ginossar et al., 
2009, Tang et al., 2009, 2008, Umbach et al., 2008).  Hsv1-miR-H6 targets ICP4, a 
transcription factor that initiates expression of most HSV-1 ORFs during lytic 
replication (Umbach et al., 2008).  Hsv2-miR-H2, -miR-H3, and -miR-H4 target 
ICP34.5, a viral neurovirulence factor, and ICP0, a viral transactivator, to control latency 
and reactivation (Tang et al., 2009).  Mdv1-miR-M4 targets UL28 and UL32 which 
suppresses cleavage and packaging of replicated viral DNA (Muylkens et al., 2010).  
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Hcmv-miR-UL112-1 targets the immediate-early ORFs IE72, UL112/113, and 
UL120/UL121 which leads to suppression of viral DNA replication and suppresses 
UL114 which acts as a uracil DNA glycosylase (Grey et al., 2007, Murphy et al., 2008, 
Stern-Ginossar et al., 2009).     
 
Gammaherpesvirus miRNAs target viral transcripts to support latency, immune evasion, 
those that lead to pathogenic effects in the host by suppressing DNA replication, 
transcription and antigens of cytotoxic T cells, and balancing pro- and anti-apoptotic 
functions (Barth et al., 2008, Bellare et al., 2009, Lo et al., 2007, Lung et al., 2009, 
Pfeffer et al., 2004).  Ebv-miR-BART2 targets the viral DNA polymerase BALF5 and  
kshv-miR-K9* targets ORF50, both of which lead to the suppression of reactivation 
from latency (Barth et al., 2008, Bellare et al., 2009, Pfeffer et al., 2004).  The ebv-miR-
BART miRNAs target the immunogenic LMP1; this supports immune evasion but also 
facilitates the development of nasopharyngeal carcinoma; inhibition of LMP1 decreases 
the sensitivity of nasopharyngeal carcinoma cells to the chemotherapy drug cisplatin (Lo 
et al., 2007, Lung et al., 2009).             
 
The suppression of cellular gene transcripts by herpesvirus miRNAs supports 
persistence and immune evasion, which together can lead to pathogenesis.  Persistence 
has been shown to be supported by targeting factors that control reactivation, cell growth 
and proliferation, cell transformation, and apoptosis.  Kshv-miR-K3 targets NFIB which 
suppresses activation of viral ORF50, reiterating the reactivation suppression observed 
by kshv-miR-K9*, and kshv-miR-K4-5p targets Rbl2 which leads to increased 
methylation of H3 K9 histones decreasing viral ORF expression (Lu et al., 2010, Lu et 
al., 2010).  Kshv-miR-K1 targets p21 which decreases the cell’s ability to initiate cell 
cycle arrest in response to p53 activation (Gottwein et al., 2010).  Hcmv-miR-US25-1 
targets a number of cellular cell cycle genes which leads to G1/S phase arrest (Grey et 
al., 2010).  KSHV miRNAs target MAF and TGFβ which leads to a transition in 
lymphatic endothelial cells to a state closer to blood vessel endothelial cells and 
promotes angiogenesis (Hansen et al., 2010, Samols et al., 2007).  The EBV BHRF1 
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miRNA cluster is associated with B cell transformation due to effects on both viral and 
cellular targets (Feederle et al., 2011).  Suppression of apoptosis by herpesvirus 
miRNAs targeting cellular targets has been observed multiple times; kshv-miR-K5 
targets BCLAF1 (signals apoptosis) kshv-miR-K10a targets TWEAKR (role in caspase 
activation) ebv-miR-BART5 targets PUMA (signals apoptosis) and mdv1-miR-M3 
targets Smad2 (member of the TGFβ pathway that results in apoptosis) (Abend et al., 
2010, Choy et al., 2008, Xu et al., 2011, Ziegelbauer et al., 2009).   
 
Immune evasion can be achieved by suppressing T cell activation by targeting 
chemokines and membrane-bound ligands.  Deletion of two mouse cytomegalovirus 
miRNAs leads to a reduction of virions produced in the salivary glands due to increased 
selectivity by natural killer and CD4+ T cells (Dölken et al., 2010).  Kshv-miR-K3 and -
K7 target LIP which leads to the increased expression of IL-6 and IL-10 by 
macrophages which results in cell growth and immune evasion (Qin et al., 2010).  Ebv-
miR-BHRF1-3 targets CXCL11/I-TAC which decreases the motility of activated T cells 
(Xia et al., 2008).  miRNAs from HCMV, KSHV, and EBV target MICB which leads to 
the evasion of stressed cells from attack by natural killer cells (Nachmani et al., 2009, 
Stern-Ginossar, et al., 2007).  Kshv-miR-K10a targeting of TWEAKR also suppresses a 
proinflammatory response to infection (Abend et al., 2010).  Wide spread cellular 
transcript regulation has also been observed by the targeting of Dicer and mimicking 
cellular miRNAs (Lizasa et al., 2010).  Cellular miR-155 plays a role in lymphocyte 
transformation so orthologs of this miRNA found in alpha- and gammaherpesviruses 
could lead to the observed pathogenic effects (Gottwein et al., 2007, Muylkens et al., 
2010, Skalsky et al., 2007, Zhao et al., 2009). 
 
Thus far, the best studied virus-miRNA interactions have been with MDV-1 and 
although it is an alphaherpesvirus, its life cycle and pathogenesis are similar to that of 
gammaherpesviruses (latency is established in transformed T cells, replication takes 
place in epithelial and B cells, and the virus causes lymphomas) (Burnside et al., 2006).  
A number of mdv1-miRs are located in the region of the genome expressed in latently-
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infected transformed and cancerous cells (including the oncomiR, mdv1-miR-M4) 
showing that herpesvirus miRNAs can be involved in the observed pathologies 
associated with herpesvirus infection (Zhao et al., 2011).          
1.6 PROJECT OUTLINE 
There is no vaccine or treatment for susceptible animals that can and/or succumb to 
MCF via OvHV-2 infection.  At the moment the only preventative measure is keeping 
natural hosts away from unnatural hosts or separating newborn lambs from the rest of 
the herd in the hopes of raising an OvHV-2-free flock.  The study of OvHV-2 continues 
to be held back due to a lack in ability to isolate cell-free virions in culture.  The 
understanding of the route of transmission is still mostly due to observation of host and 
susceptible species and the viral role in the mechanism of the pathogenesis of MCF is 
still unknown.  There must be something in sheep cellular biology that allows for a 
persistent infection that is missing in other Artiodactyla.  As discussed previously, 
persistence requires a fine balance of gene expression and herpesviruses have adapted to 
this challenge by encoding and expressing miRNAs.  miRNAs have been shown to 
regulate numerous cellular pathways and the analysis of their functions provides insight 
to greater cellular mechanisms.  This thesis will identify whether or not OvHV-2 also 
expresses miRNAs.  Next generation high throughput sequencing technology was used 
to identify the small RNA transcripts expressed by OvHV-2 in a cell line derived from 
an MCF-affected cow and secondary structure prediction software was used to identify 
if the sequenced transcripts contained the secondary structures necessary for miRNA 
biogenesis.  MCF describes a syndrome of lymphocyte-activation to unknown antigens 
and OvHV-2 miRNAs could be the answer.  If present, the identification of their targets 
and the characterization of their function could begin to unravel the mystery of MCF.   
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Table 1.3: Viral targets and functions of herpesvirus-encoded miRNAs. 
 
Sub-Family Virus miRNA Target Function 
HSV miR-H2 ICP0 
HSV-1 miR-H6 ICP4 
HSV-2 miR-H3, -H4 ICP34.5 
α 
MDV-1 miR-M4 UL28, UL32 
latency 
 
β hCMV miR-UL112 IE1/IE72/UL123, UL114 latency 
 
BART Cluster 1 LMP1 pathogenesis 
miR-BART2 BALF5 latency EBV 
miR-BART22 LMP2A immune evasion 
γ 
KSHV miR-K5, -K9* RTA/ORF50 latency 
 




Virus miRNA Target Function 
miR-M3 Smad2 anti-apoptotic 
α MDV-1 
miR-M4 




miR-UL112 MICB immune evasion hCMV 
miR-US25-1 cyclin E2 cell cycle arrest β 
mCMV miR-M23-2 CXCL16 immune evasion 
 
miR-BART2 MICB immune evasion 






miR-BHRF1-3 CXCL-11/I-TAC immune evasion 
miR-K1, -K3, -K6, 
-K11 
THBS1, SPP1, PRG1 pathogenesis 






miR-K6, -K11 MAF 
cellular 
differentiation 
miR-K1 p21 pathogenesis 
miR-K3 NFIB latency 
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All buffers, solutions, plasmid maps, and PCR primer sequences and annealing conditions can be 
found in the Appendices. 
2.1 MOLECULAR TECHNIQUES 
2.1.1 Isolation of DNA 
DNA was extracted from eukaryotic cells using the Qiagen DNeasy Kit according to the 
manufacturer’s protocol.  Cells were pelleted at 300 x g for 5 min at room temperature 
and resuspended in sterile phosphate buffer solution (SPBS).  The cells were lysed with 
proteinase K and RNA degraded with RNase A.  The lysate was combined with a 
chaotropic salt buffer to optimize DNA binding to the column membrane and remaining 
impurities were removed with two wash steps.  The DNA was eluted in the provided 
buffer.   
2.1.2 Polymerase Chain Reaction 
Polymerase chain reactions (PCRs) were carried out using either Pfu or Taq.  Pfu was 
the preferred DNA polymerase because of its additional proof reading function.  Due to 
limited supplies, Taq was used in subsequent PCR reactions.   
 
Pfu DNA Polymerase (Promega) was used according to the manufacturer’s protocol; a 
reaction mix containing 1X Pfu DNA Polymerase Buffer with MgSO4, 200 µM dNTP 
(each) 100 ng of both the forward and reverse primer (Eurofins MWG Operon) 1-100 ng 
DNA template, 1-1.5 U Pfu DNA Polymerase, and nuclease-free water for a total 
volume of 50 µl.  The PCR program consisted of 35 cycles of 30 s denaturing at 96°C, 
30 s annealing at a temperature specific to the primers, and 60 s extension at 72°C, with 
a final extension cycle of 4 min at 72°C (PCR Sprint Thermal Cycler, Thermo 
Scientific).     
 
PCRs using Taq DNA Polymerase (Invitrogen) were carried out according to the 
manufacturer’s hot start protocol; 1X PCR Buffer, 1.5 mM MgCl2, 200 µM dNTP (each) 
0.5 µM of both the forward and reverse primer, 1-100 ng DNA template, and nuclease-
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free water for a total volume of 50 µl.  Reactions were heated to 94°C for 3 min and then 
held at 80°C while 1 U Taq was added.  The program was continued with 35 cycles of 
45 s denaturing at 94°C, 45 s annealing at a specific temperature specific to the primers, 
and 60 s extension at 72°C, with a final extension cycle of 5 min at 72°C for 5 min.  
Negative controls contained water instead of DNA template.  Once the PCR product was 
ligated into a cloning vector and amplified, it was sequenced to confirm that the product 
was without mutation.     
2.1.3 Agarose Gel Electrophoresis 
10 µl of PCR product or 1 µg plasmid DNA (made up to 10 µl with nuclease-free water) 
was combined with 3 µl 6X loading dye and separated by agarose (1%) gel 
electrophoresis (0.5 g agarose [Bioline] 50 ml 1X TAE buffer, 0.05 mg ethidium 
bromide [Fisher Scientific]) in 1X TAE, using 60 V for an hour; the DNA migration was 
visualized under UV.  A DNA ladder was used for size reference (1 µl 1 Kb Plus 
Ladder, Invitrogen, 7 µl nuclease-free water and 6X loading dye). 
2.1.4 Concentration of Nucleic Acid by Ethanol Precipitation 
1/10 volume 3 M sodium acetate and 2 vols 70% ethanol was added to the nucleic acid 
sample, gently mixed, and then placed on dry ice for 20 min.  The sample was 
centrifuged at 10,000 x g for 10 min, the supernatant removed, and the sample 
centrifuged again briefly to remove any excess supernatant.  The nucleic acid sample 
was resuspended in nuclease-free water.     
2.1.5 Restriction Digestion of Plasmid DNA 
1X Buffer and 10 U of each restriction enzyme (New England Biolabs) was combined 
with 1 µg plasmid DNA and incubated for 2-3 hrs at 37°C.  The restriction enzymes 
were deactivated by incubating the reaction for ~1 hr at 65°C and then a sample was 
separated by agarose gel electrophoresis using 1% agarose, to confirm the correct 
digestion pattern.     
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2.1.6 DNA Ligation 
Two different DNA ligation methods were used depending on the vector.  plZ3-CIng-ps-
linker and psiCHECK™ were digested and purified and then ligated with the DNA 
inserts in a reaction containing 2 µl 10X Ligation Buffer, vector, insert, 1 µl T4 DNA 
Ligase (NEB) and made to 20 µl with water and incubated at room temperature 
overnight.  Successful ligations resulted from vector insert ratios of 1:1 or 3:1.  When 
using pCR®2.1-TOPO®, the TOPO TA Cloning Kit (Invitrogen) was used according to 
the manufacturer’s protocol.  2 µl purified PCR product, 0.5 µl salt solution (1.2M NaCl, 
0.06M MgCl2) and 0.5 µl TOPO TA vector were combined and incubated at room 
temperature for 5 min (see Appendix 3 for plasmid maps).   
2.1.7 Quantification of Nucleic Acid by Spectrophotometry 
Nucleic acid concentrations and purities were quantified using a NanoDrop ND1000 
Spectrophotometer (Thermo Scientific).  Nucleic acid concentrations were calculated 
using an algorithm based on an absorbance at OD260 of 1 = 50 µg ml
-1 DNA or 40 µg ml-
1 RNA.  Nucleic acid purity was calculated using the ratio of the absorbance at OD260 
and OD280 where pure DNA has an A260/280 = ~1.8 and pure RNA has an A260/280 = ~2.   
2.1.8 DNA Extraction from Agarose Gels 
DNA was purified from 1% agarose gels using the QIAquick Gel Extraction Kit 
according to the manufacturer’s protocol (Qiagen).  The excised gel slice was dissolved 
in a chaotropic salt buffer, treated with isopropanol, and applied to a QIAquick spin 
column.  The bound DNA was washed with an ethanol-containing buffer and then eluted 
with 50 µl of the provided buffer (10 mM Tris-Cl, pH 8.5) or water. 
2.1.9 Purification of PCR Products 
PCR products were purified using a QIAquick PCR Purification Kit (Qiagen) according 
to the manufacturer’s protocol.  A binding buffer was added to the PCR product, which 
was then applied to a spin column and centrifuged at 12000 x g for 30-60 s; primers, free 
nucleotides, and sample impurities passed through the column while the PCR product 
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became bound to the column membrane.  The column was washed using an ethanol-
containing buffer to remove remaining salts and the DNA was eluted with 50 µl of 10 
mM Tris-Cl or water.          
2.1.10 Sequencing of Plasmid DNA 
Plasmid DNA was sequenced using the Big Dye® Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems/Ambion).  200-500 ng in 1 µl of plasmid was added to 8.5 µl of a 
master mix (3.3 µl water, 2 µl 5X Sequencing Buffer, and 3.2 µl forward/reverse primer 
[3.2 pmol]) and 0.5 µl Big Dye.  The samples were denatured at 96°C for 10 s, annealed 
at 50°C for 5 s, and elongated at 60°C for 2 min, for 30 cycles (Veriti 96 Well Thermal 
Cycler, Applied Biosystems/Ambion) and sequenced by The Genepool, University of 
Edinburgh.  Sequences were compared to the published OvHV-2 sequence (GenBank, 
AY839756) using NCBI’s blastn algorithm; (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
2.1.11 Isolation of RNA 
Cells were centrifuged at 500 x g for 10 min at room temperature.  The supernatant was 
removed, the cells resuspended in the remaining medium, and then transferred to a 1.5 
ml microcentrifuge tube on ice.  The cells were centrifuged at 9000 x g for 30 s at room 
temperature and the remaining medium was removed.  1 ml of RNA-Bee (AMS 
Biotechnology) was added to homogenize the cells and degrade endogenous RNases. 
 
200 µl chloroform (Sigma) was added to the lysate, which was then shaken vigorously 
by hand for 15-30 s, placed on ice for 5 min, and centrifuged at 12000 x g for 15 min at 
4°C.  This separated the lysate into aqueous and organic phases; isolating the RNA in 
the aqueous phase from the DNA and proteins in the organic phase.       
 
The RNA-containing aqueous phase was removed to a clean 1.5 ml microcentrifuge tube 
and treated with 500 µl isopropanol to desalt and precipitate the RNA.  The solution was 
incubated at room temperature for 5-10 min and then centrifuged at 12000 x g for 5 min 
at 4°C to pellet the RNA.        
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The supernatant was removed and the RNA pellet was washed with 200 µl 75% (v/v) 
ethanol, made with 0.1% (v/v) diethylpyrocarbonate (DEPC)-treated water (1 ml DEPC 
in 1 L water left overnight at room temperature and then autoclaved to deactivate the 
DEPC).  The sample was vortexed briefly to ensure complete washing, and centrifuged 
at 7500 x g for 5 min at 4°C to re-pellet.  Ethanol was removed and the RNA pellet was 
allowed to air dry for 5-10 min on ice before being re-solubilized in 50 µl 0.1% DEPC-
treated 1X TE Buffer, pH 7 or 0.1% DEPC-treated water.   
2.1.12 Solexa High Throughput Sequencing of Small RNA  
10 µg of total RNA (A260/280 = 2.06) was sent to The Genepool, University of Edinburgh 
for small RNA, paired-end, high throughput sequencing using an Illumina Solexa GAII.  
Although it is now routine for The Genepool to run RNA samples they receive on a 
bioanalyser, the RNA samples sequenced by them in this study (2.1.12-13) were sent in 
2008/2009, prior to this protocol (Marian Thomson, The Genepool, communication; 
Supplemental DVD, The Genepool Communication).  Small RNAs were isolated using a 
FlashPAGE Fractionator (Applied Biosystems/Ambion); total RNA was mixed with an 
equal volume of loading buffer, heated to denature, and then loaded onto the top of a 
precast gel set up in the Fractionator.  The gel was run at 75-80 V for 12 min or until the 
loading dye began to migrate out of the gel into the Lower Buffer Chamber; the Lower 
Running Buffer contained the small RNA fraction (<40 nt).  The small RNA was 
precipitated by sodium acetate and ethanol and stored at -20°C until ready to be used 
(2.1.4).  Adapter linkers were added to the 5’ and 3’ ends of the small RNAs through 
two separate steps involving adaptor ligation and gel purification.  A primer 
complementary to the 3’ adaptor was used for reverse transcription to create a cDNA 
library of the adaptor-linked small RNAs and a primer equivalent to the 5’ adaptor was 
used to amplify the library using PCR.  The library was gel purified and then plated on 
the Illumina Solexa GAII Cluster Station Flow Cell using the 3’ adaptor to bind to the 
surface amplification primer.  The generated reads were mapped to the OvHV-2 genome 
(GenBank, AY839756) using SOAP (Short Oligonucleotide Analysis Package; Li et al., 
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2008).  SOAP is a tool specifically geared towards the alignment of small RNA tags 
sequenced from high throughput methods such as Illumina Solexa GAII.  For this study, 
SOAP was used to align the sequenced tags that were 20-26 nt in length and contained 
no mismatches or gaps to the OvHV-2 genome.   
2.1.13 Solexa High Throughput Sequencing of mRNA 
5 µg total RNA (A260/280 Sample 1 = 2.00, A260/280 Sample 2 = 2.04, A260/280 Sample 3 = 1.97) was 
sent to The Genepool for paired-end, digital expression profiling via Illumina Solexa 
GAII sequencing.  mRNA was isolated using oligo(dT) beads.  A double-stranded 
cDNA library was generated from the bead-bound mRNA and then digested with NlaIII; 
further steps apply only to 3’ cDNA fragments that remained bound to the magnetic 
beads.  A 5’ adaptor containing a MmeI site was ligated to the NlaIII cleavage site and 
then the sample was digested with MmeI, which cleaved downstream of the binding site, 
resulting in a short tag free of the magnetic bead.  A 3’ adaptor was ligated to the site of 
MmeI cleavage and those fragments with adaptors on both ends were amplified by PCR 
using primers complementary to both adaptors and gel purified.  The library was bound 
onto the amplification primers on the flow cell surface via the 3’ adaptor.  The resultant 
tags were mapped to the OvHV-2 genome using the default parameters of MAQ 
(Mapping and Assembly with Quality, http://maq.sourceforge.net) and a mapping quality 
cut off of 30; i.e. the probability of each nucleotide in the alignment being wrong is 
0.001.   
2.2 BACTERIAL TECHNIQUES 
2.2.1 Preparation of LB/Agar, AMP+ Plates 
7.5 g Bacto Agar (BD) was added to 500 ml Luria Bertani (LB) broth (Merck) and 
autoclaved.  Ampicillin (AMP) was added for a final concentration of 100 µg ml-1 and 
then poured into Petri dishes (Sterilin) and allowed to solidify.   
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2.2.2 Transformation of One-Shot Chemically Competent E. coli 
Two different strains of chemically competent E. coli were used for transformations, 
both according to the manufacturer’s protocol.  ~120 ng plasmid DNA was added to a 
50 µl aliquot of XL1-Blue competent cells (Stratagene/Agilent) that had been thawed on 
ice.  The sample was left on ice for 30 min and then heat-shocked at 42°C for 45 s.  500 
µl LB broth was added to the cells and they were placed in a 37°C shaking incubator for 
1hr (225 rpm).  The cells were centrifuged at 1800 x g for 45 s, 400 µl supernatant was 
removed, the cells were resuspended in the remaining broth, plated on LB/AMP (100 µg 
µl-1) plates and incubated at 37°C overnight.   
 
When using TOP10 chemically competent cells (Invitrogen), 10 µl ligation reaction 
(2.1.6) was added to 50 µl cells (that had been allowed to thaw on ice) and left on ice for 
another 5 min.  The sample was heat shocked at 42°C for 30 s and then placed back on 
ice.  250 µl SOC broth was added to the cells before they were placed in a shaking 
incubator at 37°C for 1 hr.  10 µl (plus 20 µl SOC broth) and 50 µl of the cells were 
spread on pre-warmed LB/AMP (100 µg ml-1) plates and incubated at 37°C overnight.                
2.2.3 Harvesting of Bacterial Colonies 
A single bacterial colony was selected using a sterile metal-hoop and deposited in LB 
broth for further growth (2.2.4, 2.2.5). 
2.2.4 Plasmid DNA Isolation from Bacteria (Small Scale) 
Plasmids were extracted from bacteria using the QIAprep Spin Miniprep Kit (Qiagen).  
Colonies were harvested and added to 5 ml LB/AMP (100 µg ml-1) broth, and placed at 
37°C in a shaking incubator for ~16 hrs.  The cells were centrifuged at 600 x g for 5 min 
and resuspended in an RNase A-containing TE buffer (0.1 mg ml-1).  The cells were 
lysed in an alkaline buffer which was neutralized before the lysate was centrifuged at 
9000 x g for 10 min.  The supernatant was applied to a column and centrifuged at top 
speed for 30-60 s and then the membrane-bound DNA was washed with a chaotropic 
salt solution and ethanol before being eluted in water.      
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2.2.5 Plasmid DNA Isolation from Bacteria (Large Scale) 
Plasmid DNA was extracted from a selected clone using the PureLink™ HiPure Plasmid 
Maxiprep Kit according to the manufacturer’s protocol (Invitrogen).  A sample from a 
frozen glycerol stock was streaked on a pre-warmed LB/AMP agar plate and incubated 
at 37°C overnight.  A sterile metal-hoop was used to take a sample of the streak of 
bacterial growth which was then harvested and added to 5 ml LB/AMP and placed in a 
37°C shaking incubator for 8 hrs.  300 µl of starter culture was added to 200 ml 
LB/AMP and incubated at 37°C shaking overnight.  The cells were centrifuged at 4000 x 
g for 10 min, the supernatant removed, and the cells resuspended in TE Buffer 
containing RNase A.  The cells were lysed in an alkaline buffer containing sodium 
dodecyl sulphate (SDS).  The lysate was neutralized and proteins precipitated with the 
addition of potassium acetate buffer.  The entire solution was added to the HiPure Filter 
Maxi Column and allowed to run through the filter by gravity.  The DNA was washed, 
eluted, and then precipitated using the PureLink™ HiPure Precipitator Module 
(Invitrogen).  After precipitation with the addition of isopropanol, the solution was 
passed through a 0.22 µm filter, washed with ethanol, and eluted in 1 ml water.                      
2.2.6 Preparation of Bacterial Stocks for Long Term Storage 
Samples of E. coli cultures containing validated clones (850 µl) were combined with 
glycerol (150 µl, autoclaved for 20 min at 15 psi on the liquid cycle) and stored at -80°C. 
2.3 NORTHERN HYBRIDIZATION 
2.3.1 Antisense RNA Probe Labelling 
Antisense RNA Probes were constructed using the miRVana miRNA Probe 
Construction Kit (Applied Biosystems/Ambion) according to the manufacturer’s 
protocol.  DNA oligonucleotide templates were ordered with the same sequences as the 
putative miRNAs with the following addition to the 3’ end; 5’-TTTTCCTGTCTC-3’; 
and diluted to 100 µM in nuclease-free water (Eurofins MWG Operon) (template 
sequence described in Appendix 2).  What would be four adenine residues on the 3’ end 
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of the RNA probe prevented cleavage by RNases A and T1.  dsDNA was formed by 
treating the DNA templates with a T7 Promoter Primer (complementary to 5’-
CCTGTCTC-3’) and extending with Exo-Klenow DNA polymerase.  The dsDNA 
template was used to transcribe a radiolabelled antisense RNA probe using α-32P UTP, 
800 Ci mmol-1, 10 mCi ml-1 (PerkinElmer).  Following transcription, the dsDNA 
template was removed by DNaseI digestion and free nucleotides were removed by 
column purification (miRVana Probe and Marker Kit [Applied Biosystems/Ambion]).  
2.3.2 RNA Electrophoresis 
20 µg total RNA was suspended in 5 µl 0.1% (v/v) DEPC-treated water and an equal 
volume of 100% deionized formamide (Applied Biosystems/Ambion) to remove 
secondary structure.  6X loading dye was added (0.25% [w/v] bromophenol blue [BDH 
Laboratory Supplies] in 30% [v/v] glycerol [Sigma]) to the RNA before denaturing the 
sample at 95°C for 1-5 min and snap-cooling on ice.  The denatured sample was then 
loaded and run on a 15% denaturing acrylamide/bis (19:1) gel (Applied 
Biosystems/Ambion) containing 7 M urea, 20 mM MOPS-NaOH (pH 7) (0.06% (w/v) 
ammonium persulfate and 0.035% (v/v) tetramethylethylenediamine (TEMED) at 300-
400 V for 2-4 hrs.  Before preparing the samples, the gel was pre-run for 10 min and 
while the samples were snap-cooling on ice, the urea that had accumulated in the wells 
was flushed out with a syringe.         
2.3.3 Transfer of RNA to Nitrocellulose Membrane 
RNA separated by gel electrophoresis was transferred to a Hybond-NX neutral nylon 
membrane (GE Healthcare Life Sciences, Amersham) sandwiched between six sheets of 
3 MM Paper pre-soaked in 0.1% DEPC-treated water, using a semi-dry electroblotter, 
run at 20 V for 20 min.   
 
The RNA-containing membrane was laid on top of a sheet of 3 MM paper (RNA side 
up) saturated with 0.16 M EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) 
hydrochloride in a 0.13 M 1-methylimidazole solution, wrapped in cling film and 
Chapter Two                                                                                       Materials & Methods 
 44 
incubated at 60°C for 1 hr to cross-link the RNA to the nylon membrane.  The 
membrane was rinsed with 0.1% DEPC-treated water to remove residual cross-linking 
solution.    
2.3.4 Probe Hybridization and Detection 
The membrane-bound RNA was hybridized using ULTRAhyb-Oligo solution (Applied 
Biosystems/Ambion) according to the manufacturer’s protocol.  The membrane was 
placed in a hybridization tube and incubated with preheated ULTRAhyb (68°C) before 
10 µl of the prepared antisense probe (2.3.1) was added and the membrane was left to 
incubate overnight in a rotating oven (42°C).  The ULTRAhyb containing the probe was 
removed and the membrane washed twice with 2X SSC, 0.5% SDS for 30 min at 42°C 
to remove any excess probe before being wrapped in cling film, exposed to film (Sigma, 
Kodak BioMax MS-1) and stored at -70°C.    
2.4 TISSUE CULTURE 
2.4.1 Growth of Established Cell Lines 
BJ1035 is an immortalized cell line, derived from the T cells of a cow naturally infected 
with OvHV-2 (Schock et al., 1998).  These cells (a gift from Dr George Russell, 
Moredun Research Institute) were grown in suspension in Iscove’s Modified Dulbecco’s 
Medium (Invitrogen) supplemented with 10% (v/v) foetal calf serum (Sera Laboratories 
International) 1% (v/v) penicillin-streptomycin (Invitrogen) 10,000 U (in 500 ml) 
interleukin 2 (IL-2) (Novartis Pharmaceuticals UK Ltd) and incubated at 37°C, 5% CO2.  
Once many large clumps of these suspension cells were visualized, the cells were 
pipetted up and down to break up the clumps and 2/3 of the volume was transferred to a 
new flask with 1/3 fresh medium. 
 
BHK cells (Stoker et al., 1964) were grown in Glasgow Modified Eagle Medium 
supplemented with 10% (v/v) newborn calf serum (Sera Laboratories International) 10% 
(v/v) tryptose phosphate broth, 1% (v/v) L-glutamine and incubated at 37°C, 5% CO2.  
Once these adherent cells had reached confluence, the medium was poured off and the 
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cells rinsed with 0.02% (w/v) EDTA.  The BHK cells were harvested using 0.05% (w/v) 
trypsin-EDTA which was neutralized by adding 2X amount of medium once the cell 
layer was floating free.  The cells were pelleted by centrifugation at 400 x g for 5 min at 
room temperature, the trypsin/medium was poured off, and the pelleted cells 
resuspended in fresh medium.  A 1:1 mix of the cell suspension and 0.4% trypan blue 
(Sigma) was applied to a haemocytometer and the unstained, live cells were counted.  
5x106 BHK cells were used to seed a new T175 flask (Nunc).       
2.4.2 Preparation of Cell Lines for Long Term Storage 
5x106 cells were suspended in 1 ml freezing medium (90% foetal calf serum, 10% (v/v) 
DMSO) and placed in a cryovial.  The vial was wrapped in cotton and placed in a 
Styrofoam box overnight at -80°C.  The next day the vial was placed in liquid nitrogen 
for long term storage.   
2.4.3 Growing Cell Lines from Frozen Stock 
A cryovial of suspension cells was removed from long term liquid nitrogen storage and 
placed on dry ice until ready to use.  The cells were thawed quickly in a 37°C water bath 
and added to a T25 flask containing 15 ml pre-warmed medium and then left to sit on 
end for 4 hrs in an incubator (37°C, 5% CO2).  10 ml medium was removed carefully in 
order to leave the settled cells undisturbed at the bottom of the flask, and then an 
additional 5 ml pre-warmed medium was added to the flask and the cells returned to the 
incubator. 
 
A cryovial of adherent cells was thawed as above, however the cell suspension was 
added to 20 ml pre-warmed medium, and centrifuged at 400 x g for 5 min and the 
supernatant removed.  Cells were resuspended in 10 ml pre-warmed medium, seeded 
into a T25 flask and placed in an incubator (37°C, 5% CO2). 
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2.4.4 Lipid-Based Transfection of Cell Line with Plasmid DNA 
For a single plasmid transfection, 1x105 cells in 500 µl normal growing medium per well 
were plated in a 24-well plate (with coverslips [SLS, 0.13 mm diameter]) and left to 
grow overnight at 37°C, 5% CO2.  In separate microcentrifuge tubes, 0.5 µg plasmid 
DNA and 4 µl Lipofectamine 2000 (Invitrogen) were diluted in 50 µl Opti-MEM® 
medium (Invitrogen) and incubated at room temperature for 5 min.  The plasmid DNA 
and Lipofectamine 2000 were combined and incubated at room temperature for a further 
20 min before 100 µl was added to each well containing 24 hr-grown cells.  The plate 
was rocked back and forth to mix and incubated at 37°C, 5% CO2 for a further 48 hrs. 
 
For co-transfection with miRNA mimics (miScript miRNA Mimics, Qiagen) 6x104 cells 
in 500 µl medium per well were prepared and placed in an incubator (37°C, 5% CO2) 
while the transfection reaction was prepared (see Appendix 2 for mimic sequences).  400 
ng plasmid DNA, varying titrations of the miRNA mimics (5 nM, 25 nM, 50 nM) and up 
to 60 µl Opti-MEM® medium were combined with 3 µl Lipofectamine 2000 and plated 
concurrently with the cells and incubated at 37°C, 5% CO2 for 24 hrs.           
2.4.5 Isolation of Ovine White Buffy Coat 
50 ml peripheral blood was obtained by jugular venous puncture with 5 U heparin per ml 
as an anti-coagulant. Ten ml aliquots were centrifuged at 2000 x g for 15 min, buffy coat 
was carefully removed and washed with PBS.     
2.4.6 Immunocytochemical Staining of Transfected Cells  
Medium was removed from plated adherent cells, washed twice with sterile PBS (SPBS) 
and fixed with 500 µl 4% (w/v) paraformaldehyde per well at room temperature for 30 
min.  The cells were washed twice with SPBS, leaving the second wash on the cells 
during storage at 4°C. 
 
Fixed cells were permeabilized with 0.3% (v/v) Triton-X100 (Sigma) in SPBS for 20 
min and then washed for 5 min, repeated three times with SPBS.  The cells were treated 
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with Cas-block (Invitrogen) for 30 min to prevent non-specific binding of antibodies and 
then treated with monoclonal murine anti-FLAG [Sigma, 1:1000]) for 90 min.  Cells 
were washed 3 times in SPBS for 12.5 min before incubation with biotinylated rabbit 
anti-mouse [Dako; 1:500] for 60 min.  To-pro3 [Invitrogen; 1:1000] and RNase A 
[Qiagen; 10 µg ml-1]) were also added for nuclear staining and RNA-degradation.  Cells 
were washed 3 times with SPBS for 12.5 min and incubated with streptavidin 
conjugated dye Alexa Fluor 546 (Invitrogen; 1:500) for 45 min in the dark.  After two 
washes with SPBS for 10 min, the coverslips were mounted on slides using Pro-long 
Gold Antifade (Invitrogen) and viewed using a confocal microscope.  All washes and 
staining took place at room temperature and all antibodies were diluted in Cas-block.     
2.5 OTHER METHODS 
2.5.1 Luciferase Activity Assay 
DNA plasmid and miRNA mimic co-transfected cells (2.4.4) were lysed and prepared 
using the Dual-Luciferase® Reporter Assay System according the manufacturer’s 
protocol (Promega) and luciferase levels were measured using the DLR-0-INJ Promega 
protocol on a GloMax® 20/20 Luminometer (Promega).  The cells were lysed in 1X 
passive lysis buffer, which stabilized the firefly and Renilla luciferase enzymes.  20 µl of 
the lysate was added to LARII (activated the firefly luciferase) and read on the 
luminometer and then 1X Stop & Glo® was used to quench the firefly activity and 
activate the Renilla to be read.      
2.5.2 Confocal Microscopy 
Slides of immunocytochemically stained cells were viewed using a Zeiss confocal laser 
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2.6 SOFTWARE 
2.6.1 The mfold Web Server 
http://www.bioinfo.rpi.edu/applications/mfold 
The mfold Web Server was used to predict pri-miRNA secondary structure by using an 
algorithm that finds the minimum free energy for each base-pair of an input RNA 
sequence under physiological conditions (temperature = 37°C, [Na+, Li+, K+, NH4
+] = 1 
M, and [Mg+2, Ca+2] = 0 M) (Zuker, 2003).  The output was selected in the form of a jpg 
or pdf file for viewing and archiving; it showed the predicted structure showing 
individual bases and the minimum free energy value.     
2.6.2 BLAST (Basic Local Alignment Search Tool) 
http://blast.ncbi.nlm.nih.gov/Blast.cgi 
The nucleotide and protein blast algorithms blastn and blastp, respectively, were used to 
align a nucleotide or protein query against nucleotide or protein databases available in 
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2.7 BIOINFORMATIC IDENTIFICATION OF OVHV-2 MIRNAS 
2.7.1 Consensus Sequence Determination 
The data output produced by The Genepool (2.1.12) provided 20-26 nt cDNA sequences 
(tags) representing the small RNAs present in BJ1035 cells, the coordinates and strand 
of alignment of the tags on the OvHV-2 genome, and the number of times the tag was 
sequenced from the small RNA sample (reads).  Minor manipulation of the tags was 
required to find the accurate RNA sequence from the given cDNA; those tags aligned to 
the plus strand of the OvHV-2 genome were given in their correct 5’-3’ orientation.  
They were then converted to RNA sequence by changing all T → U.  To obtain the 
RNA sequence for those tags aligned to the minus strand, the complementary RNA 
sequence of the cDNA tag had to be created and then inverted so as to be written 5’-3’; 
these manipulations were prepared by using an online sequence editor 
(http://www.fr33.net/seqedit.php).   
 
Initial observation of the dataset showed that a number of tags had the same 5’ 
coordinate (seed sequence; 1.3.2) with variation within the sequence or length at the 3’ 
end.  The tag with the most reads for each 5’ coordinate was used as the consensus 
sequence for that location, the tags with fewest reads at that location were discarded - 
their read numbers were added to that of the consensus sequence.          
2.7.2 Putative miRNA and miRNA* Sequence Determination 
The consensus tags were grouped together based on proximity; if they overlapped or 
were within 30 nt of each other (pre-miRNA; 1.3.1).  Read counts were used to 
determine the tag most likely to represent a mature miRNA and miRNA* (1.3.1); the tag 
with the most reads in a group was designated as the putative miRNA and the tag with 
the second highest number of reads (that did not overlap with the putative miRNA) was 
designated the putative miRNA*.   
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2.7.3 Secondary Structure Analysis  
The OvHV-2 genome (GenBank, AY839756) and the mfold Web Server (2.6.1) were 
used to predict the secondary structure of the putative pri-miRNA (1.3.1) represented by 
each group (2.7.2).  The nucleotide sequence of the OvHV-2 genome on the given strand 
(from 100 nt up- and downstream of the putative miRNA and miRNA*) was taken from 
GenBank and inputted into the RNA folding form of mfold.  The putative miRNA and 
miRNA* sequences were mapped onto the predicted secondary structures, which were 
then manually analyzed for the three features associated with miRNA biogenesis that 
had been set as criteria for the basis of miRNA identification (Ambros et al., 2003); 
stem-loop, 3’ overhangs formed by the miRNA/miRNA* duplex, and >16 bp within the 
miRNA/miRNA* duplex (3.3).  Those groups that satisfied all three secondary structure 
criteria were elevated to predicted OvHV-2 miRNA status.     
2.8 BIOINFORMATIC TARGET PREDICTION 
2.8.1 Seed Sequence Alignment 
Blastn (2.6.2) was used to align the complementary sequence to the ovhv2-miRs 
individually against the OvHV-2 (2.1.10) and bovine genomes (btau_4, 
http://www.ensembl.org/das/Bos_taurus.Btau_4.0.reference/).  Hits were reported back 
with the nucleotide coordinates of the alignment on the searched genome.  Those hits 
that contained the complementary seed sequence (3.7.1) were further analyzed while the 
others were discarded.   
2.8.2 Genome Trawl 
ORF annotation (5’ UTR, coding region, 3’ UTR) on the OvHV-2 and bovine genome 
was analyzed for all coordinates found in 2.8.1.  Those coordinates that were annotated 
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2.9 OVHV-2 TRANSCRIPTOME ANALYSIS 
The data output produced by The Genepool (2.1.13) provided 21 nt cDNA sequences 
(tags) representing the mRNAs present in BJ1035 cells, the coordinates and strand of 
alignment of the tags on the OvHV-2 genome, and the number of times the tag was 
sequenced from the given total RNA sample (reads).  Annotation of the OvHV-2 
genome available online (2.1.10) allowed for manual assignment of the tags to the 73 
ORFs encoded by the virus.  The sum of the reads for each ORF was plotted to create an 
expression profile for the overall genome. 
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Appendix 1: Buffer & Stock Solutions 
 
LB Broth     5 g yeast extract 
      10 g peptone from casein 
      10 g sodium chloride 
      12 g agar-agar 
      up to 1 L water 
 
Phosphate-buffered saline (PBS)  150 mM NaCl 
      2.5 mM KCl 
      10 mM Na2H2PO4 
      1 mM KH2PO4 (pH 7.4) 
 
1X TAE Buffer    40 mM Tris-acetate 
      1 mM EDTA (pH 8.0) 
 
10X TBE Buffer (pH 8.3)    900 mM Tris-HCl (pH 8.3) 
      900 mM Boric Acid 
      30 mM EDTA (pH 8.0) 
 
1X TE Buffer (pH 7.0)   10 mM Tris-HCl (pH 7.0) 
      1 mM EDTA (pH 8.0)   
 
 
    
 
Chapter Two                                                                                       Materials & Methods 
 53 
Appendix 2: Sequences  
 
DNA Templates for Construction of Antisense RNA Probes 

























F 48434 AACTCGAGCATGTTTCCGCTGCTCG XhoI-Orf20-
FLAG-NheI R 3’ end of FLAG AAGCTAGCCTACTTGTCATCGTCATC 
50°C 
F 40786 AACTCGAGACAACATAGTCCAGGCAAACA XhoI-Orf20 











OvHV-2 miRNA Mimics 
Ovhv2-miR Sequence (5’-3’) 
miR-5 UGAAGUUACAGCUGCACCUGGAU 
 miR-6 UAUUUUUAGCGGAGACCUCUAGG 
miR-7 GAAGGCGCAUCAUAGACACCACUUC 
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Vector pEGFP-N1 (Clontech - www.clontech.com) 





























The psiCHECK™ Vector (Promega - www.promega.com).   
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Vector pLZ3-CIng-ps-linker was obtained from Debiao Zhao at The Roslin Institute.  
This was based on pLenti6/V5-D-TOPO (Invitrogen) but the CMV promoter was 
replaced with a CAG promoter (a fusion of the CMV early enhancer element and 
chicken β actin promoter) along with an IRES-nGFP cassette and the blasticidin 
resistance gene was deleted. 
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Appendix 4: Commercial Suppliers 
 
Agilent Technologies UK Ltd, 610 Wharfedale Road, Winnersh Triangle, Wokingham, 
Berkshire RG41 5TP, UK 
http://www.home.agilent.com/agilent/home.jspx?&cc=GB&lc=eng 
 
AMS Biotechnology (Europe) Ltd, 63B Milton Park, Abingdon OX14 4RX, UK 
www.amsbio.com 
 
Applied Biosystems/Ambion, 2130 Woodward St, Austin, TX 78744-1832, USA 
www.ambion.com 
 
BDH Laboratory Supplies, Merck Ltd, Hunter Boulevard, Magna Park, Lutterworth, 
Leics LE17 4XN, UK 
www.bdh.com 
 
Becton, Dickinson U.K. Ltd, The Danby Building, Edmund Halley Road, Oxford 
Science Park, Oxford, Oxfordshire OX4 4DQ, UK 
www.bd.com/uk 
 
Bioline Ltd, 16 The Edge Business Centre, Humber Road, London NW2 6EW, UK 
www.bioline.com 
 




DJB Labcare Ltd, 20 Howard Way, Interchange Business Park, Newport Pagnell, 
Buckinghamshire MK16 9QS, England 
www.sigmacentrifuge.co.uk 
 
Eurofins MWG Operon, Anzingerstr. 7a, 85560 Ebersberg, Germany 
www.eurofinsdna.com 
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The Genepool, Ashworth Laboratories, The King’s Buildings, The University of 
Edinburgh, Edinburgh EH9 3JT, UK 
http://genepool.bio.ed.ac.uk 
 




Invitrogen Ltd, 3 Fountain Drive, Inchinnan Business Park, Paisley PA4 9RF, UK 
www.invitrogen.com 
 
Merck, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, UK 
www.merck.com 
 
LC Sciences, 2575 West Bellfort Street, Suite 270, Houston, TX 77054, USA 
www.lcsciences.com 
 
New England Biolabs (UK) Ltd, 75/77 Knowl Piece, Wilbury Way, Hitchin, Herts 
SG4 0TY, UK 
www.neb.com 
 
Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Camberley, 
Surrey GU16 7SR, UK 
www.novartis.co.uk 
 
NUNC, Thermo Fisher Scientific, Roskilde Site, Kamstrupvej 90, Postbox 280, DK-
4000, Roskilde, Denmark 
www.nuncbrand.com 
 
PerkinElmer, 940 Winter Street, Waltham, Massachusetts 02451, USA 
www.perkinelmer.com 
 




QIAGEN Ltd, QIAGEN House, Fleming Way, Crawley, West Sussex RH10 9NQ, UK 
www.qiagen.com 
 
Scientific Laboratory Supplies Ltd, Orchard House, The Square, Hessle, East Riding 
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Sera Laboratories International Ltd, Unit 44, Bolney Grange Business Park, 
Haywards Heath, West Sussex RH17 5PB, UK 
www.seralab.co.uk 
 




Sigma-Aldrich Company Ltd, Dorset, England 
www.sigmaaldrich.com 
 
Sterilin Ltd, Angel Lane, Aberbargoed, Bargoed, Caerphilly CF81 9FW, UK 
www.sterilin.co.uk 
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3.1 AIMS 
The aim of this project was to identify OvHV-2-encoded miRNAs by using high 
throughput sequencing to identify the small RNA transcripts expressed in the bovine 
LGL cell line BJ1035, bioinformatics to predict the secondary structure of the sequenced 
transcripts, and northern hybridization to validate that the sequenced transcripts were 
present as ~22-mers.     
3.2 INTRODUCTION 
miRNA identification generally involves a combination of bioinformatic analysis of 
transcript secondary structure and sequence conservation between organisms, and 
sequencing the population of small RNAs.  Many miRNAs have been identified using 
algorithms that look for sequence conservation between species where miRNAs have 
already been identified.  These programs are not appropriate for viral miRNA 
identification as there is very little sequence homology between different viruses.  
Therefore, for this project, the initial step was to sequence the small RNAs expressed in 
OvHV-2-infected cells. 
 
Sequencing the small unknown transcripts involved attaching adapters of known 
sequence to both ends, and reverse transcription to create a cDNA library where the 
sequences of interest could be found between the sequences of the known adapters 
(2.1.12).  For this project, high throughput sequencing was available which has the 
additional benefit of amplifying the adapter-bound transcripts before sequencing.  This 
allowed for more sensitive detection of transcripts that have a low abundance of 
expression.  An Illumina Solexa GAII (The Genepool, University of Edinburgh) was 
used as it specializes in sequencing short cDNA libraries and had the option of 
sequencing each molecule from both ends, further increasing the sensitivity of the 
results.   
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Once the small RNAs were isolated (2.1.11) and sequenced they could be aligned to the 
OvHV-2 genome to segregate those expressed by the virus and those from the host, and 
then bioinformatics could be used to predict the secondary structure of transcripts from 
those sequenced regions (2.7).  SOAP (Short Oligonucletide Alignment Program) was 
used by The Genepool to align the sequenced library against the OvHV-2 genome 
because, as the name suggests, it specializes in aligning short sequences.  The particular 
secondary structures inherent in miRNA biogenesis (1.5.1) lend themselves as sensitive 
markers for bioinformatic identification of miRNAs.  Therefore, the plan was to predict 
the secondary structure of the OvHV-2 aligned transcripts that had been sequenced using 
mfold (2.6.1) as it has been used successfully in other miRNA identification studies.        
3.3 RESULTS   
3.3.1 Sequencing Analysis 
The purification of small RNA from BJ1035s followed by the generation of the library 
and its subsequent sequencing (2.1.12) generated 5,702,036 sequence tags of 20-26 nt, 
404,439 (7%) of which mapped to the OvHV-2 genome.  Many of the 404,439 tags were 
replicates of each other, in fact there were only 2,260 unique tags represented by a single 
copy or up to 46,048 copies (reads).  348 of the 2,260 tags (0.12% of the reads) aligned 
to the plus strand and the remaining 1,912 tags (99.88% of the reads) aligned to the 
minus strand.  The size distribution of the tags can be seen in Figure 3.1.  The OvHV-2-
mapped tags were grouped together if they had the same 5’ genomic position, the sum of 
their reads was taken and the tag with the most reads was used as the consensus 
sequence (2.7.1).  The 348 plus strand tags were consolidated to 283 and the 1,912 
minus strand tags were consolidated to 825; Table 3.1 shows an example of the tag 
consolidation using the first 20 minus strand tags and Figure 3.2 shows the genome 































Figure 3.1A: Abundance of the 348 high throughput sequenced, OvHV-2 mapped, plus 



























Figure 3.1B: Abundance of the 1,912 high throughput sequenced, OvHV-2-mapped, 
minus strand, small RNA tags by tag length.  Note the difference in scale to Figure 3.1A.  
A 
B 




Table 3.1: OvHV-2 tag consolidation; using first 20 tags aligned to the minus strand of 
the OvHV-2 genome as an example. 
 
Original Data Consolidated Data 5’ Start 
Length (nt) Reads Length (nt) Reads 
155 21 4 21 4 
21 5 
20 11 156 
22 5 
20 21 
234 20 1 20 1 
276 20 1 20 1 
277 21 1 21 1 





489 22 4 22 4 
20 1 
21 1 490 
22 16 
22 18 
491 23 1 23 1 
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Figure 3.2A: Read count of the 283 consolidated tags generated from high-throughput sequencing plotted 

















Figure 3.2B: Read count of the 825 consolidated tags generated from high-throughput sequencing plotted 
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3.3.2 miRNA Bioinformatic Analysis 
The consensus tags were grouped together if they overlapped or were within 30 nt of 
each other (2.7.2); the 283 plus strand tags were divided into 126 groups (numbered 1-
126 5’ → 3’) and the 825 minus strand tags were divided into 261 groups (numbered 1-
261 3’ → 5’).  The twelve groups containing the most highly abundant tags (all from the 
minus strand) were analyzed initially (Table 3.2). 
 
Table 3.2: The twelve OvHV-2 small RNA consensus tags with the most reads. 
  
Group 5’ Start of Most Abundant Tag Reads of Most Abundant Tag 
5 927 10,588 
35 27903 39,169 
41 28781 21,686 
43 29052 31,227 
44 29248 14,694 
47 29637 17,508 
51 30338 24,497 
53 30510 14,966 
56 30818 11,187 
61 31462 10,378 
66 36313 16,574 
68 36575 46,048 
 
The secondary structure criteria set forth by Ambros et al., 2003 was used to determine 
if these twelve groups represented candidate miRNAs by using mfold (2.6.1, 2.7.3).  The 
required secondary structure included a stem-loop (60-110 nt, recognized by the RNase 
III enzyme Drosha) 3’ overhangs in the miRNA/miRNA* duplex (due to cleavage by the 
RNase III enzymes Drosha and Dicer) and >16 bp within the miRNA/miRNA* duplex 
(for stability within the duplex while the pre-miRNA is transported from the nucleus to 
the cytoplasm, the terminal loop is cleaved by Dicer and the duplex is transferred to 
RISC).  The most abundant tag in each group was designated the putative miRNA and 
the second most abundant, non-overlapping sequence as the putative miRNA*.  If the 
mfold predicted secondary structure contained a stem-loop, the miRNA and miRNA* 
were mapped onto it to find the remaining structural elements (Figure 3.3 gives an 
example using group 47 from the minus strand). 





5’ Start cDNA Sequence (3’-5’) Length Reads miR/miR* 
29600 ACTAAGGATCTTTTAGTGCGA 21 2  
29601 CTAAGGATCTTTTAGTGCGAA 21 6102 miRNA* 
29636 CGTTCGTCACTTAAGGATCCT 21 15  
29637 CGTTCGTCACTTAAGGATCCTT 22 17508 miRNA 
29638 CGTTCGTCACTTAAGGATCCTTG 23 50  
29639 CGTTCGTCACTTAAGGATCCTTGT 24 3  





Figure 3.3: Predicted secondary structure (mfold) with stemloop of group 47 on the 
minus strand of the OvHV-2 genome; putative miRNA (miR; green) and miRNA* 
(miR*; red) are highlighted with 3’ overhangs and 17 bp in the predicted miRNA 
duplex. 
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Eight out of the twelve minus strand groups initially analyzed adhered to these miRNA 
secondary structure standards (Table 3.3, Figure 3.4).   
 
Table 3.3: Initial predicted OvHV-2 miRNAs.  “X” signifies that the predicted 
secondary structure contains the given characteristic. 
 
Group 5’ Start Stem-loop 3’ Overhang >16 bp in Stem 
5 927 X X X 
35 27903 X X X 
41 28781 X X  
43 29052 X X  
44 29248 X X X 
47 29637 X X X 
51 30338 X X  
53 30510 X X  
56 30818 X X X 
61 31462 X X X 
66 36313 X X X 
68 36575 X X X 
 
3.3.3 Validation of Predicted OvHV-2 miRNAs 
Although the eight tags identified in section 3.3.2 met the expression (high throughput 
sequencing data) and biogenesis criteria (secondary structure) set by Ambros et al., 
2003, additional supporting evidence that the tags were expressed by OvHV-2 in vitro 
was sought by northern hybridization for small RNAs using radiolabelled 
complementary RNA probes (2.3).  Equal amounts of total RNA from BJ1035 cells, 495 
TPM cells (Theileria parva-immortalized bovine T cell line, OvHV-2-free; a gift from 
Prof Ivan Morrison), and ovine leukocytes (from an OvHV-2-infected sheep) (2.1.11, 
2.4.5) were separated by gel electrophoresis and probed for the eight predicted OvHV-2 
miRNAs along with the ubiquitous cellular miRNA bta-mir-16a as a positive control 
(Figure 3.5).  T. parva is a parasitic protozoan of cattle that causes a similar pathology to 
that of MCF and produces IL-2-dependent immortalized T cell lines (Schock et al., 
1998).    
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 No. of Reads 
Group 5 
 
     C       G   A                UU 
5’ GU AAGGCUU AUA GUAGCACU  GAG GU  A          10588 
3’ UA UUCCGAA UAU CAUCGUGA  CUC CA             586 








      AA  GAUUG       AUA        U   U              GAAUA 
5’ UGG  GA     UUUUGAC   GUUUACUG ACA GUGC CCAA AUGU     U        2201 
3’ ACC  CU     AAAACUG   UAGAUGAC UGU UACG GGUU UACA             39169 








    U             AGU       U          G     G     AAAG 
5’ G CUGCU  AAAGCA   GCACUUA CUGUAUCAUA GGGUU UGUUG    U         14694 
3’ C GACGA  UUUCGU   CGUGAAU GACGUAGUAU UCCAA ACAAC    U           420 








                   C  A    A      GGAAU 
5’ UGAUCGAC AAGGAUC UU AGUG CGAACG     U                         17508 
3’ AUUAGUUG UUCCUAG AA UCAC GCUUGC     A                          6102 





Figure 3.4A: Predicted stem-loop structure of Group 5, 35, 44, and 47 on the minus 
strand; consensus miRNA and miRNA* sequences are in bold, the miRNA seed 
sequence is underlined (number of reads of miRNA and miRNA* are on the right). 
Chapter Three                                                                     OvHV-2 miRNA Identification 
 70 
No. of Reads 
Group 56 
 
       A   C     G            CA    GAUACAAG 
5’ UGAC GGU CGUUU AAGUUACAGCUG  CCUG        C                    11187 
3’ ACUG UCG GCAGG UUCAAUGUCGGU  GGAC        C                     2241 








             U    A U        G   C A          GUGUG 
5’ UAUGC  GCA GAGC G UUAGGGGU UCU   AAAAAUACAU     A                89 
3’ GUACG  CGU CUCG U GAUCUCCA AGG   UUUUUAUGUG     U             10378 








        A      G      A    A  G          C         C      AU 
5’ GAAU    CUU    GCUU CUGG AA AAGGCG CAU  AUAGACAC ACU UC  C    16574 
3’ UUUA    GAA    CGAA GACC UU UUCCGU GUG  UAUCUGUG UGA GG        2598 








              A  UC     C         U     UUA   G 
5’ UGCUU UAUAG AG  GAGCA UUACGCUGA CCAAA   UUU U                  3732 
3’ ACGAA GUGUC UC  CUCGU AGUGCGACU GGUUU   GAA U                 46048 





Figure 3.4B: Predicted stem-loop structure of Group 56, 61, 66 and 68 on the minus 
strand; consensus miRNA and miRNA* sequences are in bold, the miRNA seed 
sequence is underlined (number of reads of miRNA and miRNA* are on the right). 

































Figure 3.5: Northern hybridization for OvHV-2-encoded miRNAs in total RNA of 
uninfected bovine T cells (495 TPM) infected bovine T cells (BJ1035) and infected 
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Specific hybridization signals were observed for bta-mir-16a in all three cell types which 
confirmed the small RNA transfer was successful.  Signals for all eight predicted 
miRNAs were observed only in OvHV-2-infected immortalized bovine T cells and 
absent in non-infected immortalized bovine T cells and ovine buffy coat (all signals 
were observed between 20-30 nt).  The absence of a signal in the sheep cells is likely 
due to the fact that following a natural infection, OvHV-2 only infects a small minority 
of cells in the buffy coat, therefore the RNA copy number could be too low for detection 
by this method.  The results from the northern hybridization confirmed that the eight 
identified tags are present in cells as ~22-mers and are expressed by OvHV-2.  These are 
the first miRNAs found to be expressed by a virus in the Macavirus genus and will be 
referred to as ovhv2-miR-1 - miR-8. 
3.3.4 Additional Predicted OvHV-2 miRNAs 
The remaining tag groups were analyzed for miRNA secondary structure as described 
previously (Supplemental DVD; Secondary Structure Prediction and Candidate 
miRNAs; raw data can be found on Microarray Informatics, Accession E-MTAB-466).  
Groups that contained a stem-loop but did not have a putative miRNA* to use for the 
establishment of 3’ overhangs or base-pairing within the stem were included in the list 
of predicted miRNAs to avoid over-stringency.  Thus, the four of the 12 candidates 
mentioned previously that were not validated by northern hybridization due to having 
less than 16 bp in the miRNA/miRNA* duplex were also reconsidered as predicted 
miRNAs.  With those four included, 38 additional predicted miRNAs were found; 3 on 
the plus strand and 35 on the minus strand (Table 3.4, Figure 3.6).  All of the predicted 
miRNAs were found in noncoding regions of the genome and the 35 predicted miRNAs 
on the minus strand were found in three distinct clusters (it is unknown whether these 
miRNA clusters are expressed from a single or multiple promoters - it is currently being 
investigated).  There was not time to find additional supporting evidence by northern 
hybridization for these additional predicted viral miRNAs but based on the bioinformatic 
criteria, it is believed that most, if not all, represent expressed miRNAs. 
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Table 3.4: Additional predicted OvHV-2 miRNAs. 
 
Group 5’ Start of Most Abundant Tag Reads of Most Abundant Tag 
Plus Strand 
3 182 25 
64 117612 2 
96 129703 1 
Minus Strand 
1 156 21 
3 526 196 
4 724 1 
6 1182 253 
13 8445 1 
34 27722 434 
36 28066 6200 
37 28209 6015 
38 28381 322 
39 28515 4717 
40 28683 1014 
41 28781 21686 
42 28888 740 
43 29052 31227 
45 29345 6487 
46 29455 9219 
48 29745 8095 
49 29945 2967 
50 30091 3794 
51 30338 24497 
53 30510 14966 
54 30632 1357 
57 30980 5457 
58 31085 942 
60 31359 351 
62 31603 1535 
63 32075 517 
67 36462 7834 
83 48585 1 
95 57413 1 
128 79692 1 
163 96435 1 
181 103953 1 
182 104758 1 
217 117122 6064 
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Figure 3.6A: Location of validated and predicted OvHV-2 miRNAs on an OvHV-2 
genome schematic; predicted ORFs are shown with closed boxes (arrows indicating 
direction of transcription) miRNA sites are shown with arrows; those in red have been 
validated by northern hybridization.  Rightward pointing arrows are transcribed from the 
plus strand of the genome, and leftward pointing arrows are transcribed from the minus 
stand.  Names of ORFs flanking regions with miRNAs have been given. 
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Figure 3.6B: Expanded regions of the OvHV-2 genome containing the three miRNA 
clusters on the minus strand that include the eight validated ovhv2-miRs (~4 kb separate 
Cluster 2 and Cluster 3).  100 bp of flanking orfs are shown by closed boxes (Ov2 and 
ORF17/17.5 are transcribed from the minus strand and ORF11 is transcribed from the 
plus strand). 
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3.3.5 LC Sciences Bioinformatic Analysis for OvHV-2 miRNAs 
To complement the bioinformatic analysis used in this study, the Solexa sequence data 
originally generated by The Genepool was sent to LC Sciences for analysis.  The data 
were subject to a number of filters to isolate the tags that represented predicted OvHV-2 
miRNAs.  The first filter eliminated those tags that matched the adaptors, were made up 
of mostly one nucleotide (A, C, G, or T) or had too many non-sequenced nucleotides.  
The second filter eliminated those tags that were less then 15 nt in length or were 
represented by less than three reads.  The third filter eliminated tags that aligned to 
sequences in mRNA, repetitive DNA, or small RNA (excluding miRNA) databases, and 
that mapped to the bovine genome database.  The resultant 294,233 reads - 5.2% of the 
original number of reads analyzed - aligned to the OvHV-2 genome.  The OvHV-2 reads 
were represented by 33 unique tags (3.88% of the reads) from the plus strand of the 
genome and 818 unique tags (96.12% of the reads) from the minus strand (Supplemental 
DVD - LC Sciences).  The size distribution of the tags selected by LC Sciences is shown 
in Figure 3.7. 
 
Reads of tags with the same 5’ start but variation in length were consolidated as 
described previously (3.2.1) resulting in 20 tags for the plus strand and 249 tags for the 
minus strand being identified (Figure 3.8). 
 
The consensus tags were grouped together as described previously (3.3); the 20 plus 
strand tags were clustered into 11 groups and the 249 minus strand tags were clustered 
into 53.  Based on the LC Sciences analysis, these groups represent OvHV-2 miRNAs; 
64 compared to 46 miRNAs found by my manual analysis (miRNAsC Levy) (3.3.4).  For 
the predicted miRNAsLC Sciences on the plus strand, only one of the 11 was also a 
predicted miRNAC Levy.  The remaining ten predicted miRNAsLC Sciences on the plus 
strand were not determined to be miRNAsC Levy based on their predicted secondary 
structure; two of the miRNAsLC Sciences were represented by a single group in The 
Genepool dataset due to overlapping and close sequences (Figure 3.9). 



























Figure 3.7A: Abundance of LC Sciences high throughput sequenced, OvHV-2-mapped, plus 

























Figure 3.7B: Abundance of LC Sciences high throughput sequenced, OvHV-2-mapped, minus 
strand, small RNA tags by length.  Note the difference in scale to Figure 3.7A.  
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Figure 3.8A: Abundance of the 20 16-26 nt tags analyzed by LC Sciences plotted along the OvHV-2 
genome plus strand.  Note the difference in scale to Figure 3.8B. 
Figure 3.8B: Abundance of 249 16-26 nt tags analyzed by LC Sciences plotted along the OvHV-2 
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Figure 3.9A: Abundance of predicted plus strand OvHV-2 miRNAs by manual and LC Sciences analysis, 
mapped along the OvHV-2 genome.  Note the difference in scale to Figure 3.9B. 
 
 
Figure 3.9B: Abundance of predicted minus strand OvHV-2 miRNAs by manual and LC Sciences 
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For the miRNAsLC Sciences on the minus strand, 36 of the 53 were also predicted as 
miRNAsC Levy (including the 8 that were validated).  Fifteen of the remaining miRNAsLC 
Sciences were not determined to be miRNAsC Levy based on their secondary structure, and 2 
miRNAsLC Sciences were not analyzed manually as they had not passed through the filters 
set by The Genepool (Figure 3.10). 
3.3.6 Predicted Target Bioinformatic Analysis 
In order to determine what potential role these miRNAs may have in OvHV-2 biology 
and pathology, it is necessary to identify their target transcripts.  There are a number of 
ways this can be accomplished; bioinformatics, microarray, and pull-down assays.  
Bioinformatics acknowledges the importance of the seed region in miRNA targeting and 
identifies complementary sequences in annotated ORFs by alignment.  Microarrays can 
be used to measure a difference in transcript abundance between miRNA-treated and 
non-treated samples.  Pull-down assays target the protein components of the RISC 
complex or the miRNA itself and pull down transcripts actively being targeted.  Due to 
time constraints for this project, optimization and testing of microarrays or pull-down 
assays was not feasible; thus, bioinformatics were used to initiate the assessment of the 
function of OvHV-2 encoded miRNAs.   
 
At this point in time, the cow genome has been fully sequenced with >5-fold coverage 
and is currently being annotated (the annotation at this point in time is not as 
comprehensive as the mouse and human genomes).  In contrast, the sheep genome is 
only incompletely sequenced and has only partial and preliminary annotation.  It is more 
likely that OvHV-2 miRNAs have evolved to target cellular transcripts of the ovine 
genome rather than the bovine genome as sheep appear to be its natural host given their 
lack of clinical symptoms upon infection.  Therefore, the complementary sequences to 
the eight validated ovhv2-miRs were aligned against the OvHV-2 and bovine genomes 
to predict targets using blastn (2.6.2).  Once the ovine genome is complete, it will be 
analyzed for OvHV-2 miRNA targets found in this study. 
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3.3.7 OvHV-2 Genome Targets 
The blastn search found 131 to 412 putative target sites on the OvHV-2 genome for each 
of the eight ovhv2-miRs.  Once these sites were manually filtered to include only those 
that involved the complementary sequence to the seed region (nucleotides 1-8, 1-7, or 2-
8) the number of potential target sites decreased to between 22 and 56 for each ovhv2-
miR.  The complete OvHV-2 genome (2.7.3) was used to determine whether these seed 
target sites fell within annotated ORFs (Table 3.5). 
 
Table 3.5: Ovhv2-miR seed alignment to OvHV-2 genome.     
  
Group Seed Hits Annotated ORF Hits Individual ORF Hits 
ovhv2-miR-1 22 17 15 
ovhv2-miR-2 31 21 19 
ovhv2-miR-3 23 18 15 
ovhv2-miR-4 31 14 14 
ovhv2-miR-5 35 30 20 
ovhv2-miR-6 56 28 25 
ovhv2-miR-7 24 24 17 
ovhv2-miR-8 56 45 33 
 
Legend: Blastn results aligning validated ovhv2-miRs against the OvHV-2 genome; 
filtered for seed regions, and filtered for annotated ORFs (5’ UTR, coding region, and 3’ 
UTR).  The “Annotated ORF Hits” value is the number of total target sites found for the 
given miRNA and the “Individual ORF Hits” value is the number of total ORF targets 
found for the given miRNA.   
 
The annotation of the OvHV-2 genome allowed for the putative target sites to be 
assigned to the different regions of the mRNA transcript - 5’ UTR, coding region, or 3’ 
UTR.  The eight ovhv2-miRs were predicted to target 65 (89.0%) of the 73 predicted 
viral ORFs (Table 3.6).  A broad targeting range was observed over the functions of the 
targeted genes; targets included those involved in replication, gene expression, structure, 
and signalling with no particular pathway standing out.    
Chapter Three                                                                     OvHV-2 miRNA Identification 
 82 










5’ UTR ORF10 miR-8 Unknown 
ORF8  Glycoprotein B 
ORF9 miR-2, -6 DNA Polymerase Subunit 
Ov5 miR-8 G-Protein Coupled Receptor (putative) 
ORF23 miR-2 Tegument Protein 
ORF32 miR-2, -8 Nuclear Capsid Localization 
ORF44  Helicase 
ORF48 miR-2 EBV BRRF2 
ORF63 miR-3, -5 Tegument Protein 
ORF64 
x3 
miR-3, -4, -7, -8 Tegument Protein 
ORF69 miR-4, -6 Nuclear Lamina Capsid Docking Protein 
Ov8.5 miR-6, -8 Unknown 
CDS 
ORF75 miR-2, -4, -7 
Formylglycinamide Ribotide Amidotransferase 
(FGARAT), Tegument Protein 
ORF7 miR-8 Terminase Subunit 
miR-1 
3’ UTR 
ORF31 miR-2, -8 EBV BDLF4 (putative glycoprotein) 
miR-2 5’ UTR ORF20 miR-5, -6, -7, -8 Nuclear Protein 
  ORF75 miR-1, -4, -7 FGARAT 
 CDS Ov2 miR-4, -5 Basic Leucine Zipper Motif 
  ORF6 x2 miR-4, -5, -7 ssDNA Binding Protein 
  ORF9 miR-1, -6 DNA Polymerase Subunit 
  ORF18 miR-7, -8 EBV BVLF1.5 
  ORF21 miR-6 Thymidine Kinase 
  ORF23 miR-1 Tegument Protein 
  ORF26 miR-3, -5, -8 Capsid Triplex Protein 
  ORF29 miR-3, -5, -6 Terminase Subunit 
  ORF32 miR-1, -8 Nuclear Capsid Localization 
  ORF39 miR-3 Glycoprotein M 
  ORF43  Capsid Portal Protein 
  ORF48 miR-1 EBV BRRF2 
  ORF56 miR-4 Primase 
  ORF75 miR-1, -4, -7 FGARAT 
miR-2 CDS Ov10 x2 miR-4, -5 Glycoprotein (putative) 
 3’ UTR ORF25 
miR-3, -4, -5, -6, 
-8 
Major Capsid Protein 
  ORF31 miR-1, -8 EBV BDLF4 
 
Legend: OvHV-2 ORFs predicted to be targeted by the eight validated ovhv2-miRs by 
target region of the mRNA (5’ UTR, coding region [CDS] or 3’ UTR); “x#” after the 
ORF name indicates the number of additional target sites on that particular ORF by the 
given ovhv2-miR.  Replication, gene expression, structural, and unknown/undesignated 
orf functions are colour-coded. 
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ORF Add. Ovhv2-miRs Predicted Function 
5’ UTR ORF58 miR-5, -7, -8 Multiple Membrane-Spanning Protein 
Ov3 miR-6, -8 Semaphorin (putative) 
ORF27 x2 miR-5, -8 EBV BDLF2 
ORF29 miR-2, -5, -6 Terminase Subunit 
ORF34 miR-8 EBV BGLF3 
ORF39 miR-2 Glycoprotein M 
ORF50 miR-5, -6, -8 Transcriptional Control 
Ov6 miR-8 Transcriptional Control (putative) 
ORF59 miR-5, -7, -8 DNA Polymerase Subunit 
ORF63 miR-1, -5 Tegument Protein 
CDS 
ORF64 miR-1, -4, -7, -8 Tegument Protein 
ORF25 x2 miR-2, -4, -5, -6, -8 Major Capsid Protein 
ORF26 x2 miR-2, -5, -8 Capsid Triplex Protein 
ORF60 miR-6, -8 Ribonucleotide Reductase Subunit 
miR-3 
3’ UTR 
ORF65  Capsid Protein 
Ov2.5  IL-10 
ORF3 miR-8 FGARAT 
Ov4.5 miR-8 Bcl-2 
ORF6 miR-2, -5, -7 ssDNA Binding Protein 
ORF25 miR-2, -3, -5, -6, -8 Major Capsid Protein 
ORF40 miR-7, -8 Complexed with Helicase and Primase 
ORF54  Deoxyuridine Triphosphatase (dUTPase) 
ORF56 miR-2 Primase 
ORF64 miR-1, -3, -7, -8 Tegument Protein 
ORF68 miR -6 Nuclear Capsid Localization 
ORF69 miR-1, -6 Nuclear Lamina Capsid Docking Protein 
ORF75 miR-1, -2, -7 FGARAT 
CDS 
Ov10 miR-2, -5 Glycoprotein (putative) 
miR-4 
3’ UTR Ov2 miR-2, -5 Basic Leucine Zipper Motif 
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5’ UTR ORF65 miR-3 Capsid Protein 
Ov2 miR-2, -4 Basic Leucine Zipper Motif 
ORF6 x2 miR-2, -4, -7 ssDNA Binding Protein 
ORF19 miR-6, -7 Portal Capping Protein (putative) 
ORF26 x2 miR-2, -3, -8 Capsid Triplex Protein 
ORF27 miR-3, -8 EBV BDLF2 
ORF29 miR-2, -3, -6 Terminase Subunit 
Ov8 miR-6 Glycoprotein (putative) 
ORF58 miR-3, -7, -8 Multiple Membrane-Spanning Protein 
ORF63 miR-1, -3 Tegument Protein 
ORF66 x3  EBV BFRF2 
Ov9 miR-6 Bcl-2 
CDS 
Ov10 miR-2, -4 Glycoprotein (putative) 
ORF20 miR-2, -6, -7, -8 Nuclear Protein 
ORF25 x3 
miR-2, -3, -4, -6, 
-8 
Major Capsid Protein 
ORF26 miR-2, -3, -8 Capsid Triplex Protein 
ORF50 miR-3, -6, -8 Transcriptional Control 
ORF59 miR-3, -6, -8 DNA Polymerase Subunit 
ORF67 x3  Nuclear Lamina Capsid Docking Protein 
miR-5 
3’ UTR 
ORF67a x3  Terminase Cofactor 
ORF50 miR-3, -5, -8 Transcriptional Control 
ORF60 miR-3, -8 Ribonucleotide Reductase Subunit 5’ UTR 
ORF73 miR-8 LANA 
Ov3 miR-3, -8 Semaphorin (putative) 
ORF9 x2 miR-1, -2 DNA Polymerase Subunit 
ORF19 miR-5, -7 Portal Capping Protein (putative) 
ORF20 miR-2, -5, -7, -8 Nuclear Protein 
ORF22  Glycoprotein H 
ORF24 x2 miR-7 HSV UL20 
ORF25 
miR-2, -3, -4, -5, 
-8 
Major Capsid Protein 
ORF29 miR-2, -3, -5 Terminase Subunit 
ORF52  HSV UL49 
ORF60 miR-3, -8 Ribonucleotide Reductase Subunit 
ORF68 miR-4 Nuclear Capsid Localization 
CDS 
Ov9 miR-5 Bcl-2 
ORF19 miR-5, -7 Portal Capping Protein (putative) 
ORF20 miR-2, -5, -7, -8 Nuclear Protein 
ORF21 miR-2 Thymidine Kinase 
Orf49 x2  Transcriptional Control 
Ov8 miR-5 Glycoprotein (putative) 
Orf61 miR-7 Ribonucleotide Reductase Subunit 
Orf62 miR-7 Capsid Triplex Protein 
Orf69 miR-1, -4 Nuclear Lamina Capsid Docking Protein 
Ov8.5 miR-1, -8 Unknown 
miR-6 
3’ UTR 
Orf73 miR-8 LANA 
Chapter Three                                                                     OvHV-2 miRNA Identification 
 85 










5’ UTR Orf58 miR-3, -5, -8 Multiple Membrane-Spanning Protein 
Orf6 x2 miR-2, -4, -5 ssDNA Binding Protein 
Orf17 x2  Maturational Protease 
Orf17.5 x2  Major Scaffold Protein 
Orf18 x2 miR-2, -8 EBV BVLF1.5 
Orf19 miR-5, -6 Portal Capping Protein (putative) 
Orf24 miR-6 HSV UL20 
Orf40 miR-4, -8 Complexed with Helicase and Primase 
Orf45  HSV UL4 
Orf57 miR-8 Post-Transcriptional Regulator 
Orf59 miR-3, -5, -8 DNA Polymerase Subunit 
Orf61 x2 miR-6 Ribonucleotide Reductase Subunit 
Orf64 x2 miR-1, -3, -4, -8 Tegument Protein 
CDS 
Orf75 miR-1, -2, -4 FGARAT 
Orf20 miR-2, -5, -6, -8 Nuclear Protein 
Orf46  Uracil DNA Glycosylase 
miR-7 
3’ UTR 
Orf62 x2 miR-6 Capsid Triplex Protein 
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Ov3 miR-3, -6 Semaphorin (putative) 
Orf10 miR-1 Unknown 
Orf18 miR-2, -7 EBV BVLF1.5 
Orf58 x2 miR-3, -5, -7 Multiple Membrane-Spanning Protein 
5’ UTR 
Orf73 x2 miR-6 LANA 
Orf3 miR-4 FGARAT 
Ov4.5 miR-4 Bcl-2 
Orf7 miR-1 Terminase Subunit 
Ov5 miR-1 G-Protein Coupled Receptor (putative) 
Orf20 miR-2, -5, -6, -7 Nuclear Protein 
Orf25 
miR-2, -3, -4, -5, 
-6 
Major Capsid Protein 
Orf26 miR-2, -3, -5 Capsid Triplex Protein 
Orf27 miR-3, -5 EBV BDLF2 
Orf32 miR-1, -2 Nuclear Capsid Localization 
Orf33  Tegument Protein 
Orf36  Protein Kinase 
Orf37  Deoxyribonuclease 
Orf40 x3 miR-4, -7 Complexed with Helicase and Primase 
Orf50 miR-3, -5, -6 Transcriptional Control 
Ov6 x2 miR-3 Transcriptional Control (putative) 
Orf57 miR-7 Post-Transcriptional Regulator 
Orf59 miR-3, -5, -7 DNA Polymerase Subunit 
Orf60 miR-3, -6 Ribonucleotide Reductase Subunit 
Orf64 x2 miR-1, -3, -4, -7 Tegument Protein 
CDS 
Ov8.5 x2 miR-1 Unknown 
Orf25 x2 
miR-2, -3, -4, -5, 
-6 
Major Capsid Protein 
Orf26 miR-2, -3, -5 Capsid Triplex Protein 
Orf31 x2 miR-1, -2 EBV BDLF4 
Orf32 miR-1, -2 Nuclear Capsid Localization 
Orf34 x2 miR-3 EBV BGLF3 
Orf35 x2  Tegument Protein 
Orf36  Protein Kinase 
miR-8 
3’ UTR 
Ov7  Glycoprotein (putative) 
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3.3.8 Bovine Genome Targets 
The blastn search found between 321 and 3,496 sites on the bovine genome where at 
least 7 consecutive nucleotides were exactly complementary to one of the eight ovhv2-
miRs.  Once these sites were manually filtered to include only those that involved the 
complementary sequence to the seed region the number of potential target sites 
decreased to between 13 and 635 for each ovhv2-miR.  The completed bovine genome 
(btau_4, http://www.ensembl.org/das/Bos_taurus.Btau_4.0.reference/) was used to 
determine whether these seed target sites fell within annotated orfs (Table 3.7).   
 
Table 3.7: Ovhv2-miR seed alignment to bovine genome.   
  
Ovhv2-miR Seed Hits Annotated Orf Hits 
miR-1 503 10 
miR-2 92 1 
miR-3 635 2 
miR-4 515 5 
miR-5 615 6 
miR-6 103 0 
miR-7 13 0 
miR-8 278 4 
 
Legend: Blastn results aligning validated OvHV-2-encoded miRNAs against the bovine 
genome; filtered for seed regions and filtered for annotated genes (5’ UTR, coding 
region, and 3’ UTR). 
 
The ORF coordinates also allowed for the putative target sites to be assigned to the 
different regions of the mRNA transcript.  The eight miRNAs were predicted to target 
29/~25,186 (0.1%) bovine ORFs (Table 3.8). 
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Target Description (Function) 
NDUFB5 
NADH Dehydrogenase (ubiquinone) 1 Beta Subcomplex 5 
(respiration) 
REPS2 
RALBP1 Associated Eps Domain Containing 2 (endocytosis of 
growth factor receptors) 
TLR7 
Toll-like Receptor 7 (pathogen recognition/innate immune 
system activation in lung, placenta, and spleen) 
LOC506828 
Alpha-2-Macroglobulin Precursor (protease inhibitor and 
cytokine transporter) 
ZBED5 Zinc Finger, BED-type Containing 5 (inactive transposon) 
ALDH3A2 
Aldehyde Dehydrogenase 3 Family, Member A2 (detoxifies 
aldehydes) 
CDS 
GTF2IRD2 GTF2I Repeat Domain 2 (putative transcription factor) 
LOC100139782 
Exportin 4 (transports proteins between nuclear and cytoplasmic 
compartments) 
ANK1 
Ankyrin 1 (cell motility, activation, proliferation, contact, and 




TP53 Apoptosis Effector (promotes desmosome assembly and 
apoptosis) 
miR-2 CDS PRSS2 
Serine Protease 2 (secreted by pancreas, activated in small 
intestine, cleaves carboxyl groups off lysine or arginine) 
CEP350 Centrosomal Protein (anchors microtubules at the centrosome) 
miR-3 CDS 
NDFIP2 
Nedd4 Family Interacting Protein 2 (activates a number of 
HECT domain-containing E3 ubiquitin-protein ligases) 
DENND4C DENN/MADD Domain Containing 4C (unknown) CDS 
LOC783920 GTPase (interferon inducer) 
LOC538441 Chromosome 9 Open Reading Frame 41 (unknown) 
MYOHD1 Myosin XIX (actin-based motor molecule)  
miR-4 
3’ UTR 
WDR59 WD Repeat Domain 59 (unknown) 
CDC25C Cell Division Cycle 25 Homologue C (regulates cell division) 
KLHL31 Kelch-like 31 (Transcriptional repressor) 
LOC616520 Splicing Factor 3B Subunit (binds pre-mRNA) 
5’ UTR 
SF3B14 Splicing Factor 3B Subunit 14 (splices pre-mRNA) 




Ubiquitin-Conjugating Enzyme E2G 1 (covalently attaches 
ubiquitin to other proteins) 
LOC782388 Copine II (calcium-dependent membrane-binding protein) 
LOC785769 Spermatogenesis Associated 13 (unknown) 
NECAB2 N-Terminal EF-Hand Calcium Binding Protein 2 (unknown) miR-8 CDS 
PITRM1 
Pitrilysin Metallopeptidase 1 (degrades mitochondrial transit 
peptides and unstructured peptides [ranging from 10 to 65 
residues]) 
 
Legend: Bovine ORFs predicted to be targeted by the eight ovhv2-miRs; ORF names are given next to the 
location on the transcript that the target site was located.  Note that ovhv2-mir-6 and -miR-7 do not have 
any predicted targets on the bovine genome.  
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3.4 DISCUSSION    
3.4.1 Nucleotide Composition & Minimal Folding Free Energy Index 
The 46 miRNAsC Levy had an average G+C content of 51%, similar to the overall OvHV-
2 genome that has a G+C content of 52% (Hart et al., 2007).  Though stem-loops are a 
main feature of pri-miRNA secondary structure, pri-miRNAs are not the only RNA 
species that can fold into this structure (for example, rRNAs, tRNAs, and mRNAs) 
(Zhang et al., 2006).  To aid in deciphering if an RNA stem-loop is likely that of a pri-
miRNA, Zhang et al., 2006 determined the minimal folding free energy index (MFEI).  
MFEI is calculated by taking a predicted folding energy (using mfold, 2.6.1) and 
adjusting it to account for nucleic acid length and G+C content;  
 
MFEI = ((MFE/lengthnt)*100)/(G+C%) 
 
They found that miRNAs tend to have higher negative MFEI than other types of RNA 
(>0.85).  This is a useful tool, but acts more as a guideline as Pan et al., 2007 observed 
MFEI as low as 0.55 and the 46 miRNAsC Levy have MFEI between 0.42 and 1.03 (Table 
3.9).  The MFEI was established using plant miRNAs which have a lower G+C content 
than viral miRNAs; thus resulting in higher MFEI.     
 
As of February 2011, 235 predicted viral pri-miRNAs containing 300 mature miRNAs 
had been published, of which 228 pri-miRNAs (288 miRNAs) were encoded by 
herpesviruses (miRBase v16.0 - http://www.mirbase.org).  So far, many of these have 
not been functionally characterized.  They ranged from 18-30 nt in length and the 46 
miRNAsC Levy fell within this range (20-26 nt; Figure 3.10). 
 
Due to time constraints, only the eight ovhv2-miRs that were validated by northern 
hybridization were aligned (via blastn) to the AlHV-1 genome.  This analysis did not 
find any sequence conserved homologues.  This was not unexpected as there has been 
very little sequence conservation of miRNAs found between herpesviruses; not even 
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Table 3.9: Nucleotide composition of the 46 predicted OvHV-2 miRNAs.   
 
Group A (nt) U (nt) G (nt) C (nt) Total (nt) A+U (%) G+C (%) MFEI 
Plus Strand 
3 3 4 8 5 20 35.0 65.0 0.81 
64 4 5 8 3 20 45.0 55.0 0.43 
96 5 6 8 3 22 50.0 50.0 0.53 
Minus Strand 
1 3 4 8 5 20 35.0 65.0 1.01 
3 2 6 10 4 22 36.4 63.6 0.49 
4-3p 4 6 10 1 21 47.6 52.4 0.49 
4-5p 3 9 8 1 21 57.1 42.9 0.59 
miR-1 8 5 6 3 22 59.1 40.9 0.51 
6 5 7 5 5 22 54.5 45.5 0.62 
13 5 4 9 4 22 40.9 59.1 0.48 
34 1 10 5 5 21 52.4 47.6 0.50 
miR-2 5 7 6 5 23 52.2 47.8 0.54 
36 3 10 6 3 22 59.1 40.9 0.76 
37 4 7 5 6 22 50.0 50.0 0.62 
38 7 7 4 3 21 66.7 33.3 0.89 
39 3 7 5 6 21 47.6 52.4 0.59 
40 3 9 8 3 23 52.2 47.8 0.64 
41 10 3 4 4 21 61.9 38.1 0.77 
42 7 5 6 5 23 52.2 47.8 0.61 
43 4 9 7 5 25 52.0 48.0 0.49 
miR-3 3 10 8 2 23 56.5 43.5 0.62 
45 7 5 8 3 23 52.2 47.8 0.62 
46 7 6 5 4 22 59.1 40.9 0.56 
miR-4 8 4 6 4 22 54.5 45.5 0.62 
48 4 6 8 3 21 47.6 52.4 0.45 
49 5 8 7 3 23 56.5 43.5 0.61 
50 3 9 7 6 25 48.0 52.0 0.51 
51 5 5 8 5 23 43.5 56.5 0.45 
53 8 5 7 2 22 59.1 40.9 0.62 
54 3 8 5 6 22 50.0 50.0 0.58 
miR-5 6 6 6 5 23 52.2 47.8 0.71 
57 7 8 6 4 25 60.0 40.0 0.75 
58 3 5 6 6 20 40.0 60.0 0.42 
60 4 5 7 4 20 45.0 55.0 0.65 
miR-6 5 8 6 4 23 56.5 43.5 0.70 
62 1 10 6 5 22 50.0 50.0 0.54 
63 5 6 6 5 22 50.0 50.0 0.57 
miR-7 8 4 5 8 25 48.0 52.0 0.50 
67 4 3 9 6 22 31.8 68.2 0.50 
miR-8 2 7 6 7 22 40.9 59.1 0.50 
83 11 3 5 7 26 53.8 46.2 0.71 
95 2 5 8 10 25 28.0 72.0 0.50 
128 3 2 13 2 20 25.0 75.0 0.47 
163 3 6 11 5 25 36.0 64.0 0.52 
181 4 2 12 3 21 28.6 71.4 0.58 
182 6 8 9 3 26 53.8 46.2 0.72 
217 7 9 2 5 23 69.6 30.4 1.03 
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Figure 3.10: Length distribution of previously discovered viral miRNAs. 
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MDV-1 and MDV-2 which are serotypes of the same virus have been found to share any 
miRNAs (Yao et al., 2007). 
3.4.2 Seed Conservation 
Alignment of the 46 miRNAsC Levy with each other resulted in the observation that the 
predicted miRNA from Group 1 on the minus strand and Group 3 on the plus strand 
were identical.  This could be due to evolutionary duplication, observed also in the 
Mardivirus member herpesvirus of turkeys (Yao et al., 2009).  Functional orthologues of 
mammalian miR-155 have been found in other herpesviruses (1.5.3) but thus far, none 
has been found in OvHV-2 (Zhao et al., 2009).  Alignment of the 46 miRNAsC Levy to all 
the miRNAs published in miRBase (Release 17; 16,772 entries - by using the miRBase 
search tool [mature miRNAs were searched for by SSEARCH with an E-value cut-off of 
100; Supplemental DVD; miRBase]) resulted in 16 miRNAsC Levy having a seed match 
with 76 sequences in the database (Table 3.10); an alignment was determined a seed 
match if nucleotides 1-7, 1-8, or 2-8 from the 5’ end of both sequences were the same, 
G:U pairings were acceptable.  Half of the seed matches were not considered to be 
significant due to being miRNA* species (15) or miRNAs that belonged to poorly 
conserved gene families, none of which have been found in OvHV-2 host species (23).  
The remaining 38 matches which all mapped to the predicted miRNA in Group 217 on 
the minus strand (represented by 6,064 reads) were all members of the mir-216 gene 
family that is broadly conserved and found in most vertebrates (Figure 3.11).  miR-216 
targets PTEN (a tumour suppressor) and Ybx1 (a translation factor) which leads to cell 
survival, hypertrophy, sclerosis, and a decreased cellular response to stress - all 
symptoms observed in MCF (Figure 3.12) (Evdokimova et al., 2006, Kato et al., 2010, 
2009).  In Addition, Ybx1 promotes transcription of HLA II and stabilization of IL-2 
mRNA (1.1.6, 1.2.1) (Chen et al., 2000, Didier et al., 1988).  A decrease in Ybx1 and 
therefore a decrease in HLA II could support immune evasion.  Without Ybx1, IL-2 
mRNA is degraded more rapidly in T cells; this could explain the depleted levels of IL-2  
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3 0/60    
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Group 217 5’-UAAUCUC GCU   A  GU  A -3’ 
miR-216  5’-UAAUCUC GCU   A  UG  A -3’ 
           A   GGC AC  UG 
 
 
Figure 3.11: Alignment of the putative OvHV-2 miRNA found in Group 217 on the 
minus strand against the vertebrate miRNA miR-216. 






















Figure 3.12: Schematic of cellular miR-216 regulation of cellular targets. 
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observed in OvHV-2-infected T cells.  The abundance of the predicted OvHV-2 miRNA 
in Group 217 and the described targets and downstream affects of miR-216 are 
compelling evidence to support that Group 217 is a genuine OvHV-2 miRNA that may 
mimic a cellular miRNA and that may have a role in the pathogenesis of MCF.  The 
remaining predicted miRNAs appear unique to OvHV-2; i.e. they have no cellular 
homologues. 
3.4.3 OvHV-2 miRNAs Predicted by LC Sciences  
The LC Sciences analysis predicted 37 out of the 46 miRNAsC Levy, plus an additional 
27.  The addition of the four candidate miRNAs that were originally passed over for 
northern hybridization validation back into the list of predicted OvHV-2 miRNAs (3.5) 
was justified given that they were also predicted to be miRNAsLC Sciences.  LC Sciences 
predicted 11 miRNAs on the plus strand of the OvHV-2 genome, but only one of them 
was also a miRNAC Levy (Group 3 - group numbers are from 3.3).  The remaining plus 
strand miRNAsLC Sciences were not miRNAsC Levy based on their secondary structure; they 
were not predicted to fold into a stem-loop, there were asymmetrical bulges in the stem, 
or the tag was not contained in the stem.  The two additional miRNAsC Levy (Group 64 
and 96) were most likely missed by LC Sciences due to their exclusion of tags that were 
represented by less than three reads; both groups were represented by one. 
 
The LC Sciences analysis predicted 53 miRNAs on the minus stand, 36 of which were 
also predicted by my study; i.e. miRNAsC Levy.  16 out of the remaining 17 miRNAsLC 
Sciences were not miRNAsC Levy due to their secondary structure prediction; they did not 
form stem-loops or the sequenced tag was not contained within the stem.  The remaining 
one was not considered by manual analysis due to The Genepool’s size filter; excluding 
any tags outside of 22-26 nt in length.  The additional seven miRNAsC Levy on the minus 
strand (Groups 4, 13, 83, 128, 163, 181, and 182) that were not predicted by LC 
Sciences is again most likely due to their read count filter. 
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Both LC Sciences and Glazov et al., 2010 filtered out underrepresented sequence tags 
(<3 for LC Sciences and <2 for Glazov et al., 2010).  These read limits appear arbitrary 
and it seems premature to dismiss these tags before all naturally infected cell types have 
been analyzed.  It may be that in epithelial cells or B cells these tags will be represented 
by a higher number of reads.  Until then, these single read tags will continue to be 
considered predicted OvHV-2 miRNAs. 
3.4.4 OvHV-2 Pre-miRNAs Predicted by Walz et al., 2010 
In 2010, Walz et al. published an article describing their global analysis of evolutionary 
conserved pre-miRNAs of 14 gammaherpesviruses (including OvHV-2) using VMir 
(http://www.hpi-hamburg.de/forschung/abteilungen-forschungsgruppen/zellulaere-
virusabwehr/software-download.html).  The VMir analysis and their following filtering 
steps retained 90% of the known gammaherpesvirus pre-miRNAs known at the time 
(miRBase Release 13 - 146 viral miRNAs; 139 herpesvirus miRNAs) and predicted 88 
candidate pre-miRNAs in OvHV-2 with a score given based on similarity to known viral 
pre-miRNAs (Figure 3.13; Supplemental DVD - Walz). 
 
45 out of the 88 pre-miRNAs predicted by Walz et al. were not represented by 
sequenced tags in this study (31 on the plus strand and 14 on the minus strand).  Out of 
the remaining 43 predicted pre-miRNAs that were represented by tags in this study, 37 
coincided with the predicted miRNAs found by manual analysis (2 on the plus strand 
and 35 on the minus strand) including the 8 that were validated in this study.  27/64 
miRNAs predicted by LC Sciences were not predicted by Walz et al., however 3 of 
these were found across from predicted pre-miRNAs by Walz et al.  9/46 miRNAs 
predicted by manual analysis were not predicted by Walz et al. (Figure 3.14).  There 
were five pre-miRNAs predicted by Walz et al. that were not considered to be candidate 
miRNAs by me based on their secondary structure (Table 3.11).  Given Walz et al.’s 
filtering process and the subsequent loss of 10% of known gammaherpesvirus miRNAs, 
it is possible that the nine miRNAs predicted in this study that Walz et al. did not detect 
were lost in the filtering process. 
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Figure 3.13: VMir scores for the 88 pre-miRNAs predicted by Walz et al., 2010.  
 
Legend: ▲ Plus Strand ♦ Minus Strand.  Legend: predicted by Walz et al. only (45), 
predicted by Walz et al. and represented by tags in The Genepool dataset but not 
predicted by me (5), predicted by Walz et al., LC Sciences and represented by tags in 
The Genepool dataset but not predicted by me (1), predicted by Walz et al. and me (1), 
predicted by Walz et al., LC Sciences, and me (36), validated ovhv2-miRs (predicted by 
all three [8]. 
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Figure 3.14: Venn diagram of predicted miRNAs by me, LC Sciences and Walz et al.; 
(A) includes all miRNA groups created in this study and (B) includes only those groups 
predicted to be miRNAs 
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Table 3.11: Pre-miRNAs predicted by Walz et al. that were not predicted in this study 
due to their secondary structure criteria. 
 
 Walz et al. Predicted Pre-miRNAs Corresponding Tags in This Study 
Group Strand Region (nt) Strand Tag 5’ Start (nt) 
2 + 52 – 124 + 101 
59 - 31174 - 31271 - 31227 
58 + 114512 - 114576 + 114555 
63 + 117491 - 117588 + 117532 
259 - 134805 - 134888 - 134811 
 
The original data in this study was given to LC Sciences to compare their computational 
analysis to this study’s manual analysis.  Their analysis did not include a secondary 
structure component, which is a major element of miRNA biogenesis (1.5.1).  Although 
a more time efficient method of analyzing high throughput sequencing, it appears that 
additional manual analysis will still be required of the investigator if they choose to use 
this kind of computational analysis.  Walz et al., 2010 investigated conserved stem-loops 
in gammaherpesviruses.  The prediction of 88 OvHV-2 pre-miRNAs by Walz et al., 
2010 supports the finding that OvHV-2 might encode a large number of miRNAs.  
Again, the pre-miRNAs that they predicted may be real and just are not expressed in the 
cell line investigated in this study.  The miRNAs predicted in this study and LC Sciences 
that were not predicted by Walz and colleagues may come from stem-loops that are not 
conserved in other gammaherpesviruses.  
3.4.5 Passenger Strands or Additional miRNAs? 
miRNAs* are reported to be present 100-fold less frequently than their duplexed 
miRNAs (Bartel, 2004).  With this gauge, out of the 46 predicted OvHV-2 miRNAs 
detected in this study, 31 may by duplexed with a secondary miRNA (ranging from 1.1-
fold decrease to 87.8-fold decrease) (Table 3.12).  Three out of the 46 were duplexed 
with miRNAs* (ranging from 102.5-fold decrease to 379-fold decrease) and the 
remaining 12 could not be analyzed due to the passenger strand being undetected.   
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Table 3.12: Fold difference between OvHV-2 miRNAs and miRNAs*. 
 
 Reads   
Group miRNA miRNA* Fold Difference Result 
Plus Strand 
3 25 unknown ----- ----- 
64 2 1 2.0 putative secondary miRNA 
96 1 unknown ----- ----- 
Minus Strand 
1 21 unknown ----- ----- 
3 196 54 3.6 putative secondary miRNA 
4 1 unknown ----- ----- 
miR-1 10588 586 18.1 putative secondary miRNA 
6 253 124 2.0 putative secondary miRNA 
13 1 unknown ----- ----- 
34 434 223 1.9 putative secondary miRNA 
miR-2 39169 2201 17.8 putative secondary miRNA 
36 6200 1825 3.4 putative secondary miRNA 
37 6015 394 15.3 putative secondary miRNA 
38 322 303 1.1 putative secondary miRNA 
39 4717 377 12.5 putative secondary miRNA 
40 1014 424 2.4 putative secondary miRNA 
41 21686 881 24.6 putative secondary miRNA 
42 740 408 1.8 putative secondary miRNA 
43 31227 1720 18.2 putative secondary miRNA 
miR-3 14694 420 35.0 putative secondary miRNA 
45 6487 1459 4.4 putative secondary miRNA 
46 9219 4065 2.3 putative secondary miRNA 
miR-4 17508 6102 2.9 putative secondary miRNA 
48 8095 152 53.3 putative secondary miRNA 
49 2967 unknown ----- ----- 
50 3794 273 13.9 putative secondary miRNA 
51 24497 274 89.4 putative secondary miRNA 
53 14966 146 102.5 miRNA* 
54 1357 660 2.1 putative secondary miRNA 
miR-5 11187 2241 5.0 putative secondary miRNA 
57 5457 446 12.2 putative secondary miRNA 
58 942 463 2.0 putative secondary miRNA 
60 351 4 87.8 putative secondary miRNA 
miR-6 10378 89 116.6 miRNA* 
62 1535 18 85.3 putative secondary miRNA 
63 517 33 15.7 putative secondary miRNA 
miR-7 16574 2598 6.4 putative secondary miRNA 
67 7834 2015 3.9 putative secondary miRNA 
miR-8 46048 3732 12.3 putative secondary miRNA 
83 1 unknown ----- ----- 
95 1 unknown ----- ----- 
128 1 unknown ----- ----- 
163 1 unknown ----- ----- 
181 1 unknown ----- ----- 
182 1 unknown ----- ----- 
217 6064 16 379 miRNA* 
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3.4.6 Ovhv2-miR Predicted Targets 
OvHV-2 Gene Targets 
It is beyond the remit of this thesis to explore the possible roles of these ovhv2-miRs in 
OvHV-2 gene regulation as there is very little, if any, means to tell a true target from a 
false positive when using bioinformatics to predict targets (Dr Finn Grey, 
communication) (2.8).  Identification of true targets requires supporting evidence from 
microarray analysis or knockdown, -up, pull-down, or luciferase assays.  However, there 
were a number of interesting targets predicted that warrant conjecture.  OvHV-2 encodes 
a number of transcription factors such as Ov2, Ov6, ORF50, and ORF57.  My analysis 
predicted that Ov2 is targeted by ovhv2-miR-2, -miR-4, and -miR-5, Ov6 is targeted by 
ovhv2-miR-3 and -miR-8, ORF50 is targeted by ovhv2-miR-3, -miR-5, -miR-6, and -
miR-8, and ORF57 is targeted by ovhv2-miR-7 and -miR-8.  The last three are 
immediate-early ORFs that may affect OvHV-2 gene expression and initiate OvHV-2 
replication (1.1.6-7) (Boyne et al., 2006, Frame et al., 2008).  Ov2 encodes a DNA 
binding protein homologous to cellular BATF, CREB, and Jun (Hart et al., 2007).  
CREB and Jun are both transcription factors associated with various cancers and BATF 
is a negative regulator of Jun (GeneCards®, KEGG PATHWAY Database; 2.6.3).  
OvHV-2 ORF20 (targeted by ovhv2-miR-2, -miR-5, -miR-6, -miR-7, and -miR-8) is 
homologous to ORFs of the same name in the gammaherpesviruses MHV-68 and 
KSHV, and BXRF1 in EBV, UL76 in the betaherpesvirus HCMV, and UL24 in the 
alphaherpesvirus HSV-1 (Nascimento et al., 2009).  UL24 is important for viral 
reactivation and replication; it mediates the distribution of cellular nucleolin (involved in 
ribosome production, and decondensing chromatin) and causes cell cycle arrest by 
indirectly inhibiting cyclin B signalling (4.1) (Nascimento et al., 2009).  ORF73 
(targeted by ovhv2-miR-6 and -miR-8) is conserved in all gammaherpesviruses and is 
required for the maintenance and segregation of latent viral genomes in dividing cells 
(1.1.6-7).  OvHV-2 miRNAs could be used to down-regulate these ORFs to balance 
latency with reactivation and/or fine-tune their expression to control downstream protein 
expression.  OvHV-2 encodes a number of viral homologues to cellular genes such as 
Ov2.5, Ov3, Ov4.5, and Ov9.  My analysis predicted that Ov2.5 is targeted by ovhv2-
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miR-4, Ov3 is targeted by ovhv2-miR-3, -miR-6, and -miR-8, Ov4.5 is targeted by 
ovhv2-miR-4 and -miR-8, and Ov9 is targeted by ovhv2-miR-5 and -miR-6.  Ov2.5 
encodes an IL-10 homologue which can also initiate transcription by activating the JAK-
STAT pathway (GeneCards®).  In addition, IL-10 can inhibit NF-κB which can lead to 
the development of abnormal immune cells, and suppress cytokine expression by T 
helper cells, antigen presentation by MHC class II, and macrophage activation.  Ov3 
encodes a homologue of SEMA7A which is a membrane-bound signalling protein found 
on activated lymphocytes (Hart et al., 2007).  Ov4.5 and Ov9 both encode Bcl-2 
homologues; Ov4.5 encodes a viral Bcl-2 similar to that found in EBV (BALF1) and 
Ov9 encodes a viral Bcl-2 protein that most closely resembles cellular BAX.  BAX is 
anti-apoptotic and BALF1 acts indirectly to regulate BAX (Hardwick et al., 2003).  
Interestingly, over-expression of cellular anti-apoptotic Bcl-2 can lead to 
lymphoproliferation.  OvHV-2 miRNA regulation of these ORFs could support immune 
evasion by balancing restriction of the infected cell’s ability to respond to stress-stimuli 
with necessary transcription as well as balancing apoptotic factors so that an increased 
number of newly synthesized virions can accumulate before the host cell lyses.    
 
Ov5 (predicted to be targeted by ovhv2-miR-1 and -miR-8) encodes a homologue of the 
transmembrane EBV G protein-coupled receptor BILF1 (Hart et al., 2007).  BILF1 
suppresses expression of MHC class I on the cell surface (by marking cell surface MHC 
class I and newly translated MHC class I for degradation) suppresses CXCL12 
signalling (promotes T cell migration) by binding to its receptor CXCR4, and is 
involved in cell transformation (Lyngaa et al., 2010, Nijmeijer et al., 2010, Zuo et al., 
2011).  ORF58 (targeted by ovhv2-miR-3, -miR-5, -miR-7, and -miR-8) is a member of 
the BMRF2 gene family that is conserved in all gammaherpesviruses and is involved 
with viral spread to neighbouring cells (Gill et al., 2008).  ORF58 is necessary for 
transport of ORF27 to the plasma membrane; this then initiates actin polymerization to 
form frond-like protrusions that carry newly exocytosed virions to adjacent uninfected 
cells.  These ORFs could be targeted by miRNAs to influence virion production and 
spread or to maintain latency.                                 
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Five miRNAsC Levy are encoded directly opposite six OvHV-2 ORFs which suggests that 
these ORFs may be regulated by viral miRNAs (Table 3.13).  They include ORFs that 
express three tegument proteins (ORF3, ORF33, ORF64) an immediate-early 
transcription factor (Ov6) a putative glycoprotein (ORF31) and a nuclear capsid 
localization factor (ORF32).  However, none of these miRNAsC Levy were predicted by 
LC Sciences or Walz et al. (stem-loop secondary structure is not predicted to be 
conserved in other herpesviruses) and taken alongside their low read count (reads = 1) 
their genomic locations (far from the three miRNA clusters) and that some of the 
validated miRNAs in this study have been predicted to target some of these same ORFs 
without having to be directly opposite them, these tags may not represent expressed 
OvHV-2 miRNAs; validation by knock-down assays would be necessary. 
 
Table 3.13: Predicted OvHV-2 miRNAs encoded opposite OvHV-2 Orfs; all from the 
minus strand. 
 
Group Reads Target 
13 1 Orf3 
Orf31 
Orf32 95 1 
Orf33 





Bovine Gene Targets 
Aside from the interesting predicted viral targets of the ovhv2-miRs, there were also a 
number of interesting predicted bovine targets.     
 
ALDH3A2 and NDUFB5 (targeted by ovhv2-miR-1) are involved in cellular 
metabolism; ALDH3A2 catalyzes the oxidation of long-chain aliphatic aldehydes to 
fatty acids which are used for energy and NDUFB5 is involved in mitochondrial 
respiration as a subunit of NADH:ubiquinone oxidoreductase - a resultant depletion of 
ATP in the cytosol due to downregulation of these two proteins could trigger apoptosis 
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(Hardwick et al., 2003).  PERP (also targeted by ovhv2-miR-1) activates the p53-
dependent apoptotic pathway; transformed cell lines contain more p53 than normal cells, 
therefore it is conceivable that more available p53 would increase the incidence of 
PERP-activated apoptosis.  Ovhv-2 miRNA targeting of these proteins could balance 
pro- and anti-apoptotic pathways.   
 
A2M (targeted by ovhv2-miR-1) inhibits proteases and Splicing Factor 3B and SF3B14 
(both targeted by ovhv2-miR-5) are associated with spliceosomes.  ANK1 (also targeted 
by ovhv2-miR-1) links the lymphocyte membrane glycoprotein CD44 to the 
cytoskeleton.  CD44 is a hyaluronic acid receptor, which when bound to its ligand leads 
to lymphocyte activation (proliferation).  OvHV-2 miRNA targeting of these proteins 
could influence protein expression, and signal transduction to support viral persistence.        
 
REPS2 (targeted by ovhv2-miR-1) inhibits growth factor signalling by causing the 
internalization of growth factor receptors.  CEP350 (targeted by ovhv2-miR-3) anchors 
microtubules at the centrosome in preparation for cell division and CDC25C (targeted 
by ovhv2-miR-5) activates the Cdk1:cyclin B complex which initiates entry into mitosis.  
OvHV-2 miRNA targeting of these proteins would support cell growth and viral 
replication by delaying cytokinesis until the viral genome was duplicated and tethered to 
the cellular chromatin (1.1.6). 
 
There were also a number of predicted cellular targets that could influence control of 
cellular processes.  Exportin 4 (targeted by ovhv2-miR-1) shuttles proteins from the 
nucleus to the cytosol with the same cofactor associated with Exportin 5 in miRNA 
biogenesis (1.3.1) (GeneCards®); OvHV-2 miRNA targeting of Exportin 4 could 
increase the availability of its cofactor to associate with Exportin 5, thus supporting 
miRNA biogenesis.  UBE2G1 (targeted by ovhv2-miR-5) is an E2 ubiquitin-conjugating 
enzyme and NDFIP2 (targeted by ovhv2-miR-3) activates a number of E3 ubiquitin-
ligases which have a vast number of regulatory roles in cell biology; of interest, 
implication in the regulation and differentiation of lymphoid cells, involvement in the 
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budding of many viruses, inhibition of TGF-β signalling by targeting Smad2 and 
TGFR1 for degradation (anti-apoptotic; Table 1.4) and inhibits activation-induced cell 
death in T cells.  MYO19 (targeted by ovhv2-miR-4) is an actin filament transport 
molecule and KLHL31 and CREM (both targeted by ovhv2-miR-5) repress or initiate 
transcription.  OvHV-2 miRNA targeting of these proteins could fine tune any number 
of biological processes.  
 
CREB and CREM are both involved in human T cell lymphotropic virus type 1 (HTLV-
1) infection (KEGG PATHWAY Database).  HTLV-1 is a human retrovirus that causes 
adult T cell leukaemia (ATL) from infected CD4+ T cells and uses CREB and CREM to 
initiate viral transcription (Lemasson et al., 2007).  The evidence that another 
mammalian virus uses these cellular proteins for transcription supports the finding that 
OvHV-2 might encode a CREB-like protein (Ov2) and target it and CREM in order to 
control its transcription.  Lastly, TLR7 (targeted by ovhv2-miR-1) is a single-stranded 
RNA receptor that is associated with the production of autoantibodies (Green et al., 
2011).  Activation by nucleic acids leads to activation of NF-κB, cytokine secretion, and 
inflammation (GeneCards®).  Targeting of this protein by viral miRNAs could support 
immune evasion.   
 
The pathology of MCF is thought to be due to the deregulation of cellular processes in 
the presence of OvHV-2.  This deregulation leads to lymphoproliferation and 
cytotoxicity.  OvHV-2 is now known to express miRNAs which could have an affect on 
many biological pathways.  The small selection of predicted viral and cellular targets 
looked at above for just 8 of the 46 predicted miRNAs highlight a number of biological 
pathways that could be involved in various pathogenic effects, such as transcription 
factors and inhibitors of pathways that control the cell’s ability to respond to stress and 
abnormalities.  miRNAs are used as a means to fine tune biological processes and too 
much or too little of an effect could have significant consequences for the cell and the 
animal as a whole.    
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4.1 AIMS 
The aim of this project was to determine if the predicted ovhv2-miR-5, -miR-6, and -
miR7 target sites in the 3’ UTR of OvHV-2 ORF20 were functional by dual luciferase 
assay.   
4.2 INTRODUCTION 
The breadth of potential ORF targeting by the ovhv2-miRs suggests that the virus may 
use self-encoded miRNAs to regulate gene expression (3.7).  OvHV-2 ORF20 was 
selected for initial target validation because in related viruses, it is involved in 
controlling the cell cycle (a major feature in the pathogenesis of MCF; 3.8.5) and was 
predicted to be targeted by ovhv2-miR-5, -miR-6, and -miR-7 in the 3’ UTR (Figure 
4.1).  Nascimento et al., 2009, 2007 characterized orf20 in MHV68 and three of its 
homologues across the herpesvirus subfamilies (HSV-1, HCMV, and KSHV) and found 
that it localized in the nucleus and caused G2/M cell cycle arrest and eventually 
apoptosis.  Through an as yet unknown mechanism, presence of orf20 was found to keep 
the Cdk1:cyclin B complex in its inactive state by maintaining phosphorylation of Cdk1.  
As discussed previously in section 3.4.6, activation of the Cdk1:cyclin B complex by 
CDC25C is necessary for the initiation of mitosis.  Their evidence suggested that 
apoptosis was not directed by orf20.  Cell cycle arrest has been suggested to benefit 
herpesvirus replication and immune evasion (Davy et al., 2007) (Figure 4.2). 
 
Before a functional analysis of ovhv2-miRs on OvHV-2 ORF20, the cellular localization 
of orf20 was characterized to assess its similarity to the characterized homologues in 
other herpesviruses.  Immunocytochemical staining of cells transfected with a tagged 
orf20 expressing-plasmid was used to determine the occupied cellular compartment.  A 
dual luciferase assay was used for the functional analysis because knockdown of 
luciferase expression that contains a miRNA target site upon treatment with the 
corresponding miRNA is easily measurable and has the additional benefit of co-
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expressing firefly luciferase unaffected by miRNA treatment to control for discrepancies 
in expression readings.     
4.3 RESULTS 
4.3.1 Cellular Localization of Orf20 
BHK cells were transfected with tagged ORF20-expressing plasmids to determine the 
protein’s cellular localization.  AlHV-1 ORF20 was used due to the conservation of this 
ORF in all herpesviruses (1.2, 3.8.5) AlHV-1 ORF20 and OvHV-2 ORF20 have 60% 
sequence identity at the amino acid level (Figure 4.3) and the availability of the cloned 
FLAG-tagged gene (Aschman, 2008).  To insert ORF20-FLAG into the pLZ3-CIng-ps-
linker plasmid, a 5’ XhoI and 3’ NheI restriction site was added to the insert by PCR, 
using Pfu DNA polymerase (2.1.2, Appendix 2-3).  PLZ3-CIng-ps-linker was used for 
co-localization purposes as it contains nEGFP (nuclear enhanced green fluorescent 
protein) and an internal ribosome entry site (IRES) to allow co-expression.  The 
transfection of BHK cells was optimized using the EGFP expressing plasmid pEGFP-N1 
by varying the ratio of plasmid DNA to the lipid transfection reagent, Lipofectamine 
2000 (2.4.4, Appendix 3).  The transfected cells were viewed, and the optimal conditions 
were determined by florescence microscopy.  Florescence was observed in every well 
but the optimal ratio was determined to be 1:8.  Successful transfection of BHKs with 
pLZ3-CIng-ps-linker[ORF20-FLAG] was observed by expression of nEGFP (Figure 
4.4) and orf20 was observed to localize in both the nucleus and cytoplasm based on 
staining for FLAG (2.4.6) (Figure 4.5).  This suggests that OvHV-2 orf20 could act 
similarly to MHV-68 orf20 as it also localizes in the nucleus. 
4.3.2 OvHV-2 miRNA Regulation of ORF20 
To determine if the predicted target sites for ovhv2-miR-5, -miR-6, and -miR-7 in the 3’ 
UTR of OvHV-2 ORF20 were functional, a dual luciferase assay was designed so that a 
measure of miRNA silencing could be made (2.5.1).  pEGFP-N1 was used as a 
transfection control, and a psiCHECK™ vector with the complementary sequence to  
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Figure 4.1: OvHV-2 ORF20 3’ UTR (boundaries are in yellow) isolated by PCR; 5’ 
XhoI and 3’ NotI restriction sites  are in red and putative ovhv2-miR target sites (from 5’ 
→ 3’, miR-5, miR-7, and miR-6) are in green. 













































Figure 4.2: Simplified schematic of M phase initiation by Cdk1:cyclin B and the 
observed affect in the presence of herpesvirus orf20.  





CLUSTAL 2.1 multiple sequence alignment 
 
 
AlHV-1 MFP-LLGQSACAALNSLPAKRKKAGLQAHRKVYKQLLQYHSFTKINKFLELKHPDPKKVK 59 
OvHV-2 MFQSILSQRPICALSSLPAKRKVAGLNAHRKVYKQLMLYTSFGKVNKFLGLQHICPKKVK 60 
       **  :*.* . .**.******* ***:*********: * ** *:**** *:*  ***** 
 
AlHV-1 YRLFFEVSLGPRIVDVIVLTSYETERVCYVVELKTCLGSEFNFTSVRAAQRTQGLCQLYD 119 
OvHV-2 YKLFFEVSLGPRIADIIVLASQGEQRMCYIIELKTCLGAHFVPNPIKLAQRSQGLCQLHD 120 
       *:***********.*:***:*   :*:**::*******:.*  ..:: ***:******:* 
 
AlHV-1 STKYLSNNAPLGGERWEVRAHLLFKSQSAMKTLYVEHPGFQFNQLQCTTGALSVFLKSRE 179 
OvHV-2 STKYLCNNAPRGEERWVVQAHLLFKSQVSLKTLHSEHPTFPFALIQSKEEALSAFLRLRE 180 
       *****.**** * *** *:******** ::***: *** * *  :*..  ***.**: ** 
 
AlHV-1 DVACRQLLYQGLQCAALAKKMRVLGTKSTKRARDKPTQVSRVPAQRSPVQKARGRKQAES 239 
OvHV-2 DAEFKQVLRQGCPPAEVAKGMRLLGPKPQERARYKPPKVPRAQAQRLALPKARGRKQNAS 240 
       *.  :*:* **   * :** **:**.*. :*** **.:*.*. *** .: *******  * 
 
AlHV-1 HKKGASKGRAG 250 
OvHV-2 HKKGAVKNGA- 250 























Figure 4.3: Amino acid conservation between AlHV-1 ORF20 and OvHV-2 ORF20 
using ClustalW2 (2.6.3). 











Figure 4.4: Confocal images of BHK transfection controls after 48 hrs; (A-B) non-
transfected cells - (A) shows Topro-3 nuclear staining and (B) shows the same cells for 
FLAG staining; (C-D) pLZ3-CIng-ps-linker transfected cells - (C) shows Topro-3 















Figure 4.5: Confocal images of BHK transfection with pLZ3-CIng-ps-linker[ORF20-
FLAG] after 48 hrs; (A-B) nuclear localized orf20 - (A) shows Topro-3 nuclear staining 
and (B) shows the same cells for FLAG staining; (C-D) cytoplasm localized orf20 - (C) 




Chapter Four                                  Analysis of OvHV-2 ORF20 as an Ovhv2-miR Target 
 116 
 
mcmv-miR-M23-2 (kindly donated by Dr Amy Buck, University of Edinburgh) co-
transfected with a mimic of mcmv-miR-M23-2 was used as a positive control.  Mimics 
of OvHV-2 miRNAs that were not predicted to target ORF20 (ovhv2-miR-1, -miR-2, 
and -miR-3) were used as additional negative controls (Table 4.1).  
 
The non-transfected and mock transfected samples were used to correct for background 
luciferase readings; the average of the six firefly readings was subtracted from all the 
other firefly readings (the same was done with the Renilla readings).  The reading ratio 
of Renilla to firefly (R/F) was used to normalize the Renilla readings.  The negative 
control psiCHECK™ co-transfected with ovhv2-miR-5, -miR-6, and -miR7 mimics 
showed significant up-regulation with a miRNA mimic concentration of 50 nM (p = 
0.008), but there was no significant difference when treated with 5 nM or 25 nM miRNA 
mimics (p5nM = 0.037 and p25nM = 0.072) (Figure 4.6, Table 4.2).  The positive control 
psiCHECK™[comp. miR-M23-2] co-transfected with mcmv-miR-M23-2 mimic showed 
significant down-regulation for all three mimic concentrations (p5nM = 0.00004, p25nM = 
0.00009, and p50nM = 0.000001).  Dual luciferase assay readings can be found in the 
Supplemental DVD; Luciferase Assay - 3 replicates.  
 
The negative control psiCHECK™[ORF20 3’ UTR] co-transfected with ovhv2-miR-1, -
miR-2, and -miR3 mimics showed no significant difference for all three mimic 
concentrations (p5nM = 0.558, p25nM = 0.122, and p50nM = 0.280) (Figure 4.7, Table 4.3).  
psiCHECK™[ORF20 3’ UTR] co-transfected with ovhv2-miR-5, -miR-6, and -miR-7 
mimics also showed no significant difference for all three mimic concentrations (p5nM = 
0.490, p25nM = 0.435, and p50nM = 0.337). 
 
The dual luciferase assay was repeated with higher concentrations of miRNA mimic and 
using a GloMax® luminometer that could read 96-well plates allowed for six replicates 
in the hopes of decreasing the variability observed between three replicates (Table 4.4). 
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Table 4.1: miRNA silencing dual luciferase triplicate assay co-transfection conditions. 
 
Well Vector miR mimic [miR Mimic] 
Controls 
1-3 untransfected   
4-6 mock transfected   
7-9 pEGFP-N1   
10-12 psiCHECK™   
22-24 psiCHECK™ miR-5, -6, -7 5 nM 
25-27 psiCHECK™ miR-5, -6, -7 25 nM 
28-30 psiCHECK™ miR-5, -6, -7 50 nM 
31-33 psiCHECK™[comp. miR-m23-2]   
34-36 psiCHECK™[comp. miR-m23-2] miR-m23-2 5 nM 
37-39 psiCHECK™[comp. miR-m23-2] miR-m23-2 25 nM 
40-42 psiCHECK™[comp. miR-m23-2] miR-m23-2 50 nM 
43-45 psiCHECK™[ORF20 3’ UTR]   
46-48 psiCHECK™[ORF20 3’ UTR] miR-1, -2, -3 5 nM 
49-51 psiCHECK™[ORF20 3’ UTR] miR-1, -2, -3 25 nM 
52-54 psiCHECK™[ORF20 3’ UTR] miR-1, -2, -3 50 nM 
Test 
55-57 psiCHECK™[ORF20 3’ UTR] miR-5, -6, -7 5 nM 
58-60 psiCHECK™[ORF20 3’ UTR] miR-5, -6, -7 25 nM 
61-63 psiCHECK™[ORF20 3’ UTR] miR-5, -6, -7 50 nM 
 
Table 4.2: miRNA silencing dual luciferase sextuplicate assay co-transfection 
conditions. 
 
Well Vector miR Mimic [Mimic]  
Controls 
1-6 Untransfected   
7-12 mock transfected   
13-18 psiCHECK™[comp. miR-m23-2]   
19-24 psiCHECK™[comp. miR-m23-2] miR-m23-2 100 nM 
25-30 psiCHECK™[ORF20 3’ UTR]   
31-36 psiCHECK™[ORF20 3’ UTR] scrambled 50 nM 
37-42 psiCHECK™[ORF20 3’ UTR] scrambled 100 nM 
Test 
43-48 psiCHECK™[ORF20 3’ UTR] miR-5, -6, -7 50 nM 
49-54 psiCHECK™[ORF20 3’ UTR] miR-5, -6, -7 100 nM 
55-60 psiCHECK™[ORF20 3’ UTR] miR-5 100 nM 
61-66 psiCHECK™[ORF20 3’ UTR] miR-6 100 nM 
67-72 psiCHECK™[ORF20 3’ UTR] miR-7 100 nM 
 
The luminometer readings were corrected and normalized in the same way described 
previously (Supplemental DVD; Luciferase Assay - 6 replicates).  The positive control 
psiCHECK™[comp. miR-m23-2] treated with 100 nM mcmv-miR-M23-2 mimic 
showed significant down-regulation (Figure 4.8, Table 4.5). 































































































































































Figure 4.6: Controls for OvVH-2 ORF20 3’ UTR miRNA silencing triplicate dual 
luciferase assay; untreated or control-treated samples are shown in green while the 




Table 4.3: P-values for triplicate dual luciferase controls. 
 
Control Vector Treatment P-value Result 
5 nM ovhv2-miR-5-7 0.037 
Not 
Significant 




50 nM ovhv2-miR-5-7 0.008 Significant 
5 nM mcmv-miR-m23-2 0.00004 Significant 
25 nM mcmv-miR-m23-2 0.00009 Significant psiCHECK™[comp. miR-m23-2] 
50 nM mcmv-miR-m23-2 0.000001 Significant 
 
Legend: A two-tailed, independent t-test, α = 0.025 was used against the psiCHECK™ 
vector and a one-tailed, independent t-test α = 0.050 was used against the 
psiCHECK™[comp. miR-m23-2] vector. 

















































































































































































Figure 4.7: Negative control and sample for miRNA silencing triplicate dual luciferase 
assay; untreated or control-treated samples are shown in green while the experimentally-







Table 4.4: P-values for triplicate dual luciferase assay. 
 
Control Vector Treatment P-value Result 
5 nM ovhv2-miR-1-3 0.558 Not Significant 
25 nM ovhv2-miR-1-3 0.122 Not Significant psiCHECK™[ORF20 3’ UTR] 
50 nM ovhv2-miR-1-3 0.280 Not Significant 
5 nM ovhv2-miR-1-3 5 nM ovhv2-miR-5-7 0.490 Not Significant 
25 nM ovhv2-miR-1-3 25 nM ovhv2-miR-5-7 0.435 Not Significant 
50 nM ovhv2-miR-1-3 50 nM ovhv2-miR-5-7 0.337 Not Significant 
 
Legend: A two-tailed, independent t-test, α = 0.025 was used against the 
psiCHECK™[ORF20 3’ UTR] vector and a one-tailed, independent t-test α = 0.050 was 
used against the control mimics ovhv2-miR-1, -miR-2, and -miR-3. 
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Figure 4.8: Positive control for miRNA silencing sextuplicate dual luciferase assay; 
untreated or control-treated samples are shown in green while the experimentally-treated 







Table 4.5: P-values for sextuplicate dual luciferase control. 
 
Control Vector Treatment P-value Result 
psiCHECK™[comp. miR-m23-2] 100 nM mcmv-miR-m23-2 0.000003 Significant 
 
Legend: A one-tailed, independent t-test α = 0.050 was used against the 
psiCHECK™[comp. miR-m23-2] vector. 
 
 



















































































































































































Figure 4.9: miRNA silencing sextuplicate dual luciferase assay, untreated or control-






Table 4.6: P-values for sextuplicate dual luciferase assay. 
 
Control Vector Treatment P-value Result 




















Legend: A one-tailed, independent t-test α = 0.050 was used. 
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The negative control psiCHECK™[ORF20 3’ UTR] was co-transfected with a 
scrambled miRNA mimic which was used to compare luciferase levels with the same 
plasmid that had been co-transfected with targeting mimics.  Regardless of 
concentration, all luciferase levels read from samples treated with targeting mimics were 
significantly higher than the controls (p50nM ovhv2-miR-5-7 = 0.034, p100nM ovhv2-miR-5-7 = 
0.005, p100nM ovhv2-miR-5 = 0.0004, p100nM ovhv2-miR-6 = 0.00000009, and p100nM ovhv2-miR-7 = 
0.004) (Figure 4.9, Table 4.6). 
4.4 DISCUSSION 
Two dual-luciferase assays (one in triplicate with manual mixing of the assay reagents 
and one with six replicates with automatic mixing of the assay reagents) were performed 
to elucidate the ability of ovhv2-miR-5, -miR-6, and -miR-7 to knock down OvHV-2 
ORF20.  The negative and positive controls used in the assays showed that the assays 
worked.  Addition of non-specific mimics (those not predicted to target transcripts 
expressed from the vector) resulted in a noticeable increase (significant in one case of 
six) in luciferase expression.  5 nM and 25 nM mimic treatment increased luciferase 
expression by ~32% (not significant; p5nM = 0.037 and p25nM = 0.072) while 50nM 
mimic treatment gave rise to a 43% increase (significant; p = 0.008).  There was a ~ 
97% knockdown observed for psiCHECK™[comp. miR-m23-2] treated with mcmv-
miR-m23-2 mimic in both assays, however knock-down of ORF20 was not observed.  
The luciferase expression of psiCHECK™ and psiCHECK™[comp. miR-m23-2] were 
not significantly different (p = 0.032) however psiCHECK™[ORF20 3’ UTR] luciferase 
expression was significantly lower (ppsiCHECK™ = 0.004 and ppsiCHECK™[comp. miR-m23-2] = 
0.0001) (Table 4.7).  This may be due to the size of the target region inserted into the 
vector; psiCHECK™[comp. miR-m23-2] had the addition of ~21 bp downstream of the 
Renilla luciferase whereas psiCHECK™[ORF20 3’ UTR] had ~1530 bp.          
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Table 4.7: P-values of the three test vectors. 
 
 Triplicate Study Sextuplicate Study 




psiCHECK™ ------- ------- ------- ------- ------- ------- 
psiCHECK™[comp. 
miR-m23-2] 
0.032 ------- ------- ------- 0.000006 0.000006 
psiCHECK™[ORF20 
3’ UTR] 
0.004 0.0001 ------- ------ ------- ------- 
 
Legend: Two-tailed, independent t-test p-values comparing luciferase expression levels 
of the three test plasmids (α = 0.025); psiCHECK™, psiCHECK™[comp. M23-2] 
(M23-2) and  psiCHECK™[ORF20 3’ UTR] (ORF20). 
 
In the triplicate assay, there was no significant difference (Table 4.3) in luciferase 
expression of psiCHECK™[ORF20 3’ UTR] when treated with control miRNA mimics 
or targeting miRNA mimics.  The sextuplicate assay resulted in a significant increase 
(Table 4.6) of luciferase expression when treated with targeting mimics; all three 
together or individually.  50 nM ovhv2-miR mimics caused a luciferase expression 
increase of 15% and 100 nM ovhv2-miR mimics caused an increase of 26%.  
Transfection with individual ovhv2-miRs resulted in a 49% increase with ovhv2-miR-5, 
a 43% increase with ovhv2-mir-6, and a 44% increase with ovhv2-miR-7.  Based on 
these results, it does not appear that ovhv2-miR-5, -miR-6, or -miR-7 downregulate 
OvHV2 ORF20 by binding to the 3’ UTR.  It is feasible however that they may still 
target ORF20 and affect its rate of translation.  It does not appear that the three ovhv2-
miRs synergize as the greater effect was observed when they were expressed 
individually.  Further repeats of these assays are currently being conducted in the lab.           
 
It is interesting that two factors that interact with the Cdk1:cyclin B mechanism of the 
cell cycle have been predicted as OvHV-2 miRNA targets; OvHV2 ORF20 and cellular 
CDC25C (both are predicted to be targets of ovhv2-miR-5).  As stated previously, the 
mechanism of regulation of the cell cycle by orf20 is unknown, but the presence of orf20 
inhibits the activation of the Cdk1:cyclin B complex by maintaining Cdk1 in its 
phosphorylated form.  CDC25C is the protein that activates the complex by 
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dephosphorylating Cdk1.  It is possible that orf20 interacts with CDC25C to cause cell 
cycle arrest while OvHV-2 expressed miRNAs fine tune this interaction for the benefit 
of the virus’s survival.    
 
If ovhv2-miR-5, -miR-6, and -miR-7 do target the 3’ UTR of ORF20, it does not appear 
that they downregulate it.  If they do, it may be that their binding to the transcript 
impedes other suppressing factors allowing more efficient translation (as seen in the 
sextuplicate assay).  Again, OvHV-2 miRNA targeting of ORF20 is still being looked at 
in the lab, but this also shows the inherent difficulty in the study of miRNAs.  Although 
bioinformatic analysis predicted three miRNA target sites in the 3’ UTR of ORF20, 
there is the very real possibility that ORF20 is a false target.  Before hypotheses about 
OvHV-2 miRNA regulation can be made, true targets need to be identified, and that 
work is continuing.   
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5.1 AIMS 
To characterize OvHV-2 gene expression by using high throughput sequencing to 
identify the mRNA transcripts expressed in the bovine LGL cell line BJ1035, and 
bioinformatics to determine the genes transcribed. 
5.2 INTRODUCTION 
At present, high throughput sequencing transcriptomic investigations involving 
herpesviruses has only covered the changes in the cellular transcriptome in response to a 
gammaherpesvirus protein expressed during the lytic cycle (orf37 in KSHV and MHV-
68) (Clyde et al., 2011).  Previous studies on OvHV-2 gene expression have so far 
focused on a handful of genes and have determined that their expression differs 
depending on if the virus is undergoing lytic or latent replication or has infected a 
reservoir or susceptible host.  In the reservoir host, OvHV-2 maintains a low-level of 
ORF expression and can clearly be defined as latent; in susceptible species, ORF 
expression is increased - BJ1035s contain a mixed population of OvHV-2 activity, with 
a low level of reactivity occurring (5.4, Thonur et al., 2006).  The Illumina Solexa GAII 
used in the identification of the OvHV-2 miRNAs (Chapter Three) provided the 
opportunity to take the first look at the OvHV-2 transcriptome in a susceptible host.  
This method was used as it is reported to be more sensitive than microarray.  Analysis of 
the specific activation of certain ORFs could lead to insight on the mechanism of MCF.   
5.3 RESULTS 
5.3.1 RNA Extraction  
Three RNA samples were extracted from BJ1035 cells (2.1.11) and sent to The 
Genepool to isolate the mRNA, construct and sequence cDNA libraries made up of 21 nt 
tags, and map to the OvHV2 genome (2.1.13).      
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5.3.2 Sequencing Analysis 
For the three RNA samples, the sequenced reads were mapped to the OvHV-2 genome 
using the default settings of MAQ with a mapping quality of 30 (2.1.13; Table 5.1). 
 
Table 5.1: Summary of Solexa high throughput sequencing results. 
 
  Mapped to OvHV-2 
Sample Total Reads Reads Plus Strand Minus Strand 
1 7,230,508 31,512 (0.44%) 12,077 19,435 
2 16,450,709 30,229 (0.18%) 6,536 23,693 
3 16,335,916 47,108 (0.29%) 19,667 27,441 
 
There were 2,046 unique tags mapped to the OvHV-2 genome; 1,507 tags were found in 
at least two samples and 697 tags contained point mutations between samples at the 
same genome location (Supplemental DVD; Tables 5.1 and 5.2). 
5.3.3 Determining OvHV-2 Open Reading Frame Parameters 
The coordinates for the 73 predicted OvHV-2 genes were compiled using the OvHV-2 
genome published in GenBank (AY839756; 2.9; Hart et al., 2007) (Supplemental DVD; 
Table 5.3).  This genome was isolated from BJ1035 cells, the same cell line used in this 
study.      
5.3.4 OvHV-2 Expression Profile in BJ1035 Cells 
Using the compiled gene locations (5.3.3) sequenced tags for the three RNA samples 
could be assigned to OvHV-2 ORFs (Figure 5.1).  Attention was given to genes that 
were expressed more (i.e. had a higher read count) than genes in the rest of each sample.  
Initially, highly expressed genes were attempted to be isolated by determining the mean 
read count and taking those genes that were expressed a given standard deviation above 
the mean.  This however resulted in too few highlighted genes in some samples and too 
many in others (Table 5.3).  Using the TATA and polyA signal coordinates (5.3.1) the 
sum of the reads for each viral ORF was determined and the mean for the three samples 
was taken to analyze the relative ORF expression levels throughout the genome (Figure 
5.2, Table 5.2).        
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Figure 5.1: Frequency of Solexa sequenced tags mapped along the OvHV-2 genome for 
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Figure 5.2: Mean read frequency of the three samples in Figure 5.1 with the mean sum 
of the reads contained within ORFs, along the OvHV-2 genome with labelled peaks of 
interest; predicted ORFs are shown between the plus and minus tag frequencies - ORF in 
blue and the coding region in black. 
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Ov2 7263 18700 5784 10582.3 7068.9 
Ov2.5 103 2 0 35.0 58.9 
Ov3 90 26 192 102.7 83.7 
Ov3.5 35 2 53 30.0 25.9 
ORF3 392 53 487 310.7 228.1 
ORF3/Ov4.5 0 0 0 0.0 0.0 
Ov4.5 14 1 17 10.7 8.5 
ORF6 255 25 511 263.7 243.1 
ORF6/ ORF7 46 17 2 21.7 22.4 
ORF7 213 433 1949 865.0 945.2 
ORF7/ORF8 267 64 214 181.7 105.3 
ORF7/ORF8/ORF9 0 2 0 0.7 1.2 
ORF9 318 8 780 368.7 388.5 
Ov5 63 6 27 32.0 28.8 
Ov5/ORF10 165 11 325 167.0 157.0 
Ov5/ORF10/ORF11 81 4 122 69.0 59.9 
ORF17/ORF17.5 153 38 478 223.0 228.2 
ORF17 0 0 6 2.0 3.5 
ORF18 74 5 34 37.7 34.6 
ORF19/ORF20 165 4 174 114.3 95.7 
ORF20 147 1 5 51.0 83.2 
ORF21 158 1181 91 476.7 610.9 
ORF21/ORF22 129 64 456 216.3 210.1 
ORF23 64 73 39 58.7 17.6 
ORF23/ORF24 16 0 12 9.3 8.3 
ORF24 107 6 175 96.0 85.0 
ORF25 338 15 597 316.7 291.6 
ORF25/ORF26 117 1 81 66.3 59.4 
ORF25/ORF26/ORF27 36 4 80 40.0 38.2 
ORF29 254 31 473 252.7 221.0 
ORF30 0 1 1 0.7 0.6 
ORF30/ORF31 114 29 84 75.7 43.1 
ORF31 0 0 0 0.0 0.0 
ORF31/ORF32 17 15 106 46.0 52.0 
ORF31/ORF32/ORF33 86 4 87 59.0 47.6 
ORF34 76 22 53 50.3 27.1 
ORF34/ORF35 28 2 50 26.7 24.0 
ORF34/ORF35/ORF36 76 8 127 70.3 59.7 
ORF34/ORF35/ORF36/ORF37 78 4 114 65.3 56.1 
ORF37 0 0 0 0.0 0.0 
ORF37/ORF38 40 0 58 32.7 29.7 
ORF39 54 22 11 29.0 22.3 
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ORF40 163 834 361 452.7 344.8 
ORF42/ORF43 77 7 141 75.0 67.0 
ORF43 70 19 322 137.0 162.2 
ORF44 166 16 186 122.7 92.9 
ORF45/ORF46 208 852 603 554.3 324.7 
ORF46 21 0 1 7.3 11.8 
ORF46/ORF47/ORF48 84 4 356 148.0 184.5 
ORF47/ORF48 1 0 0 0.3 0.6 
ORF48 213 16 94 107.7 99.2 
ORF49 56 3 367 142.0 196.6 
ORF50 126 25 318 156.3 148.8 
Ov6 3 1 0 1.3 1.5 
Ov7 22 0 3 8.3 11.9 
Ov8 166 164 427 252.3 151.3 
ORF52 22 28 59 36.3 19.9 
ORF53 75 61 22 52.7 27.5 
ORF54 30 6 4 13.3 14.5 
ORF55 70 45 71 62.0 14.7 
ORF56 218 37 457 237.3 210.7 
ORF56/ORF57 58 1 46 35.0 30.0 
ORF57 144 42 161 115.7 64.4 
ORF58/ORF59 239 190 367 265.3 91.4 
ORF58/ORF59/ORF60 48 0 47 31.7 27.4 
ORF60 47 1 60 36.0 31.0 
ORF60/ORF61/ORF62 0 0 0 0.0 0.0 
ORF61/ORF62 244 71 612 309.0 276.3 
ORF62 78 6 121 68.3 58.1 
ORF63 197 42 530 256.3 249.4 
ORF63/orf64 20 4 53 25.7 25.0 
ORF64 688 109 1398 731.7 645.6 
ORF65 170 69 2926 1055.0 1621.1 
ORF65/ORF66/ORF67/ORF67a 0 0 0 0.0 0.0 
ORF66/ORF67/ORF67a 871 1201 695 922.3 256.9 
ORF67/ORF67a 9 19 170 66.0 90.2 
ORF67a 0 0 0 0.0 0.0 
ORF68 56 37 89 60.7 26.3 
ORF68/ORF69 100 19 447 188.7 227.4 
ORF69 24 11 0 11.7 12.0 
Ov8.5 95 9 262 122.0 128.6 
ORF73 115 129 65 103.0 33.6 
ORF73/ORF75 0 0 0 0.0 0.0 
ORF75 519 22 446 329.0 268.4 
Ov9 108 6 524 212.7 274.4 
Ov10 62 8 7 25.7 31.5 
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Among the 52 annotated OvHV-2 polyA signals from the NCBI Database (AY839756) 
two signals were used; AATAAA (77%) and ATTAAA (23%).  A search through the 
genome for these two sequences resulted in an additional 138 polyA signals; AATAAA 
(59%) and ATTAAA (41%) (Supplemental DVD; Table 5.4).  29 of the additional 
polyA signals were found within predicted ORFs (Table 5.4).   
5.4 DISCUSSION 
The transcriptome of OvHV-2 in BJ1035 cells was sequenced to examine viral gene 
expression in the susceptible host.  In the process of determining the relative levels of 
OvHV-2 gene expression, additional polyA signals were found throughout the entire 
length of the genome (Figure 5.3).  Many were found to cluster close together, some 
with a published polyA signal; these may reinforce the “stopping” signal to RNA 
polymerase.  Others were found within ORFs so may denote shorter or longer transcripts 
stemming from a single promoter.  Interestingly, though there was observed transcript 
expression for ORF18, there was no published polyA site, and even with the newly 
discovered sites, the closest polyA site was within ORF21/ORF22 (3622 bp away).  
There were also a number found in regions without predicted ORFs; it may be that they 
belong to unidentified ORFs.  Although the current number of predicted OvHV-2 ORFs 
is well within the normal range for gammaherpesviruses (73 protein coding ORFs 
compared to an average of 78±6, n=12 gammaherpesviruses with full sequenced 
genomes) it is possible that it could encode more.  
(GenBank; http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=10374)   
 
To support this hypothesis, sequenced mRNA tags were found to map to these 
undesignated regions (Figure 5.4).  Some of these undefined transcripts could also 
represent pri-miRNAs, although interestingly, there were no transcripts detected 
corresponding to the location of ovhv2-miR-1, -miR-3, or -miR-4.  This could be due to 
the location of NlaIII restriction sites in the genome, which were used to produce the 
transcript tags that make up the transcriptome.  This could also explain why there were 
no transcripts found for one or more exons for Ov2, Ov2.5, and Ov6. 
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Table 5.3: Number of peaks to be labelled if based on mean read count and standard 
deviation. 
 
 Standard Deviations on Either Side of Mean 
Sample 0.25 0.5 0.75 1 1.25 1.5 1.75 2 
1 44 19 9 6 6 6 6 4 
2 9 7 6 4 3 3 1 1 
3 121 82 51 35 29 23 18 17 
 
 
Table 5.4: Unpublished polyA signals found within predicted ORFs. 
 
Tag Frequency 5’ of PolyA Signal 











Ov2 - 2804 162 27 41 77 74 
Ov2.5 + 4393 84 2 0 29 48 
ORF3 + 9990 191 245 570 335 205 
18007 213 433 1949 865 945 
ORF7/ORF8 + 
20279 426 63 175 221 186 
ORF9 + 23194 310 4 773 362 387 
Ov5 + 24266 0 0 1 0 1 
ORF21 + 43166 403 1214 467 695 451 
ORF24 - 47856 207 13 294 171 144 
ORF25/ORF26/ORF27 + 54411 467 18 705 397 349 
56059 49 1 103 51 51 
56655 248 159 689 365 284 ORF29 - 
59731 103 24 319 149 153 
ORF31/ORF32 + 58289 17 15 106 46 52 
69140 0 0 0 0 0 
ORF43 - 
69370 466 96 391 318 196 
72698 182 801 572 518 313 
ORF45/ORF46 - 
73565 23 0 1 8 13 
ORF48 - 75990 16 0 97 38 52 
ORF50 + 76171 1 0 1 1 1 
79556 3 1 0 1 2 
Ov6 + 
80192 18 0 0 6 10 
ORF53 - 84655 63 67 154 95 51 
ORF54 + 85614 112 9 212 111 102 
ORF60 - 93779 14 0 0 5 8 
ORF63 + 100305 827 366 1603 932 625 
ORF65 - 108282 91 61 2896 1016 1628 
ORF68 + 112942 435 814 646 632 190 
ORF73 - 119325 115 129 65 103 34 
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Figure 5.3: OvHV-2 genome schematic detailing the location of polyA signals in 
relation to predicted ORFs and miRNAs; circles representing polyA signals to the left of 
the genome line are on the positive strand, those to the right are on the minus strand. 
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Figure 5.4: OvHV-2 genome schematic detailing the location of undesignated 
transcripts in relation to predicted ORFs, miRNAs and polyA signals.  
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Within the three samples sequenced, the most highly expressed OvHV-2 genes were 
Ov2, ORF7, ORF21, ORF40, ORF45/ORF46, ORF64, ORF65, and 
ORF66/ORF67/ORF67a (Table 5.5). 
   
Table 5.5: Highly expressed OvHV-2 genes in BJ1035 cell line. 
 
Name Strand Description 
Ov2 - basic leucine zipper; putative transcription factor 
ORF7 + terminase subunit; interacts with ORF29 and ORF67a 
ORF21 + thymidine kinase; tegument protein associated with capsid 
ORF40 + helicase-primase 
ORF45 - Unknown 
ORF46 - uracil-DNA glycosylase 
ORF64 + tegument protein 
ORF65 - capsid protein 
ORF66 - Unknown 
ORF67 - UL34, nuclear egress tegument protein 
ORF67a - packaging protein; interacts with terminase 
 
It has been observed that the first ORF encoded in gammaherpesvirus genomes is often 
involved in cell transformation (Coulter et al., 2001, Damania et al., 2000).  Although 
no sequence homology has been observed between genera and very little between 
species, these ORFs encode membrane-bound proteins that oligomerize and stimulate 
lymphocyte activation pathways.  The genome location of Ov2, its homology to cellular 
transcription factors (3.8.5) and its observed high transcript expression in immortalized 
T cells supports the role of Ov2 in the pathogenesis of MCF; the alphaherpesvirus 
MDV-1 also expresses a Jun-like protein called Meq which is expressed in transformed 
cells and lymphomas (Burnside et al., 2006).  Currently, Aayesha Riaz is undertaking in 
situ hybridizations to determine whether Ov2 is expressed primarily in latent or 
reactivated cells as well as conducting dual luciferase assays to see if the predicted target 
site by ovhv2-miR-4 in the 3’ UTR of Ov2 is functional.  Initially, the assays reported 
that there was no regulation by ovhv2-miR-4, but further analysis identified a T → C 
point mutation in the region complementary to the seed sequence (Riaz, A., unpublished 
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results).  This could be due to RNA editing and explain the high expression of Ov2 
observed in the transcriptome.    
 
This transcript profile appears to differ from that described by Thonur et al, 2006 who 
focused on the “unique” genes (Ov2-Ov10) and genes used as markers for latency 
(ORF73) and reactivation (ORF9 and ORF50) using Gardella gels and Southern blots.  
They found that the OvHV-2 genome was predominately circular and in a latent state in 
ovine T cells (reservoir species) with restricted gene expression; most notably Ov3.5 and 
ORF73.  Treatment with doxorubicin caused a shift towards linear genomes and 
reactivation with expression of all “unique” genes and ORF9 and ORF50 along with 
ORF73.  The BJ1035 cell line contained both circular and linear viral genomes, with an 
unusual transcript profile from that observed in latent or productive virus in sheep; all 
the “unique” genes were expressed (Ov8 and Ov8.5 being the most highly expressed and 
Ov2 the least) as in the reactivated ovine cells, but ORF50 was undetectable as in the 
latent ovine cells.  Treatment with doxorubicin did not have as strong of an effect on the 
bovine cells, though expression of Ov3 increased and ORF50 was detected.  In this 
study, all the genes focussed on by Thonur et al. were expressed in the BJ1035 cells, but 
to differing degrees; Ov2 was expressed over 40 times more than Ov8, and ORF50 was 
detectable without treatment with doxorubicin.  Although the cells were grown in the 
same conditions in both studies, there are a number of explanations for why different 
levels of gene expression were observed.  First, the experimental methodology differed; 
Thonur et al. used Southern blots whereas I used high throughput sequencing.  
Secondly, OvHV-2 may not exert the same control over gene expression in bovine cells 
as it does in sheep cells.  Alternatively, given what seems to be a mix of latent and 
productive virus in bovine cells, it may be that over the four years between the studies, 
the cell line holds a different ratio of latent:reactivated virus.  Based on the selection of 
genes with high expression in this study (those involved in viral DNA replication and 
packaging) and a comparably low expression of ORF73, an increase in reactivated virus 
is surmised.  It would be beneficial to determine the ratio of latent:reactivated virus-
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infected cells and determine which cell-state is expressing each of the highly abundant 
transcripts detected. 
 
This preliminary study of the OvHV-2 transcriptome suggests that the deregulation of 
host cells that contribute to the development of MCF may be due to a deregulation of the 
virus itself.  Although sheep and cattle are related and therefore both can carry OvHV-2, 
there may be enough of a difference in their molecular biology which enables the virus 
to maintain a symbiotic relationship with one and a harmful relationship with the other.    
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Malignant catarrhal fever and its etiological agent OvHV-2 present an interesting 
scientific conundrum and challenge.  Infection with OvHV-2 in sheep shows no overt 
clinical symptoms, but can cause a fatal disease in cattle brought upon by the activation 
of an immune response that involves lymphoproliferation and non-classical MHC 
restricted non-antigen-specific cytotoxicity.  The key question in MCF is why infection 
of two closely related ruminant species results in such differing disease outcomes.   
 
This project was concerned with understanding how OvHV-2 interacts with bovine 
lymphocytes at the molecular level to affect lymphocyte growth and differentiation, i.e. 
how OvHV-2 causes disease.  Major candidates for virus-control of viral and cellular 
gene expression are virus-encoded miRNAs, which can, and have been found to, target 
transcription factors (1.5.2-3).  miRNAs are involved in numerous biological pathways 
and the study of them and their function brings to light subtle interactions that can have 
far reaching effects.  The previous discoveries of miRNAs in herpesviruses and their 
involvement in regulating viral replication, the cell cycle, and viral pathogenesis, 
supported the hypothesis that OvHV-2 may also express these regulatory RNAs.  
Identification and characterization of these may lead to an understanding of why there is 
a difference in persistence between reservoir and susceptible species and of the 
mechanisms behind the various clinical symptoms of MCF.              
 
During this study, it was known that the pathogenic effects of OvHV-2 infection were 
derived from virally-infected, immortalized T cells.  Thus, the bovine cell line BJ1035 
was used, representing the CD4+ T cell population infected and immortalized by OvHV-
2. 
 
Forty six OvHV-2 miRNAs were predicted by high throughput sequencing and 
bioinformatics; eight of which had additional supporting evidence by northern 
hybridization and are currently named ovhv2-miR-1 - miR-8.  This represents the first 
report of the expression of virally encoded miRNAs in the Macavirus genus of 
herpesviruses.  The success of this study was dependent upon the use of a number of 
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complementary techniques; next generation high throughput sequencing provided the 
amplification and identification of real transcripts transcribed by the cell, bioinformatics 
provided the prediction of miRNA biogenic secondary structure, and northern 
hybridization provided the verification that the transcripts sequenced were present as 
~22-mers.  Each technique by itself would not have been enough to prove the presence 
of miRNAs.  An additional marker for miRNA prediction has been found in a sequence 
motif (CTCCGCCC) ~200 bp upstream of C. elegans miRNAs (Ohler et al., 2004).  
This particular sequence is not present upstream of any of the predicted OvHV-2 
miRNAs found in this study, but it does suggest that there may be mammalian or viral 
sequence motifs yet to be discovered with a similar role. 
 
These miRNAs are located throughout the genome (mostly on the minus strand), in 
regions that do not contain predicted ORFs.  The majority of the miRNAs are localized 
in three clusters; one cluster is located at the left-hand end of the genome, 5’ of Ov2, the 
other two are in the 9.3 kb non-coding region between ORF11 and ORF17/17.5.  This 
clustering of miRNAs has been observed in other herpesviruses however to date no other 
herpesvirus has been shown to contain as many miRNAs as predicted in this study (3.4).   
 
All but one of the predicted OvHV-2 miRNAs are novel, i.e. shares no seed homology 
with any other miRNA present in the miRBase database.  The exception shares a 
conserved seed sequence with the well conserved vertebrate miRNA miR-216, and may 
act as a mimic to increase the regulatory activity of that miRNA in virus-infected host 
cells (3.8.2).          
 
Using blastn, many viral and cellular targets were predicted for the eight ovhv2-miRs, 
however thus far no target has been identified experimentally.  There is increasing 
interest in the role of miRNAs in host-virus interactions, cellular biology, and as 
treatments for disease.  However, miRNAs can only be used as a tool once their function 
is known, which is why the identification of the targets of virus-encoded miRNAs is 
essential.  Several mechanisms have been used to identify miRNA targets (3.3.6) and the 
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bioinformatics used in this study is a good starting point, but definitive evidence that a 
predicted target site is functional is necessary to begin to understand the role they play in 
their environment.  There are several possible approaches to functionally identifying 
mRNAs targeted by individual miRNAs: RISC pull-down assays followed by 
microarray analysis have already been discussed (3.7) and improvements to this 
approach are continually being developed.  This allows the mRNAs targeted by the 
miRNA to be directly identified.  An alternative approach involves miRNA sponges 
whereby a transgene expresses a small RNA complementary to a miRNA of interest 
which then binds to its target, thus decreasing the miRNA’s effect on the cell allowing 
resultant changes in phenotype or transcriptome to be assessed.  Functional studies using 
these methods are currently being adopted in our laboratory.  It is my suggestion that the 
predicted OvHV-2 miRNAs in the first cluster be focussed on initially as it may be 
involved in the transformation and pathology of the virus; this cluster is in a similar 
location to the oncogenic-associated miRNA cluster in MDV-1 and may be expressed 
from the same promoter as the Meq-like Ov2 (Burnside et al., 2006).        
 
In addition to miRNA identification, a first examination of the OvHV-2 transcriptome 
was undertaken.  The results confirm Thonur et al.’s observations that in susceptible 
species there is an increase in ORF expression; however the ORF expression observed in 
this study differed from that previously reported.  It may be that in susceptible hosts, 
latency is not as tightly controlled leading to varying expression profiles and thus, the 
different symptoms and severities of MCF observed.   
 
The high levels of OvHV-2 gene expression in T cells of susceptible species may be the 
trigger that initiates the development of MCF.  It may be beneficial to analyze the 
OvHV-2 transcriptomes from sheep and a susceptible host exhibiting clinical signs of 
MCF for a direct comparison.  In this way, specific viral ORFs associated with 
pathogenesis may be identified.  Until then, the data in this study has highlighted a 
number of viral ORFs that could be investigated for interactions in the myriad of 
pathways that could lead to the deregulation of the host’s immune system. 
Chapter Six                                                                                                         Conclusion 
 143 
 
Given additional time, a comparison with other gammaherpesviruses could garner 
additional information; do they have undesignated polyA sites, and/or do they encode 
ORFs in similar locations to the “empty” regions in the OvHV2 genome?  The sequence 
of these regions could also be used to search for homologues in other viruses or host 
species. 
 
While the aim of this project was focussed on OvHV-2 miRNA and mRNA, the process 
of sequencing the RNA samples also provided small RNA and transcriptome data for 
cattle; http://www.mirz.unibas.ch/cloningprofiles/ provides miRNA profiles for a large 
number of cell types, including T cells.  The small RNA data could be analyzed for the 
reads of the 662 published bovine miRNAs and this profile could be compared to that of 
an uninfected T cell.  One point of interest for this comparison would be expression of 
the cellular miR-17/92 cluster which targets PTEN (3.8.2) (Xiao et al., 2008).  This 
targeting is associated with lymphoproliferation and autoimmunity so it would be 
expected for this cluster to be more highly expressed in BJ1035 cells than uninfected T 
cells.  The transcriptome of uninfected cattle could be sequenced as well and any 
differences between the two could aid in our understanding of the changes made to the 
cellular environment by OvHV-2.      
 
OvHV-2 and MCF remain difficult to study due to a lack in a cell culture system and the 
variance of disease developed by susceptible species ranging from those that recover and 
those that die days after the onset of clinical symptoms.  The finding that OvHV-2 
encodes and expresses miRNAs in immortalized cells and the predicted viral and 
cellular targets found with bioinformatics for a small number of them supports the 
hypothesis that OvHV-2 miRNAs may have a role in viral and cellular gene expression, 
viral persistence, and MCF pathogenesis.  The ovhv2-miRs can be used as a tool to 
study the biological pathways affected by this virus and should increase our 
understanding of OvHV-2 biology. 
 











Chapter Six                                                                                                         Conclusion 
 145 
Abend, J. R., T. Uldrick, et al. (2010). “Regulation of tumor necrosis factor-like weak 
inducer of apoptosis receptor protein (TWEAKR) expression by Kaposi’s sarcoma-
associated herpesvirus microRNA prevents TWEAK-induced apoptosis and 
inflammatory cytokine expression.” Journal of Virology 84(23): 12139-12151. 
 
Ackermann, M. (2006). “Pathogenesis of gammaherpesvirus infections.” Veterinary 
Microbiology 113(3-4): 211-222. 
 
Alwine, J. C., W. L. Steinhart, et al. (1974). “Transcription of herpes simplex type 1 
DNA in nuclei isolated from infected HEp-2 and KB cells.” Virology 60(1): 302-307.  
 
Ambros, V., B. Bartel, et al. (2003). “A uniform system for microRNA annotation.” 
Rna-a Publication of the RNA Society 9(3): 277-279. 
  
Aparicio, O., N. Razquin, et al. (2006). “Adenovirus virus-associated RNA is processed 
to functional interfering RNAs involved in virus production.” Journal of Virology 80(3): 
1376-1384. 
 
Arvin, A. M. (1996). “Varicella-zoster virus.” Clinical Microbiology Reviews 9(3): 361-
381. 
 
Ascherio, A. and K. L. Munger (2010). “Epstein-Barr virus infection and multiple 
sclerosis: A review.” Journal of Neuroimmune Pharmacology 5(3): 271-277. 
 
Aschman, N. (2008). Characterisation of the protein encoded by Orf20 of alcelaphine 
herpesvirus 1. Edinburgh, University of Edinburgh: 1-33. 
 
Babcock, G. J. and D. A. Thorley-Lawson (2000). “Tonsillar memory B cells, latently 
infected with Epstein-Barr virus, express the restricted pattern of latent genes previously 
found only in Epstein-Barr virus-associtated tumors.” Proceedings of the National 
Academy of Sciences of the United States of America 97(22): 12250-12255.  
 
Babcock, G. J., L. L. Decker, et al. (1999). “Epstein-Barr virus-infected resting memory 
B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of 
immunosuppressed patients.” Journal of Experimental Medicine 190(4): 567-576. 
 
Backovic, M. and T. Jardetzky (2011). Class III Viral Membrane Fusion Proteins. Cell 
Fusion in Health and Disease Ii: Cell Fusion in Disease. Berlin, Springer-Verlag Berlin. 
714: 91-101. 
 
Bartel, D. P. (2004). “MicroRNAs: Genomics, biogenesis, mechanism, and function.” 
Cell 116(2): 281-297. 
 
Chapter Six                                                                                                         Conclusion 
 146 
Bartel, D. P. and C. Z. Chen (2004). “Micromanagers of gene expression: the potentially 
widespread influence of metazoan microRNAs.” Nature Reviews Genetics 5(5): 396-
400. 
 
Barth, S., T. Pfuhl, et al. (2008). “Epstein-Barr virus-encoded microRNA miR-BART2 
down-regulates the viral DNA polymerase BALF5.” Nucleic Acids Research 36(2): 666-
675. 
 
Basyuk, E., F. Suavet, et al. (2003). “Human let-7 stem-loop precursors harbour features 
of RNase III cleavage products.” Nucleic Acids Research 31(22): 6593-6597. 
 
Baxter, S. I. F., A. Wiyono, et al. (1997). “Identification of ovine herpesvirus 2 infection 
in sheep.” Archives of Virology 142(4): 823-831. 
 
Baxter, S. I. F., I. Pow, et al. (1993). “PCR Detection of the sheep-associated agent of 
malignant catarrhal fever.” Archives of Virology 132(1-2): 145-159. 
 
Bellare, P. and D. Ganem (2009). “Regulation of KSHV lytic switch protein expression 
by a virus-encoded microRNA: An evolutionary adaptation that fine-tunes lytic 
reactivation.” Cell Host & Microbe 6(6): 570-575. 
 
Boehmer, P. E. and I. R. Lehman (1997). “Herpes simplex virus DNA replication.” 
Annual Review of Biochemistry 66: 347-384. 
 
Borza, C. M. and L. M. Hutt-Fletcher (2002). “Alternate replication in B cells and 
epithelial cells switches tropism of Epstein-Barr virus.” Nature Medicine 8(6): 594-599. 
 
Boyne, J. R. and A. Whitehouse (2006). “Nucleolar trafficking is essential for nuclear 
export of intronless herpesvirus mRNA.” Proceedings of the National Academy of 
Sciences of the United States of America 103(41): 15190-15195. 
 
Brault, S. A., B. H. Bird, et al. (2011). “Genetic heterogeneity and variation in viral load 
during equid herpesvirus 2 infection of fouls.” Veterinary Microbiology 147(3-4): 253-
261. 
 
Braun, D. K., G. Dominguez, et al. (1997). “Human herpesvirus 6.” Clinical 
Microbiology Reviews 10(3): 521-567. 
 
Bridgen, A. and H. W. Reid (1991). “Derivation of a DNA clone corresponding to the 
viral agent of sheep-associated malignant catarrhal fever.” Research in Veterinary 
Science 50(1): 38-44. 
 
Burnside, J., Bernberg, E., et al. (2006). “Marek’s disease virus encodes microRNAs 
that map to meq and the latency-associated transcript.” Journal of Virology 80(17): 
8778-8786. 
Chapter Six                                                                                                         Conclusion 
 147 
Burrells, C. and H. W. Reid. (1991). “Phenotypic analysis of lymphoblastoid cell-lines 
derived from cattle and deer affected with sheep-associated malignant catarrhal fever.” 
Veterinary Immunology and Immunopathology 29(1-2): 151-161. 
 
Cai, X. Z., A. Schafer, et al. (2006). “Epstein-barr virus microRNAs are evolutionarily 
conserved and differentially expressed.” Plos Pathogens 2(3): 236-247. 
 
Cai, X. Z. (2004). “Human microRNAs are processed from capped, polyadenylated 
transcripts that can also function as mRNAs.” RNA - A Publication of the RNA Society 
10(12): 1957-1966. 
 
Carel, J. C., B. L. Myones, et al. (1990). “Structural requirements for C3d,g/Epstein-
Barr virus receptor (CR2/CD21) ligand binding, internaliztion, and viral infection.” 
Journal of Biological Chemistry 265(21): 12293-12299. 
 
Cerutti, L., N. Mian, et al. (2000). “Domains in gene silencing and cell differentiation 
proteins: the novel PAZ domain and redefinition of the Piwi domain.” Trends in 
Biochemical Sciences 25(10): 481-482. 
 
Chang, Y., E. Cesarman, et al. (1994). “Identification of herpesvirus-like DNA-
sequences in AIDS-associated Kaposi’s sarcoma.” Science 266(5192): 1865-1869. 
 
Chen, C. Y., R. Gherzi, et al. (2000). “Nucleolin and YB-1 are required for JNK-
mediated interleukin-2 mRNA stabilization during T-cell activation 
 
Chen, C. Z., L. Li, et al. (2004). “MicroRNAs modulate hematopoietic lineage 
differentiation.” Science 303(5654): 83-86. 
 
Chen, Z. L., X. H. Zhao, et al. (2011). “microRNA-92a promotes lymph node metastasis 
of human esophageal squamous cell carcinoma via E-cadherin.” Journal of Cellular 
Physiology 226(6): 1479-1488. 
 
Choy, E. Y. W., K. L. Siu, et al. (2008). “An Epstein-Barr virus-encoded microRNA 
targets PUMA to promote host cell survival.” Journal of Experimental Medicine 
205(11): 2551-2560. 
 
Clyde, K. and B. A. Glaunsinger (2011). “Deep sequencing reveals direct targets of 
gammaherpesvirus-induced mRNA decay and suggests that multiple mechanisms 
govern cellular transcript escape.” Plos One 6(5): e19655. 
 
Collery, P. and A. Foley (1996). “An outbreak of malignant catarrhal fever in cattle in 
the Republic of Ireland.” Veterinary Record 139(1): 16-17. 
 
Chapter Six                                                                                                         Conclusion 
 148 
Cook, C. G. and G. A. Splitter (1988). “Lytic function of bovine lymphokines-activated 
killer cells from a normal and a malignant catarrhal fever virus-infected animal.” 
Veterinary Immunology and Immunopathology 19(2): 105-118. 
 
Costa, E. A., A. D. Viott, et al. (2010). “Transmission of ovine herpesvirus 2 from 
asymptomatic boars to sows.” Emerging Infectious Diseases 16(12): 2011-2012. 
 
Costa, É. A., E. Bastianetto, et al. (2009). “An outbreak of malignant catarrhal fever in 
Murrah buffaloes in Minas Gerais, Brazil.” Pesquisa Veterinária Brasileira 29(5): 395-
400. 
 
Cotter, M. A. and E. S. Robertson (1999). “The latency-associated nuclear antigen 
tethers the Kaposi’s sarcoma-associated herpesvirus genome to host chromosomes in 
body cavity-based lymphoma cells.” Virology 264(2): 254-264. 
 
Coulter, L. J., H. Wright, et al. (2001). “Molecular genomic characterization of the 
viruses of malignant catarrhal fever.” Journal of Comparative Pathology 124(1): 2-19. 
 
Crawford, T. B., D. O’Toole, et al. (1999). Malignant Catarrhal Fever. Current 
Veterinary Therapy, 4th Edition - Food Animal Practices. J. L. Howard. Philadelphia, 
PA, W.B. Saunders Company: 306-309. 
 
Crough, T. and R. Khanna (2009). “Immunology of human cytomegalovirus: from 
bench to bedside.” Clinical Microbiology Reviews 22(1): 76-98. 
 
Cui, C., A. Griffiths, et al. (2006). “Prediction and identification of herpes simplex virus 
1-encoded microRNAs.” Journal of Virology 80(11): 5499-5508. 
 
Cullen, B. R. (2006). “Viruses and microRNAs.” Nature Genetics 38: S25-S30. 
 
Cunha, C. W., D. L. Traul, et al. (2008). “Detection of ovine herpesvirus 2 major capsid 
gene transcripts as an indicator of virus replication in shedding sheep and clinically 
affected animals.” Virus Research 132(1-2): 69-75. 
 
Damania, B., J. K. Choi, et al. (2000). “Signaling activities of gammaherpesvirus 
membrane proteins.” Journal of Virology 74(4): 1593-1601. 
 
Dasgupta, A. and D. W. Wilson (1999). “ATP depletion blocks herpes simplex virus 
DNA packaging and capsid maturation.” Journal of Virology 73(3): 2006-2015. 
 
Davison, A. J., R. Eberle, et al. (2009). “The order Herpesvirales.” Archives of Virology 
154(1): 171-177. 
 
Davy, C. and J. Doorbar (2007). “G2/M cell cycle arrest in the life cycle of viruses.” 
Virology 368(2): 219-226. 
Chapter Six                                                                                                         Conclusion 
 149 
del Solar, G., R. Giraldo, et al. (1998). “Replication and control of circular bacterial 
plasmids.” Microbiology and Moloecular Biology Reviews 62(2): 434-464. 
 
Didier, D. K., J. Schiffenbauer, et al. (1988). “Characterization of the cDNA encoding a 
protein binding to the major histocampatibility complex class II Y box.” Proceedings of 
the National Academy of Sciences of the United States of America 85(): 7322-7326.  
 
Dittmer, D., M. Lagunoff, et al. (1998). “A cluster of latently expressed genes in 
Kaposi’s sarcoma-associated herpesvirus.” Journal of Virology 72(10): 8309-8315. 
 
Doench, J. G. and P. A. Sharp (2004). “Specificity of microRNA target selection in 
translational repression.” Genes & Development 18(5): 504-511. 
 
Doench, J. G., C. P. Petersen, et al. (2003). “siRNAs can function as miRNAs.” Genes 
& Development 17(4): 438-442. 
 
Dölken, L., A. Krmpotic, et al. (2010). “Cytomegalovirus microRNAs facilitate 
persistent virus infection in salivary glands.” Plos Pathogens 6(10): e1001150. 
 
Elbashir, S. M., W. Lendeckel, et al. (2001). “RNA interference is mediated by 21- and 
22-nucleotide RNAs.” Nature 411(6836): 494-498. 
 
Ellis, J. A., D. T. O’Toole, et al. (1992). “Predominance of BoCD8-positive T 
lymphocytes in vascular lesions in a 1-year-old cow with concurrent malignant catarrhal 
fever and bovine viral diarrhea virus infection.” Veterinary Pathology 29(6): 545-547.  
 
Epstein, M. A., B. G. Achong, et al. (1964). “Virus particles in cultured lymphoblasts 
from Burkitt’s lymphoma.” Lancet 1(733): 702-703. 
 
Evdokimova, V., P. Ruzanov, et al. (2006). “Akt-mediated YB-1 phosphorylation 
activates translation of silent mRNA species.” Molecular and Cellular Biology 26(1): 
277-292. 
 
Farrell, P. (2002). “Cell-switching and kissing.” Nature Medicine 8(6): 559-560. 
 
Feederle, R., S. D. Linnstaedt, et al. (2011). “A viral microRNA cluster strongly 
potentiates the transforming properties of a human herpesvirus.” Plos Pathogens 7(2): 
e1001294. 
 
Field, N., W. Low, et al. (2003). “KSHV vFLIP binds to IKK-gamma to activate IKK.” 
Journal of Cell Science 116(18): 3721-3728. 
 
Fields (2007). Virology. Philadelphia, Lippincott Williams & Wilkins. 
 
Chapter Six                                                                                                         Conclusion 
 150 
Fish, J. E., M. M. Santoro, et al. (2008). “MiR-126 regulates angiogenic signalling and 
vascular integrity.” Developmental Cell 15(2): 272-284. 
 
Frame, F. M. and R. G. Dalziel (2008). “Transcriptional control by the R-transactivator 
protein of Alcelaphine Herpesvirus-1.” Veterinary Research Communications 32(3): 
215-223. 
 
Gaidatzis, D., E. van Nimwegen, et al. (2007). “Inference of miRNA targets using 
evolutionary conservation and pathway analysis.” Bmc Bioinformatics 8. 
 
Ganem, D. (1997). “KSHV and Kaposi’s sarcoma: The end of the beginning?” Cell 
91(2): 157-160. 
 
Garber, A. C., J. H. Hu, et al. (2002). “Latency-associated nuclear antigen (LANA) 
cooperatively binds to two sites within the terminal repeat, and both sites contribute to 
the ability of LANA to suppress transcription and to facilitate DNA replication.” Journal 
of Biological Chemistry 277(30): 27401-27411. 
 
Gill, M. B., R. Edgar, et al. (2008). “A gamma-herpesvirus glycoprotein complex 
manipulates actin to promote viral spread.” Plos One 3(3): e1808. 
 
Glazov, E. A., P. F. Horwood, et al. (2010). “Characterization of microRNAs encoded 
by the bovine herpesvirus 1 genome.” Journal of General Virology 91: 32-41. 
 
Gottwein, E. and B. R. Cullen (2010). “A human herpesvirus microRNA inhibits p21 
expression and attenuates p21-mediated cell cycle arrest.” Journal of Virology 84(10): 
5229-5237. 
 
Gottwein, E., N. Mukherjee, et al. (2007). “A viral microRNA functions as an 
orthologue of cellular miR-155.” Nature 450(7172): 1096-U17. 
 
Götze, R., and J. Liess. (1930). Deutsche Tierärztliche Wochenschrift 37: 433. 
 
Grey, F., R. Tirabassi, et al. (2010). “A viral microRNA down-regulates multiple cell 
cycle genes through mRNA 5’UTRs.” Plos Pathogens 6(6): e1000967. 
 
Grey, F., H. Meyers, et al. (2007). “A human cytomegalovirus-encoded microRNA 
regulates expression of multiple viral genes involved in replication.” Plos Pathogens 
3(11): 1593-1602. 
 
Griffiths-Jones, S., H. K. Saini, et al. (2008). “miRBase: tools for microRNA 
genomics.” Nucleic Acids Research 36(Database Issue): D154-158. 
 
Chapter Six                                                                                                         Conclusion 
 151 
Griffiths-Jones, S., R. J. Grocock, et al. (2006). “miRBase: microRNA sequences, 
targets and gene nomenclature.” Nucleic Acids Research 34(Database Issue): D140-
D144. 
 
Griffiths-Jones, S. (2004). “The microRNA Registry.” Nucleic Acids Research 
32(Database Issue): D109-D111. 
 
Grishok, A., A. E. Pasquinelli, et al. (2001). “Genes and mechanisms related to RNA 
interference regulate expression of the small temporal RNAs that control C. elegans 
developmental timing.” Cell 106(1): 23-34. 
 
Grundhoff, A. and C. S. Sullivan (2011). “Virus-encoded microRNAs.” Virology 
411(2): 325-343. 
 
Haddad, R. S. and L. M. Hutt-Fletcher (1989). “Depletion of glycoprotein gp85 from 
virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with 
virus receptor-bearing cells.” Journal of Virology 63(12): 4998-5005. 
 
Hammond, S. M., E. Bernstein, et al. (2000). “An RNA-directed nuclease mediates post-
transcriptional gene silencing in Drosophila cells.” Nature 404(6775): 293-296. 
 
Han, J. J., Y. Lee, et al. (2006). “Molecular basis for the recognition of primary 
microRNAs by the Drosha-DGCR8 complex.” Cell 125(5): 887-901. 
 
Hansen, A., S. Henderson, et al. (2010). “KSHV-encoded miRNAs target MAF to 
induce endothelial cell reprogramming.” Genes & Development 24(2): 195-205. 
 
Hardwick, J. M. and D. S. Bellows (2003). “Viral versus cellular BCL-2 proteins.” Cell 
Death and Differentiation 10(Suppl. 1): S68-S76. 
 
Hart, J., M. Ackermann, et al. (2007). “Complete sequence and analysis of the ovine 
herpesvirus 2 genome.” Journal of General Virology 88(1): 28-39. 
 
Henson, B. W., E. M. Perkins, et al. (2009). “Self-assembly of Epstein-Barr virus 
capsids.” Journal of Virology 83(8): 3877-3890. 
 
Hu, J. H., A. C. Garber, et al. (2002). “The latency-associated antigen of Kaposi’s 
sarcoma-associated herpesvirus supports latent DNA replication in dividing cells.” 
Journal of Virology 76(22): 11677-11687. 
 
Hunt, R. (2011). Virology - Chapter Eleven: Herpes viruses, University of South 
Carolina School of Medicine. 2011. http://pathmicro.med.sc.edu/virol/herpes.htm  
 
Chapter Six                                                                                                         Conclusion 
 152 
Hüssy, D., F. Janett, et al. (2002). “Analysis of the pathogenetic basis for shedding and 
transmission of ovine gamma herpesvirus 2.” Journal of Clinical Microbiology 40(12): 
4700-4704. 
 
Hüssy, D., N. Stäuber, et al. (2001). “Quantitative fluorogenic PCR assay for measuring 
ovine herpesvirus 2 replication in sheep.” Clinical and Diagnostic Laboratory 
Immunology 8(1): 123-128. 
 
Hutvágner, G. and P. D. Zamore (2002). “A microRNA in a multiple-turnover RNAi 
enzyme complex.” Science 297(5589): 2056-2060. 
 
Hutvágner, G., J. McLachlan, et al. (2001). “A cellular function for the RNA-
interference enzyme Dicer in the maturation of the let-7 small temporal RNA.” Science 
293(5531): 834-838. 
 
Jackson, A. L., S. R. Bartz, et al. (2003). “Expression profiling reveals off-target gene 
regulation by RNAi.” Nature Biotechnology 21(6): 635-637.  
 
Johnson, D. C., T. W., et al. (2011). “Herpes simplex virus glycoproteins gB and gD 
function in a redundant fashion to promote secondary envelopment.” Journal of 
Virology 85(10): 4910-4926. 
 
Johnston, R. J. and O. Hobert (2003). “A microRNA controlling left/right neuronal 
asymmetry in Caenorhabditis elegans.” Nature 426(6968): 845-849. 
 
Jurak, I., M. F. Kramer, et al. (2010). “Numerous conserved and divergent microRNAs 
expressed by herpes simplex viruses 1 and 2.” Journal of Virology 84(9): 4659-4672. 
 
Kato, M., L. Wang, et al. (2010). “Post-transcriptional up-regulation of Tsc-22 by Ybx1, 
a target of miR-216a, mediates TGF-β-induced collagen expression in kidney cells.” 
Journal of Biological Chemistry 285(44): 34004-34015. 
 
Kato, M., S. Putta, et al. (2009). “TGF-β activates Akt kinase through a microRNA-
dependent amplifying circuit targeting PTEN.” Nature Cell Biology 11(7): 881-U263. 
 
Kaufmann, S. H. E. (1996). “γ/δ and other unconventional T lymphocytes: What do they 
see and what do they do?” Proceedings of the National Academy of Sciences 93(6): 
2272-2279.  
 
Kelly, B. J., C. Fraefel, et al. (2009). “Functional roles of the tegument proteins of 
herpes simplex virus type 1.” Virus Research 145(2): 173-186. 
 
Ketting, R. F., S. E. J. Fischer, et al. (2001). “Dicer functions in RNA interference and 
in synthesis of small RNA involved in developmental timing in C. elegans.” Genes & 
Development 15(20): 2654-2659. 
Chapter Six                                                                                                         Conclusion 
 153 
Khvorova, A., A. Reynolds, et al. (2003). “Functional siRNAs and miRNAs exhibit 
strand bias.” Cell 115(2): 209-216. 
 
Kim, O., H. Li, et al. (2003). “Demonstration of sheep-associated malignant catarrhal 
fever virions in sheep nasal secretions.” Virus Research 98(2): 117-122. 
 
Kim, Y. K., J. Yu, et al. (2009). “Functional links between clustered microRNAs: 
Suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer.” Nucleic 
Acids Research 37(5): 1672-1681. 
 
Kozomara, A. and S. Griffiths-Jones (2011). “miRBase: integrating microRNA 
annotation and deep-sequencing data.” Nucleic Acids Research 39(Database Issue): 
D152-D157.  
 
Kurtze, H. (1950). Deutsche Tierärztliche Wochenschrift 57: 261. 
 
Lai, E. C. (2002). “MicroRNAs are complementary to 3’UTR sequence motifs that 
mediate negative post-transcriptional regulation.” Nature Genetics 30(4): 363-364. 
 
Latimer, E., J. C. Zong, et al. (2011). “Detection and evaluation of novel herpesviruses 
in routine and pathological samples from Asian and African elephants: Identification of 
two new probosciviruses (EEHV-5 and EEHV-6) and two new gammaherpesviruses 
(EGHV-3B and EGHV-5).” Veterinary Microbiology 147(1-2): 28-41. 
 
Lau, N. C., L. P. Lim, et al. (2001). “An abundant class of tiny RNAs with probably 
regulatory roles in Caenorhabditis elegans.” Science 294(5543): 858-862. 
 
Lee, J. Y., J. J. Song, et al. (2010). “Transcriptional profiling of host gene expression in 
chicken embryo lung cells infected with laryngotracheitis virus.” BMC Genomics 11: 
445. 
 
Lee, R. C. and V. Ambros (2001). “An extensive class of small RNAs in Caenorhabditis 
elegans.” Science 294(5543): 862-864. 
 
Lee, R. C., R. L. Feinbaum, et al. (1993). “The C. elegans herterchronic gene lin-4 
encodes small RNAs with antisense complementarity to lin-14.” Cell 75(5): 843-854. 
 
Lee, Y., C. Ahn, et al. (2003). “The nuclear RNase III Drosha initiates microRNA 
processing.” Nature 425(6956): 415-419. 
 
Leight, E. R. and B. Sugden (2000). “EBNA-1: A protein pivotal to latent infection by 
Epstein-Barr virus.” Reviews in Medical Virology 10(2): 83-100. 
 
Chapter Six                                                                                                         Conclusion 
 154 
Lemasson, I., M. R. Lewis, et al. (2007). “Human T-cell leukemia virus type 1 (HTLV-
1) bZIP protein interacts with the cellular transcription factor CREB to inhibit HTLV-1 
transcription.” Journal of Virology 81(4): 1543-1553. 
 
Lewis, B. P., I. H. Shih, et al. (2003). “Prediction of mammalian microRNA targets.” 
Cell 115(7): 787-798. 
 
Li, H., G. Karney, et al. (2008). “Long distance spread of malignant catarrhal fever virus 
from feedlot lambs to ranch bison.” Canadian Veterinary Journal 49(2): 183-185. 
 
Li, H., N. S. Taus, et al. (2004). “Shedding of ovine herpesvirus 2 in sheep nasal 
secretions: The predominant mode of transmission.” Journal of Clinical Microbiology 
42(12): 5558-5564. 
 
Li, H., G. Snowder, et al. (1999). “Production of malignant catarrhal fever virus-free 
sheep.” Veterinary Microbiology 65(2): 167-172. 
 
Li, H., G. Snowder, et al. (1998). “Transmission of ovine herpesvirus 2 in lambs.” 
Journal of Clinical Microbiology 36(1): 223-226. 
 
Li, Q. X., M. K. Spriggs, et al. (1997). “Epstein-Barr virus uses HLA class II as a 
cofactor for infection of B lymphocytes.” Journal of Virology 71(6): 4657-4662. 
 
Li, Q. X., S. M. Turk, et al. (1995). “The Epstein-Barr virus (EBV) BZLF2 gene product 
associates with the gH and gL homologs of EBV and carries an epitope critical to 
infection of B cells but not of epithelial cells.” Journal of Virology 69(7): 3987-3994.  
 
Li, R., Y. Li, et al. (2008). “SOAP: short oligonucleotide alignment program.” 
Bioinformatics 24(5): 713-714. 
 
Li, Y. P., J. M. Gottwein, et al. (2011). “MicroRNA-122 antagonism against hepatitis C 
virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the 
HCV 5’UTR.” Proceedings of the National Academy of Sciences of the United States of 
America 108(12): 4991-4996. 
 
Liggitt, H. D. and J. C. DeMartini (1980). “The pathomorphology of malignant catarrhal 
fever: I. Generalized lymphoid vasculitis.” Veterinary Pathology 17(1): 58-72. 
 
Lin, H. R. and D. Ganem (2011). “Viral microRNA target allows insight into the role of 
translation in governing microRNA target accessibility.” Proceedings of the National 
Academy of Sciences of the United States of America 108(13): 5148-5153. 
 
Lingel, A., B. Simon, et al. (2003). “Structure and nucleic-acid binding of the 
Drosophila argonaute 2 PAZ domain.” Nature 426(6965): 465-469. 
 
Chapter Six                                                                                                         Conclusion 
 155 
Liu, J. D., M. A. Valencia-Sanchez, et al. (2005). “MicroRNA-dependent localization of 
targeted mRNAs to mammalian P-bodies.” Nature Cell Biology 7(7): 719-U118. 
 
Liu, J. D., M. A. Carmell, et al. (2004). “Argonaute2 is the catalytic engine of 
mammalian RNAi.” Science 305(5689): 1437-1441. 
 
Lizasa, H., B. E. Wulff, et al. (2010). “Editing of Epstein-Barr virus-encoded BART6 
microRNAs controls their Dicer targeting and consequently affects viral latency.” 
Journal of Biological Chemistry 285(43): 33358-33370. 
 
Lo, A. K. F., K. F. To, et al. (2007). “Modulation of LMP1 protein expression by EBV-
encoded microRNAs.” Proceedings of the National Academy of Sciences of the United 
States of America 104(41): 16164-16169. 
 
Løken, T., M. Aleksandersen, et al. (1998). “Malignant catarrhal fever caused by ovine 
herpesvirus-2 in pigs in Norway.” Veterinary Record 143(17): 464-467.  
 
Lu, C. C., Z. H. Li, et al. (2010). “MicroRNAs encoded by Kaposi’s sarcoma-associated 
herpesvirus regulate viral life cycle.” Embo Reports 11(10): 784-790. 
 
Lu, F., W. Stedman, et al. (2010). “Epigenetic regulation of Kaposi’s sarcoma-
associated herpesvirus latency by virus-encoded microRNAs that target Rta and the 
cellular Rb12-DNMT pathway.” Journal of Virology 84(6): 2697-2706. 
 
Lund, E., S. Guttinger, et al. (2004). “Nuclear export of microRNA precursors.” Science 
303(5654): 95-98. 
 
Lung, R. W. M., J. H. M. Tong, et al. (2009). “Modulation of LMP2A expression by a 
newly identified Epstein-Barr virus-encoded microRNA miR-BART22.” Neoplasia 
11(11): 1174-U89. 
 
Lyngaa, R., K. Norregaard, et al. (2010). “Cell transformation mediated by the Epstein-
Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signalling.” 
Oncogene 29(31): 4388-4398. 
 
Maniataki, E and Z. Mourelatos (2005). “A human, ATP-independent, RISC assembly 
machine fuelled by pre-miRNA.” Genes & Development 19(24): 2979-2990. 
 
McCormick, C. and D. Ganem (2005). “The kaposin B protein of KSHV activates the 
p38/MK2 pathway and stabilizes cytokine mRNAs.” Science 307(5710): 739-741. 
 
McGeoch, D. J., F. J. Rixon, et al. (2006). “Topics in herpesvirus genomics and 
evolution.” Virus Research 117(1): 90-104. 
 
Chapter Six                                                                                                         Conclusion 
 156 
McGeoch, D. J. and A. J. Davison (1999). The molecular evolutionary history of the 
herpesviruses. Origin and Evolution of Viruses. E. Domingo, R. Webster and J. Holland. 
London, Academic Press: 441-465. 
 
Meier-Trummer, C. S., B. Ryf, et al. (2010). “Identification of peripheral blood 
mononuclear cells targeted by ovine herpesvirus 2 in sheep.” Veterinary Microbiology 
141(3-4): 199-207. 
 
Meier-Trummer, C. S., H. Rehrauer, et al. (2009). “Malignant catarrhal fever of cattle if 
associated with low abundance of IL-2 transcript and a predominately latent profile of 
ovine herpesvirus 2 gene expression.” Plos One 4(7): e6265. 
 
Meister, G. and T. Tuschl (2004). “Mechanisms of gene silencing by double-stranded 
RNA.” Nature 431(7006): 343-349. 
 
Mettam, R. W. M. (1923). “Snotsiekte in cattle.” Ninth and Tenth Reports of the 
Director Veterinary Education and Research, Union S. Africa. p 395. 
 
Metzler, A. E. (1991). “The malignant catarrhal fever complex.” Comparative 
Immunology Microbiology and Infectious Diseases 14(2): 107-124. 
 
Miller, N. and L. M. Hutt-Fletcher (1988). “A monoclonal-antibody to glycoprotein 
gp85 inhibits fusion but not attachment of Epstein-Barr virus.” Journal of Virology 
62(7): 2366-2372. 
 
Molesworth, S. J., C. M. Lake, et al. (2000). “Epstein-Barr virus gH is essential for 
penetration of B cells but also plays a role in attachment of virus to epithelial cells.” 
Journal of Virology 74(14): 6324-6332. 
 
Moore, D. A., P. Kohrs, et al. (2010). “Outbreak of malignant catarrhal fever among 
cattle associated with a state livestock exhibition.” Journal of the American Veterinary 
Medical Association 237(1): 87-92. 
 
Mourelatos, Z., J. Dostie, et al. (2002). “miRNPs: a novel class of ribonucleoproteins 
containing numerous microRNAs.” Genes & Development 16(6): 720-728. 
 
Muller-Doblies, U. U., J. Egli, et al. (2001). “Epidemiology of malignant catarrhal fever 
in Switzerland.” Schweizer Archiv Fur Tierheilkunde 143(4): 173-183. 
 
Murphy, E., J. Vanicek, et al. (2008). “Suppression of immediate-early viral gene 
expression by herpesvirus-coded microRNAs: Implications for latency.” Proceedings of 
the National Academy of Sciences of the United States of America 105(14): 5453-5458.  
 
Chapter Six                                                                                                         Conclusion 
 157 
Muylkens, B., D. Coupeau, et al. (2010). “Marek’s disease virus microRNA designated 
Mdv1-pre-miR-M4 targets both cellular and viral genes.” Archives of Virology 155(11): 
1823-1837. 
 
Mwangi, W. N., L. P. Smith, et al. (2011). “Clonal structure of rapid-onset MDV-driven 
CD4+ lymphomas and responding CD8+ T cells.” Plos Pathogens 7(5): e1001337. 
 
Nachmani, D., N. Stern-Ginossar, et al. (2009). “Diverse herpesvirus microRNAs target 
the stress-induced immune ligand MICB to escape recognition by natural killer cells.” 
Cell Host & Microbe 5(4): 376-385. 
 
Nascimento, R., J. D. Dias, et al. (2009). “The conserved UL24 family of human alpha, 
beta and gamma herpesviruses induces cell cycle arrest and inactivation of the 
cyclinB/cdc2 complex.” Archives of Virology 154(7): 1143-1149. 
 
Nascimento, R. and R. M. E. Parkhouse (2007). “Murine gammaherpesvirus 68 ORF20 
induces cell-cycle arrest in G(2) by inhibiting the Cdc2-cyclin B complex.” Journal of 
General Virology 88: 1446-1453. 
 
Nelson, D. D., W. C. Davis, et al. (2010). “CD8+/perforin+/WC1- γδ T cells, not CD8+ 
αβ T cells, infiltrate vasculitis lesions of American bison (Bison bison) with 
experimental sheep-assiciated malignant catarrhal fever.” Veterinary Immunology and 
Immunopathology 136(3-4): 284-291. 
 
Nevels, M., A. Nitzsche, et al. (2011). “How to control an infectious bead string: 
nucleosome-based regulation and targeting of herpesvirus chromatin.” Reviews in 
Medical Virology 21(3): 154-180. 
 
Nijmeijer, S., R. Leurs, et al. (2010). “The Epstein-Barr virus-encoded G protein-
coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Gαi 
proteins, and constitutively impairs CXCR4 functioning.” Journal of Biological 
Chemistry 285(38): 29632-296-41. 
 
Nykanen, A., B. Haley, et al. (2001). “ATP requirements and small interfering RNA 
structure in the RNA interference pathway.” Cell 107(3): 309-321. 
 
Ohler, U., S. Yekta, et al. (2004). “Patterns of flanking sequence conservation and a 
characteristic upstream motif for microRNA gene identification.” RNA - A Publication 
of the RNA Society 10(9): 1309-1322. 
 
Okamura, K., M. D. Phillips, et al. (2008). “The regulatory activity of microRNA star 
species has substantial influence on miRNA and 3’UTR evolution.” Nature Structural & 
Molecular Biology 15(4): 354-363. 
 
Chapter Six                                                                                                         Conclusion 
 158 
Olsen, P. H. and V. Ambros (1999). “The lin-4 regulatory RNA controls developmental 
timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the 
initiation of translation.” Developmental Biology 216(2): 671-680. 
 
O’Toole, D., H. Li, et al. (1997). “Chronic and recovered cases of sheep-associated 
malignant catarrhal fever in cattle.” Veterinary Record 140(20): 519-524. 
 
Otsubo, T., Y. Akiyama, et al. (2011). “MicroRNA-126 inhibits Sox2 expression and 
contributes to gastric carcinogenesis.” Plos One 6(1): e16617 
 
Pall, G. S. and A. J. Hamilton (2008). “Improved northern blot method for enhanced 
detection of small RNA.” Nature Protocols 3(6): 1077-1084. 
 
Pan, X., B. Zhang, et al. (2007). “Characterizing viral microRNAs and its application on 
identifying new microRNAs in viruses.” Journal of Cellular Physiology 211(1): 10-18.  
 
Pasquinelli, A. E., B. J. Reinhart, et al. (2000). “Conservation of the sequence and 
temporal expression of let-7 heterochronic regulatory RNA.” Nature 408(6808): 86-89. 
 
Paulus, C., A. Nitzsche, et al. (2010). “Chromatinisation of herpesvirus genomes.” 
Reviews in Medical Virology 20(1): 34-50. 
 
Petrocca, F., R. Visone, et al. (2008). “E2F1-regulated microRNAs impair TGFβ-
dependent cell-cycle arrest and apoptosis in gastric cancer.” Cancer Cell 13(3): 272-286. 
 
Pfeffer, S., A. Sewer, et al. (2005). “Identification of microRNAs of the herpesvirus 
family.” Nature Methods 2(4): 269-276. 
 
Pfeffer, S., M. Zavolan, et al. (2004). “Identification of virus-encoded microRNAs.” 
Science 304(5671): 734-736. 
 
Plowright, W., R. D. Ferris, et al. (1960). “Blue wildebeest and the ætiological agent of 
malignant catarrhal fever.” Nature 188(4757): 1167-1169.  
 
Poffenberger, K. L. and B. Roizman (1985). “A noninverting genome of a viable herpes-
simplex virus-1-presence of head-to-tail linkages in packaged genomes and requirements 
for circularization after infection.” Journal of Virology 53(2): 587-595. 
 
Powers, J. G., D. C. VanMetre, et al. (2005). “Evaluation of ovine herpesvirus 2 
infections, as detected by competitive inhibition ELISA and polymerase reaction assay 
in dairy cattle without clinical signs of malignant catarrhal fever.” Journal of the 
American Veterinary Medical Association 227(4): 606-611. 
 
Chapter Six                                                                                                         Conclusion 
 159 
Qin, Z. Q., P. Kearney, et al. (2010). “Kaposi’s sarcoma-associated herpesvirus 
(KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by 
macrophages and monocytes.” Journal of Leukocyte Biology 87(1): 25-34. 
 
Ratcliff, F., B. D. Harrison, et al. (1997). “A similarity between viral defences and gene 
silencing in plants.” Science 276(5318): 1558-1560. 
 
Reinhart, B. J., F. J. Slack, et al. (2000). “The 21-nucleotide let-7 RNA regulates 
developmental timing in Caenorhabditis elegans.” Nature 408(6772): 901-906. 
 
Roizmann, B., R. C. Desrosiers, et al. (1992). “The family Herpesviridae - an update.” 
Archives of Virology 123(3-4): 425-449. 
 
Rosbottom, J., R. G. Dalziel, et al. (2002). “Ovine herpesvirus 2 lytic cycle replication 
and capsid production.” Journal of General Virology 83(12): 2999-3002. 
 
Rossi, J. J. (2005). “RNAi and the P-body connection.” Nature Cell Biology 7(7): 643-
644. 
 
Rossiter, P. B. (1983). “Antibodies to malignant catarrhal fever virus in cattle with non-
wildebeest-associated malignant catarrhal fever.” Journal of Comparative Pathology 
93(1): 93-97. 
 
Rossiter, P. B. (1981). “Antibodies to malignant catarrhal fever virus in sheep.” Journal 
of Comparative Pathology 91(2): 303-311. 
 
Russell, G. C., J. P. Stewart, et al. (2009). “Malignant catarrhal fever: A review.” 
Veterinary Journal 179(3): 324-335. 
 
Samols, M. A., R. L. Skalsky, et al. (2007). “Identification of cellular genes targeted by 
KSHV-encoded microRNAs.” Plos Pathogens 3(5): 611-618. 
 
Samols, M. A., J. H. Hu, et al. (2005). “Cloning and identification of a microRNA 
cluster within the latency-associated region of Kaposi’s sarcoma-associated 
herpesvirus.” Journal of Virology 79(14): 9301-9305. 
 
Sanford, S. E. and P. B. Little (1977). “The gross and histopathological lesions of 
malignant catarrhal fever in three captive sika deer (Cervus nippon) in southern 
Ontario.” Journal of Wildlife Disease 13(1): 29-32. 
 
Schock, A., R. A. Collins, et al. (1998). “Phenotype, growth regulation and cytokine 
transcription in Ovine herpesvirus-2 (OvHV-2)-infected bovine T-cell lines.” Veterinary 
Immunology and Immunopathology 66(1): 67-81. 
 
Chapter Six                                                                                                         Conclusion 
 160 
Schwarz, D. S., G. Hutvágner, et al. (2003). “Asymmetry in the assembly of the RNAi 
enzyme complex.” Cell 115(2): 199-208. 
 
Simon, S., H. Li, et al. “The vascular lesions of a cow and bison with sheep-associated 
malignant catarrhal fever contain ovine herpesvirus 2-infected CD8+ T lymphocytes.” 
Journal of General Virology 84(8): 2009-2013. 
 
Skalsky, R. L., M. A. Samols, et al. (2007). “Kaposi’s sarcoma-associated herpesvirus 
encodes an ortholog of miR-155.” Journal of Virology 81(23): 12836-12845. 
 
Song, J. J., S. K. Smith, et al. (2004). “Crystal structure of argonaute and its implications 
for RISC slicer activity.” Science 305(5689): 1434-1437. 
 
Song, J. J., J. D. Liu, et al. (2003). The crystal structure of the Argonaute2 PAZ domain 
reveals an RNA binding motif in RNAi effector complexes.” Nature Structural Biology 
10(12): 1026-1032. 
 
Stampfer, S. D., H. A. Lou, et al. (2010). “Structural basis of local, pH-dependent 
conformational changes in glycoprotein B from herpes simplex virus type 1.” Journal of 
Virology 84(24): 12924-12933. 
 
Stark, A., J. Brennecke, et al. (2005). “Animal microRNAs confer robustness to gene 
expression and have a significant impact on 3’ UTR evolution.” Cell 123(6): 1133-1146. 
 
Stern-Ginossar, N., N. Saleh, et al. (2009). “Analysis of human cytomegalovirus-
encoded microRNA activity during infection.” Journal of Virology 83(20): 10684-
10693. 
 
Stern-Ginossar, N., N. Elefant, et al. (2007). “Host immune system gene targeting by a 
viral miRNA.” Science 317(5836): 376-381. 
 
Stoker, M., I. Macpherson (1964). “Syrian hamster fibroblast cell line BHK21 and its 
derivatives.” Nature 203(495): 1355-1357. 
 
Szekely, L., F. Chen, et al. (1998). “Restricted expression of Epstein-Barr virus (EBV)-
encoded, growth transformation-associated antigens in an EBV- and human herpesvirus 
type 8-carrying body cavity lymphoma line.” Journal of General Virology 79(6): 1445-
1452. 
 
Tahbaz, N., F. A. Kolb, et al. (2004). “Characterization of the interactions between 
mammalian PAZ PIWI domain proteins and Dicer.” EMBO Reports 5(2): 189-194. 
 
Tang, S., A. Patel, et al. (2009). “Novel less-abundant viral microRNAs encoded by 
herpes simplex virus 2 latency-associated transcript and their roles in regulating ICP34.5 
and ICP0 mRNAs.” Journal of Virology 83(3): 1433-1442. 
Chapter Six                                                                                                         Conclusion 
 161 
Tang, S., A. S. Bertke, et al. (2008). “An acutely and latently expressed herpes simplex 
virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor.” 
Proceedings of the National Academy of Sciences of the United States of America 
105(31): 10931-10936. 
 
Taus, N. S., D. A. Schneider, et al. (2010). “Sheep (Ovis aries) airway epithelial cells 
support ovine herpesvirus 2 lytic replication in vivo.” Veterinary Microbiology 145(1-2): 
47-53. 
 
Tay, Y., J. Q. Zhang, et al. (2008). “MicroRNAs to Nanog, Oct4 and Sox2 coding 
regions modulate embryonic stem cell differentiation.” Nature 455(7216): 1124-U12. 
 
Thonur, L., G. C. Russell, et al. (2006). “Differential transcription of ovine herpesvirus 2 
genes in lymphocytes from reservoir and susceptible species.” Virus Genes 32(1): 27-35. 
 
Traul, D. L., H. Li, et al. (2007). “Resistance to malignant catarrhal fever in American 
bison (Bison bison) is associated with MHC class IIa polymorphisms.” Animal Genetics 
38(2): 141-146. 
 
Uldrick, T. S. and D. Whitby (2011). “Update on KSHV epidemiology, Kaposi Sarcoma 
pathogenesis, and treatment of Kaposi Sarcoma.” Cancer Letters 305(2): 150-162. 
 
Umbach, J. L., M. F. Kramer, et al. (2008). “MicroRNAs expressed by herpes simplex 
virus 1 during latent infection regulate viral mRNAs.” Nature 454(7205): 780-U108. 
 
Verma, S. C., K. Lan, et al. (2007). Structure and function of latency-associated nuclear 
antigen. Kaposi Sarcoma Herpesvirus: New Perspectives. 312: 101-136  
 
Walz, N., T. Christalla, et al. (2010). “A global analysis of evolutionary conservation 
among known and predicted gammaherpesvirus microRNAs.” Journal of Virology 
82(2): 716-728. 
 
Wang, S. S., A. B. Aurora, et al. (2008). “The endothelial-specific microRNA miR-126 
governs vascular integrity and angiogenesis.” Developmental Cell 15(2): 261-271. 
 
Wang, X., W. J. Kenyon, et al. (1998). “Epstein-Barr virus uses different complexes of 
glycoproteins gH and gL to infect B lymphocytes and epithelial cells.” Journal of 
Virology 72(7): 5552-5558. 
 
Wang, X. and L. M. Hutt-Fletcher (1998). “Epstein-Barr virus lacking glycoprotein 
gp42 can bind to B cells but is not able to infect.” Journal of Virology 72(1): 158-163. 
 
Wiebusch, L., A. Neuwirth, et al. (2008). “Cell cycle-independent expression of 
immediate-early gene 3 results in G1 and G2 arrest in murine cytomegalovirus-infected 
cells.” Journal of Virology 82(20): 10188-10198. 
Chapter Six                                                                                                         Conclusion 
 162 
Wightman, B., I. Ha, et al. (1993). “Posttranscriptional regulation of the heterochronic 
gene lin-14 by lin-4 mediates temporal pattern-formation in C. elegans.” Cell 75(5): 
855-862. 
 
Wightman, B., T. R. Burglin, et al. (1991). “Negative regulatory sequences in the lin-14 
3’-untranslated region are necessary to generate a temporal switch during 
Caenorhabditis elegans development.” Genes & Development 5(10): 1813-1824. 
 
Xia, T., A. O’Hara, et al. (2008). “EBV microRNAs in primary lymphomas and 
targeting of CXCL-11 by ebv-mir-BHRF1-3.” Cancer Research 68(5): 1436-1442. 
 
Xiao, C. C., L. Srinivasan, et al. (2008). “Lymphoproliferative disease and 
autoimmunity in mice with increased miR-17-92 expression in lymphocytes.” Nature 
Immunology 9(4): 405-414. 
 
Xu, N., T. Papagiannakopoulos, et al. (2009). “MicroRNA-145 regulates Oct4, Sox2, 
and KLF4 and represses pluripotency in human embryonic stem cells.” Cell 137(4): 647-
658. 
 
Xu, P. Z., S. Y. Vernooy, et al. (2003). “The Drosophila miRNA miR-14 suppresses cell 
death and is required for normal fat metabolism.” Current Biology 13(9): 790-795. 
 
Xu, S., C. Y. Xue, et al. (2011). “Marek’s disease virus type 1 microRNA miR-M3 
suppresses cisplatin-induced apoptosis by targeting Smad2 of the transforming growth 
factor beta signal pathway.” Journal of Virology 85(1): 276-285. 
 
Yan, K. S., S. Yan, et al. (2003). “Structure and conserved RNA binding of the PAZ 
domain.” Nature 426(6965): 469-474. 
 
Yao, Y. X., Y. G. Zhao, et al. (2009). “Novel microRNAs (miRNAs) encoded by 
herpesvirus of turkeys: Evidence of miRNA evolution by duplication.” Journal of 
Virology 83(13): 6969-6973. 
 
Yao, Y. X., Y. G. Zhao, et al. (2007). “Marek’s disease virus type 2 (MDV-2)-encoded 
microRNAs show no sequence conservation with those encoded by MDV-1.” Journal of 
Virology 81(13): 7164-7170. 
 
Yekta, S., I. H. Shih, et al. (2004). “MicroRNA-directed cleavage of HOXB8 mRNA.” 
Science 304(5670): 594-596. 
 
Yi, R., Y. Qin, et al. (2003). “Exportin-5 mediates the nuclear export of pre-microRNAs 
and short hairpin RNAs.” Genes & Development 17(24): 3011-3016. 
 
Chapter Six                                                                                                         Conclusion 
 163 
Yu, X. K., S. Shah, et al. (2011). “Biochemical and structural characterization of the 
capsid-bound tegument proteins of human cytomegalovirus.” Journal of Structural 
Biology 174(3): 451-460. 
 
Zeng Y. and B. R. Cullen (2005). “Efficient processing of primary microRNA hairpins 
by drosha requires flanking nonstructured RNA sequences.” Journal of Biological 
Chemistry 280(30): 27595-27603. 
 
Zeng Y., R. Yi, et al. (2003). “MicroRNAs and small interfering RNAs can inhibit 
mRNA expression by similar mechanisms.” Proceedings of the National Academy of 
Sciences of the United States of America 100(17): 9779-9784. 
 
Zdobnov, E. M. and R. Apweiler (2001). “InterProScan - an integration platform for the 
signature-recognition methods in InterPro.” Bioinformatics 17(9): 847-848. 
 
Zhang, B. H., X. P. Pan, et al. (2006). “Evidence that miRNAs are different from other 
RNAs.” Cellular and Molecular Life Sciences 63(2): 246-254. 
 
Zhao, Y. G., H. T. Xu, et al. (2011). “Critical role of the virus-encoded microRNA-155 
ortholog in the induction of Marek’s disease lymphomas.” Plos Pathogens 7(2): 
e1001305 
 
Zhao, Y. G., Y. X. Yao, et al. (2009). “A functional microRNA-155 ortholog encoded 
by the oncogenic Marek’s disease virus.” Journal of Virology 83(1): 489-492. 
 
Zheng, S. Q., Y. X. Li, et al. (2011). “miR-101 regulates HSV-1 replication by targeting 
ATP5B.” Antiviral Research 89(3): 219-226. 
 
Zhong, W. D., H. Wang, et al. (1996). “Restricted expression of Kaposi sarcoma-
associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma.” Proceedings of 
the National Academy of Sciences of the United States of America 93(13): 6641-6646. 
 
Ziegelbauer, J. M., C. S. Sullivan, et al. (2009). “Tandem array-based expression screens 
identify host mRNA targets of virus-encoded microRNAs.” Nature Genetics 41(1): 130-
134. 
 
Zuker, M. (2003). “Mfold web server for nucleic acid folding and hybridization 
prediction.” Nucleic Acids Research 31(13): 3406-3415. 
 
Zuo, J. M., L. L. Quinn, et al. (2011). “The Epstein-Barr virus-encoded BILF1 protein 
modulates immune recognition of endogenously processed antigen by targeting major 
histocompatibility complex class I molecules trafficking on both the exocytic and 
endocytic pathways.” Journal of Virology 85(4): 1604-1614. 
 
 
